US20120178735A1 - 2h-chromene compound and derivative thereof - Google Patents

2h-chromene compound and derivative thereof Download PDF

Info

Publication number
US20120178735A1
US20120178735A1 US13/396,861 US201213396861A US2012178735A1 US 20120178735 A1 US20120178735 A1 US 20120178735A1 US 201213396861 A US201213396861 A US 201213396861A US 2012178735 A1 US2012178735 A1 US 2012178735A1
Authority
US
United States
Prior art keywords
lower alkyl
oxy
methyl
preparation example
chromen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/396,861
Inventor
Hironori Harada
Kazuyuki Hattori
Kazuya Fujita
Sunao Imada
Tatsuaki Morokata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to US13/396,861 priority Critical patent/US20120178735A1/en
Publication of US20120178735A1 publication Critical patent/US20120178735A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • Ring A represents a cyclic group
  • Ring B represents a cyclic group which may further have a substituent
  • X represents a binding arm or a spacer having one to eight atoms in the main chain, in which one atom of the spacer may be combined with a substituent of the Ring B to form a ring which may have a substituent
  • Y represents a binding arm or a spacer having one to ten atoms in the main chain, in which one atom of the spacer may be combined with a substituent of the Ring B to form a ring which may have a substituent
  • Z represents an acidic group which may be protected
  • n represents 0 or 1, provided that in the case where n is 0, m represents 1, and further, R 1 represents a hydrogen atom or a substituent, in the case where n is 1, m represents 0 or an integer of 1 to 7, and further, R 1 represents a substituent (when m is 2 or more, a plurality of R 1 s may be the same as
  • L represents lower alkylene, lower alkenylene, lower alkynylene, -(lower alkylene)-O—, —O-(lower alkylene)-, or -(lower alkylene)-O-(lower alkylene)-,
  • Y represents O, S, or —CH 2 —, provided that wherein Y is —CH 2 —, Q is S,
  • n 0 or 1
  • R 4B represents lower alkyl substituted with a group selected from Group G or cycloalkyl substituted with a group selected from Group
  • the present invention relates to a method for preventing or treating diseases induced by undesirable lymphocyte infiltration associated with S1P 1 , particularly, rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation, or multiple sclerosis in humans or animals, which involves administering to a patient an effective amount of the 2H-chromene compound of the formula (I) or a derivative thereof or a salt thereof.
  • halogen means F, Cl, Br, or I. Preferably, examples thereof include F and Cl.
  • the “lower alkyl” is linear or branched alkyl having one to six carbon atoms (hereinafter simply referred to as C 1-6 ), and examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like, in another embodiment, C 1-4 alkyl, and in a further embodiment, methyl, ethyl, and isopropyl.
  • the “lower alkenylene” is linear or branched C 2-6 alkenylene and examples thereof include vinylene, ethylidene, propenylene, butenylene, pentenylene, hexenylene, 1,3-butadienylene, 1,3-pentadienylene, and the like, in another embodiment, C 2-4 alkenylen, and in a further embodiment, vinylene and ethylidene.
  • aryl is a C 6-14 monocyclic to tricyclic aromatic hydrocarbon ring group, and examples thereof include phenyl and naphthyl, and in another embodiment, phenyl.
  • heteroaryl is 5- to 6-membered monocyclic heteroaryl containing one to four hetero atoms selected from N, S, and O, and bicyclic heteroaryl formed by condensation thereof with a benzene ring or 5- to 6-membered monocyclic heteroaryl, and may be partially saturated.
  • examples thereof include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, triazolyl, triazinyl, tetrazolyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thienyl, furyl, benzothiazolyl, and indolyl, in another embodiment, heteroaryl of a 5-membered ring, which may be condensed with a benzene ring, and in an even further embodiment, pyrrolyl, imidazolyl, thiazolyl, thienyl, benzothiazolyl, and indolyl.
  • the reducing agent examples include NaBH 3 CN, NaBH(OAc) 3 , NaBH 4 , and the like. It may be preferable in some cases to carry out the reaction in the presence of a dehydrating agent such as molecular sieves and the like, or an acid such as acetic acid, hydrochloric acid, a titanium (IV) isopropoxide complex, and the like.
  • a dehydrating agent such as molecular sieves and the like
  • an acid such as acetic acid, hydrochloric acid, a titanium (IV) isopropoxide complex, and the like.
  • An imine that is a reaction intermediate may be isolated as a stable intermediate, and by reducing the imine intermediate, the compound (I) can be obtained.
  • the compound (A-1) can be prepared by a Sonogashira reaction from a compound (D).
  • the Step 7-5 is a chromene ring-constituting reaction.
  • the compound (T) can be prepared by adding an acrolein derivative to the compound (S), followed by stirring under any temperature condition from room temperature to heating in the presence of an inorganic base such as K 2 CO 3 and the like.
  • an inorganic base such as K 2 CO 3 and the like.
  • the vehicle include aromatic hydrocarbons; ethers; halogenated hydrocarbons; MeCN, and a mixed vehicle thereof.
  • ether-based vehicles such as THF, DME, dioxane, and the like are used.
  • some compounds represented by the formula (I) can also be prepared by any combination of the steps that can usually be employed by a person skilled in the art, such as known alkylation, acylation, substitution reaction, oxidation, reduction, hydrolysis, deprotection, halogenation, and the like, from the compound of the present invention prepared as above.
  • acylation can employ an acylation reaction that is usually used by a person skilled in the art can be employed, but the acylation is carried out in an organic vehicle which is inert to the reaction, such as ethers; aromatic hydrocarbons; halogenated hydrocarbons; esters such as EtOAc, and the like; MeCN; aprotic vehicles, and the like, using a condensing agent such as EDCI.HCl, CDI, diphenylphosphorylanide, and the like, depending on the reaction condition, but usually under cooling, under any temperature condition from cooling to room temperature, or under any temperature condition room temperature to heating, particularly in the presence of HOBt.
  • an organic vehicle which is inert to the reaction
  • ethers such as ethers; aromatic hydrocarbons; halogenated hydrocarbons; esters such as EtOAc, and the like
  • MeCN MeCN
  • aprotic vehicles, and the like using a condensing agent such as EDCI.HCl, CDI, diphenylphospho
  • the compound of the formula (I) of the present invention has an excellent S1P 1 agonist action and has a potent action of reducing the number of the lymphocytes in the peripheral blood even at 4 hours or 24 hours after administration in the pharmacological test using rats.
  • the pulmonary artery end of the graft and the abdominal aorta of the recipient were anastomosed and the pulmonary artery end of the graft and the vena cava of the recipient were anastomosed to prepare a model (grouped into 6 to 10 examples per group).
  • the rejection determination of the transplanted heart promotes the recipient's abdominal palpation every 29 days after transplantation, and the presence or absence of the beating of the graft is determined on the rejection.
  • the compound of the present invention is suspended in 0.5% methylcellulose-containing distilled water and orally administered once or twice a day for 14 days from the date of the transplant.
  • the measurement data were read (for a total evaluation time of 20 minutes) from a chart of the values before administration, at 1, 2, 5, and 10 min after the start of constant infusion, and at 1, 2, 5, and 10 min after the completion of infusion, and thus, for the heart rate and the blood pressure before administration, the decrease rates (%) before and after infusion were calculated.
  • a pharmaceutical composition containing one or two or more kinds of the compound of the formula (I) or a salt thereof as an active ingredient can be prepared using excipients that are usually used in the art, that is, excipients for pharmaceutical preparations, carriers for pharmaceutical preparations, and the like, according to the methods usually used.
  • the injections for parenteral administration include sterile, aqueous or non-aqueous solutions, suspensions, or emulsions.
  • aqueous solvent for example, distilled water for injection or physiological saline is included.
  • non-aqueous solvent include propylene glycol, polyethylene glycol, vegetable oils such as olive oil and the like, alcohols such as ethanol and the like, polysorbate 80 (pharmacopeia), etc.
  • Such a composition may further contain a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizer, or a solubilizing aid.
  • These are sterilized, for example, by filtration through a bacteria-retaining filter, blending with bactericides, or irradiation.
  • these can also be used by producing a sterile solid composition, and dissolving or suspending it in sterile water or a sterile vehicle for injection prior to its use.
  • Examples of the formulation for external use include ointments, plasters, creams, jellies, patches, sprays, lotions, eye-drops, eye ointments, and the like.
  • the drug contains generally used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, or the like.
  • Examples of the ointment bases or lotion bases include polyethylene glycol, propylene glycol, white vaseline, bleached beeswax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, sorbitan sesquioleate, and the like.
  • the daily dose is suitably from 0.001 to 100 mg/kg per body weight, preferably from 0.1 to 30 mg/kg, and more preferably from 0.1 to 10 mg/kg, and this is administered in one portion or dividing it into 2 to 4 portions.
  • the daily dose is suitably from about 0.0001 to 10 mg/kg per body weight, and this is administered once a day or two or more times a day.
  • a transmucosal agent is administered at a dose from about 0.001 to 100 mg/kg per body weight, and this is administered once a day or two or more times a day.
  • the dose is appropriately decided in response to an individual case by taking the symptoms, the age, the gender, and the like into consideration.
  • crossed double bonds in the structural formula mean a mixture of a cis-form and a trans-form.
  • tetramethylsilane is used as an internal standard unless otherwise specifically described, and ⁇ (ppm) (integrated value, disintegrated pattern) of signals in 1 H-NMR in which DMSO-d 6 is used as a measurement vehicle.
  • NMR represents 1 H-NMR: Proton
  • Methyl 5,6-dichloronicotinate (1.5 g) and 60% sodium hydride (640 mg) were dissolved in THF (45 mL).
  • 1,3-Difluoropropan-2-ol (1.5 g) was added thereto at 0° C., followed by stirring at 0° C. for 3 hours, and the reaction solution was quenched with aqueous NH 4 Cl. After extraction with EtOAc, the organic layer was dried over MgSO 4 and then filtered, and the desiccant was removed.
  • reaction liquid was stirred at room temperature for 6 hours, and then water was added thereto, followed by extraction with chloroform.
  • the organic layer was washed with brine, dried over MgSO 4 , and concentrated under reduced pressure.
  • the reaction liquid was concentrated under reduced pressure and the residue was washed with MeCN to obtain 1-[(7- ⁇ [2,4-bis(trifluoromethyl)phenyl]ethynyl ⁇ -5-fluoro-2H-chromen-3-yl)methyl]pyrrolidine-3-carboxylic acid hydrochloride (185 mg) as a pale yellow solid.
  • Pr29-5 NMR 5.00(2H, d), 7.09-7.11(1H, m), 7.24(1H, dd), 7.47(1H, d), 7.65-7.72(2H, m), 7.81(1H, dm), 7.88(1H, dm), 7.93-7.96(1H, m), 9.61(1H, s) Pr29-6 NMR: 5.00(2H, d), 6.99-7.03(1H, m), 7.18(1H, dd), 7.49(1H, d), 7.61-7.69(2H, m), 7.75(1H, t), 7.84(2H, t), 9.61(1H, s) Pr29-7 NMR: 1.27-1.86(10H, m), 2.58-2.71(1H, m), 4.95(2H, s), 6.83-6.84(1H, m), 7.00 (1H, dd), 7.36(1H,
  • the compound of the present invention has an S1P 1 agonist action and can be used for prevention or treatment of diseases induced by undesirable lymphocyte infiltration, for example, autoimmune diseases or inflammatory diseases such as graft rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, lung disorders, asthma, atopic dermatitis, inflammatory bowel disease, arteriosclerosis, ischemic reperfusion disorder, and diseases induced by abnormal proliferation or accumulation of cells, for example, cancer, leukemia, and the like.
  • diseases induced by undesirable lymphocyte infiltration for example, autoimmune diseases or inflammatory diseases such as graft rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)

Abstract

Provided is a 2H-chromene compound or a derivative thereof which has an excellent S1P1 agonist action. The 2H-chromene compound or derivative is particularly useful for preventing and/or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells.

Description

    TECHNICAL FIELD
  • The present invention relates to a 2H-chromene compound and a derivative thereof, which are useful as an active ingredient for a pharmaceutical composition, particularly a pharmaceutical composition for preventing or treating diseases induced by undesirable lymphocyte infiltration or diseases induced by abnormal proliferation or accumulation of cells.
    • BACKGROUND ART
  • Sphingosine 1-phosphate is a metabolite of sphingolipid which is a physiologically active substance secreted from an activated platelet (Annual Review Biochemistry, 2004, Vol. 73, pp. 321-354). The sphingosine 1-phosphate receptor is a G-protein-binding type, and belongs to an Edg-family which is the endothelial differentiation gene. Up to now, five receptors of S1P1 (Edg1), S1P2 (Edg5), S1P3 (Edg3), S1P4 (Edg6), and S1P5 (Edg8) have been found. All of these receptors are broadly distributed in cells and tissues throughout the body, but S1P1, S1P3, and S1P4 are predominantly expressed in lymphocyte and endothelial cells, S1P2 is predominantly expressed in vascular smooth muscle cells, S1P5 is predominantly expressed in brain and spleen, and amino acid sequences thereof are well-conserved among humans and rodents (Annual Review Biochemistry, 2004, Vol. 73, pp. 321-354).
  • Many receptors bind to G-proteins by stimulation of sphingosine 1-phosphate. S1P1 binds to Gi/0, S1P2 and S1P3 binds to Gi/0, Gq, G12/13, and Gs, S1P4 binds to Gi/0, G12/13, and Gs, S1P5 binds to Gi/0 and G12/13, and cell proliferation caused by activation of MAPK, changes in the cytoskeletal system and cell infiltration caused by activation of Rac (and/or Rho), and production of cytokine and mediators caused by activation of PLC and calcium influx into cell, and the like (Annual Review Biochemistry, 2004, Vol. 73, pp. 321-354) are induced.
  • It has been known that through the stimulating action of S1P1 of sphingosine 1-phosphate, migration of lymphocyte, inhibition of apoptosis, production of cytokine, and sequestration of lymphocytes in the thymus and other secondary lymphoid tissues are induced, and angioplasty in vascular endothelial cells is promoted (Nature Review Immunology, 2005, Vol. 5, pp. 560-570). On the other hand, expression of S1P3 is also found on cardiomyocyte, and a transient decrease in the heart rate (infrequent pulse) or in the blood pressure through the stimulation of sphingosine 1-phosphate is observed (Japanese Journal of Pharmacology, 2000, Vol. 82, pp. 338-342). Infrequent pulse is not observed through the stimulation of sphingosine 1-phosphate in knockout mice wherein S1P3 is genetically deficient (Journal of Pharmacology and Experimental Therapeutics, 2004, Vol. 309, pp. 758-768).
  • It has been known that FTY720 and an FTY720 phosphate which is an active main body thereof have an excellent S1P1 agonist action and thus induce lymphocyte sequestration, and their effects on skin graft or multiple sclerosis, which are autoimmune diseases, is reported (Cellular & Molecular Immunology, 2005, Vol. 2, No. 6, pp. 439-448; and The New England Journal of Medicine, 2006, Vol. 355, pp. 1124-40). However, there have also been reported side effects such as infrequent pulse, reduced lung function (Transplantation, 2006, 82, pp. 1689-1967). It is reported that the FTY720 phosphate has a non-selective agonist action on S1P3, S1P4, and S1P5 (Science, 2002, Vol. 296, pp. 346-349), and between them, a clinical trial result that infrequent pulse induced by a stimulating action through S1P3 is expressed with high frequency as an undesirable side-effect has been reported (Journal of American Society of Nephrology, 2002, Vol. 13, pp. 1073-1083).
  • As a compound having an S1P1 agonist action, Patent Document 1 discloses a compound of the following general formula (A):
  • Figure US20120178735A1-20120712-C00001
  • [wherein n represents 1 or 2; A represents —C(O)OR9 or the like; R9 represents hydrogen or alkyl; X represents a bond, C1-4 alkylene, —X1OX2—, or the like, in which X1 and X2 are independently selected from a bond and C1-3 alkylene; Y represents a condensed 5,6- or 6,6-hetero bicyclic ring system containing at least one aromatic ring, in which the condensed bicyclic ring system of Y may be substituted, if desired; R1 is selected from C6-10 aryl and C2-9 heteroaryl, in which any aryl or heteroaryl is substituted with C6-10 aryl C0-4 alkyl, C2-9 heteroaryl, C0-4 alkyl, C1-6 alkyl, or the like, if desired, R2, R3, R5, R6, R7, and R8 independently represent hydrogen, C1-6 alkyl, halo, or the like; R4 represents hydrogen or C1-6 alkyl; or R7 and any one of R2, R4 or R5 are combined with an atom to which they bind to form a 4- to 7-membered ring; in which the 4- to 7-membered ring is saturated or partially unsaturated] and a pharmaceutically acceptable salt, a hydrate, a solvate, an isomer, and a prodrug thereof (for details, refer to Patent Document 1), and as a specific compound thereof, for example, the benzothienyl compound above is disclosed as Example 1.
  • Furthermore, Patent Document 2 discloses that a compound of the following general formula (B):
  • Figure US20120178735A1-20120712-C00002
  • [in the general formula, Ring A represents a cyclic group; Ring B represents a cyclic group which may have a substituent; X represents a spacer having one to eight atoms in the main chain, or the like; Y represents a spacer having one to ten atoms in the main chain, or the like; n represents 0 or 1; in the case where n is 0, m represents 1, and further, R1 represents a hydrogen atom or a substituent; in the case where n is 1, m represents 0 or an integer of 1 to 7, and further, R1 represents a substituent (when m is 2 or more, a plurality of R1 may be the same as or different from each other)], a salt thereof, a solvate thereof, or a prodrug thereof (for details, refer to Patent Document 2) has an S1P receptor-binding ability, and as a specific compound thereof, for example, a tetrahydronaphthalene derivative is disclosed as Example 31-06.
  • Moreover, Patent Document 3 discloses that a compound of the following general formula (C):
  • Figure US20120178735A1-20120712-C00003
  • [wherein Ring A represents a cyclic group, Ring B represents a cyclic group which may further have a substituent, X represents a binding arm or a spacer having one to eight atoms in the main chain, in which one atom of the spacer may be combined with a substituent of the Ring B to form a ring which may have a substituent, Y represents a binding arm or a spacer having one to ten atoms in the main chain, in which one atom of the spacer may be combined with a substituent of the Ring B to form a ring which may have a substituent, Z represents an acidic group which may be protected, and n represents 0 or 1, provided that in the case where n is 0, m represents 1, and further, R1 represents a hydrogen atom or a substituent, in the case where n is 1, m represents 0 or an integer of 1 to 7, and further, R1 represents a substituent (when m is 2 or more, a plurality of R1s may be the same as or different from each other)], a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof as a compound having an S1P receptor-binding ability. As a specific compound thereof, for example, a tetrahydronaphthalene derivative represented by Example 37-6 is disclosed.
  • However, up to now, there has been a desire for a novel and highly stable S1P1 agonist having the potent S1P1 agonist action of a sphingosine 1-phosphate, and correspondingly, having an excellent lymphocyte sequestering action, and further, having no undesirable actions such as infrequent pulse, reduced lung function, and the like, which have been reported with regard to conventional S1P1 agonists.
    • PRIOR ART DOCUMENT Patent Document
    • [Patent Document 1] Pamphlet of International Publication WO 2005/000833
    • [Patent Document 2] Pamphlet of International Publication WO 2005/020882
    • [Patent Document 3] Pamphlet of International Publication WO 2006/064757
    DISCLOSURE OF INVENTION Problems to be Solved by the Invention
  • A compound which is useful as an active ingredient of a pharmaceutical composition, particularly a pharmaceutical composition for preventing or treating diseases induced by undesirable lymphocyte infiltration or diseases induced by abnormal proliferation or accumulation of cells, on the basis of an S1P1 agonist action, is provided.
    • Means for Solving the Problems
  • The present inventors have made extensive studies on a compound having an S1P1 agonist action, and as a result, they have found that a 2H-chromene compound represented by the formula (I) below or a derivative thereof has an excellent S1P1 agonist action and is useful as an active ingredient of a pharmaceutical composition for preventing or treating diseases induced by lymphocytic infiltration or diseases induced by abnormal proliferation or accumulation of cells, thereby completing the present invention.
  • Thus, the present invention relates to a 2H-chromene compound represented by the following formula (1):
  • Figure US20120178735A1-20120712-C00004
  • (wherein
  • A represents lower alkyl, cycloalkyl, aryl, or heteroaryl,
  • wherein aryl and heteroaryl may respectively be substituted with one to five R1s which are the same as or different from each other,
  • R1 represents halogen, —CN, —NO2, lower alkyl, lower alkenyl, lower alkynyl, halogeno-lower alkyl, aryl, heteroaryl, cycloalkyl, —OH, —O-(lower alkyl), —O-(halogeno-lower alkyl), —O-(aryl), —O-(cycloalkyl), —O-(heteroaryl), —NH2, —NH(lower alkyl), —NH(halogeno-lower alkyl), —N(lower alkyl)2, or cyclic amino,
  • wherein aryl, heteroaryl, cycloalkyl, and cyclic amino may respectively be substituted with one to five substituents which are the same as or different from each other and selected from the group consisting of halogen, —CN, lower alkyl and halogeno-lower alkyl,
  • L represents lower alkylene, lower alkenylene, lower alkynylene, -(lower alkylene)-O—, —O-(lower alkylene)-, or -(lower alkylene)-O-(lower alkylene)-,
  • Q represents S or —C(R2B)═C(R2C)—,
  • R2A, R2B, and R2C are the same as or different from each other and represent —H, halogen, lower alkyl, halogeno-lower alkyl, —O-(lower alkyl), or —O-(halogeno-lower alkyl),
  • Y represents O, S, or —CH2—, provided that wherein Y is —CH2—, Q is S,
  • m represents 0 or 1,
  • R3 represents —H, halogen, lower alkyl, or aryl,
  • R4A represents —H or lower alkyl,
  • R4B represents lower alkyl substituted with a group selected from Group G or cycloalkyl substituted with a group selected from Group
  • or R4A and R4B are combined with N to which they bind to form cyclic amino substituted with a group selected from Group G, in which the cyclic amino may further contain one to four substituents which are the same as or different from each other and selected from the group consisting of halogen, lower alkyl, and halogeno-lower alkyl, and
  • Group G represents, —C(═O)OH, tetrazolyl, —C(═O)NHS(═O)2(lower alkyl), -(lower alkylene)-C(═O)OH, or
  • Figure US20120178735A1-20120712-C00005
  • or a derivative thereof, or a salt thereof.
  • In this regard, in a case where the symbols in any of the chemical formulae in the present specification are also used in other chemical formulae, the same symbols denote the same meanings, unless specifically described otherwise.
  • Further, the present invention relates to a pharmaceutical composition, which includes the 2H-chromene compound of the formula (I), or a derivative thereof or a salt thereof and a pharmaceutically acceptable excipient, in particular, (1) an S1P1 agonist, (2) a pharmaceutical composition for preventing or treating diseases induced by undesirable lymphocyte infiltration associated with S1P1, (3) a pharmaceutical composition for preventing or treating rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation, autoimmune diseases, or inflammatory diseases in humans or animals, (4) a pharmaceutical composition for preventing or treating rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation in humans or animals, (5) a pharmaceutical composition for preventing or treating multiple sclerosis, (6) a pharmaceutical composition for preventing or treating diseases induced by abnormal proliferation or accumulation of cells associated with S1P1, and (7) a pharmaceutical composition for preventing or treating cancer or leukemia.
  • Furthermore, the present invention relates to a method for preventing or treating diseases induced by undesirable lymphocyte infiltration associated with S1P1, particularly, rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation, or multiple sclerosis in humans or animals, which involves administering to a patient an effective amount of the 2H-chromene compound of the formula (I) or a derivative thereof or a salt thereof. Further, the present invention includes use of the 2H-chromene compound of the formula (I) or a derivative thereof or a salt thereof for prevention or treatment of diseases induced by undesirable lymphocyte infiltration associated with S1P1, particularly rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation, or multiple sclerosis in humans or animals, and the 2H-chromene compound of the formula (I) or a derivative thereof or a salt thereof to be used for prevention or treatment of diseases induced by undesirable lymphocyte infiltration associated with S1P1, particularly rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation, or multiple sclerosis in humans or animals.
    • Effects of the Invention
  • The compound of the formula (I) or a salt thereof of the present invention has an S1P1 agonist action and can be used for prevention or treatment of diseases induced by undesirable lymphocyte infiltration, for example, autoimmune diseases or inflammatory diseases such as rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, lung disorders, asthma, atopic dermatitis, inflammatory bowel disease, arteriosclerosis, ischemic reperfusion disorder, and diseases induced by abnormal proliferation or accumulation of cells, for example, cancer, leukemia, and the like.
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • Hereinbelow, the present invention will be explained in detail.
  • In the specification, the “halogen” means F, Cl, Br, or I. Preferably, examples thereof include F and Cl.
  • In the present specification, the “lower alkyl” is linear or branched alkyl having one to six carbon atoms (hereinafter simply referred to as C1-6), and examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, and the like, in another embodiment, C1-4 alkyl, and in a further embodiment, methyl, ethyl, and isopropyl.
  • The “lower alkenyl” is linear or branched C2-6 alkenyl, and examples thereof include vinyl, propenyl, butenyl, pentenyl, 1-methylvinyl, 1-methyl-2-propenyl, 1,3-butadienyl, 1,3-pentadienyl, and the like, and in another embodiment, C2-4 alkenyl.
  • The “lower alkylene” is linear or branched C1-6 alkylene and examples thereof include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, propylene, methylmethylene, ethylethylene, 1,2-dimethylethylene, 1,1,2,2-tetramethylethylene, and the like, in another embodiment, C1-4 alkylene, and in a further embodiment, methylene and ethylene.
  • The “lower alkenylene” is linear or branched C2-6 alkenylene and examples thereof include vinylene, ethylidene, propenylene, butenylene, pentenylene, hexenylene, 1,3-butadienylene, 1,3-pentadienylene, and the like, in another embodiment, C2-4 alkenylen, and in a further embodiment, vinylene and ethylidene.
  • The “lower alkynylene” is linear or branched C2-6 alkynylene and examples thereof include ethynylene, propynylene, butynylene, pentynylene, hexynylene, 1,3-butadiynylene, 1,3-pentadiynylene, and the like, in another embodiment, C2-4 alkynylene, and in a further embodiment, ethynylene, propynylene, butynylene, and pentynylene.
  • The “halogeno-lower alkyl” is C1-6 alkyl substituted with one or more halogen atoms, in another embodiment, lower alkyl substituted with one to five halogen atoms, in a further embodiment, C1-3 lower alkyl substituted with one to five halogen atoms, and in an even further embodiment, examples thereof include —CF3, —CH2CF3, —CH(CH3)CF3, and —CH(CH2F)2.
  • The “cycloalkyl” is a C3-10 saturated hydrocarbon ring group, which may have a bridge. Examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl, and the like, in another embodiment, C3-8 cycloalkyl, in a further embodiment, C3-6 cycloalkyl, and in an even further embodiment, cyclopropyl, cyclopentyl, and cyclohexyl.
  • The “aryl” is a C6-14 monocyclic to tricyclic aromatic hydrocarbon ring group, and examples thereof include phenyl and naphthyl, and in another embodiment, phenyl.
  • The “heteroaryl” is 5- to 6-membered monocyclic heteroaryl containing one to four hetero atoms selected from N, S, and O, and bicyclic heteroaryl formed by condensation thereof with a benzene ring or 5- to 6-membered monocyclic heteroaryl, and may be partially saturated. In another embodiment, examples thereof include pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, triazolyl, triazinyl, tetrazolyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thienyl, furyl, benzothiazolyl, and indolyl, in another embodiment, heteroaryl of a 5-membered ring, which may be condensed with a benzene ring, and in an even further embodiment, pyrrolyl, imidazolyl, thiazolyl, thienyl, benzothiazolyl, and indolyl.
  • The “nitrogen-containing monocyclic heteroaryl” means monocyclic heteroaryl, in which one of the ring-constituting atoms is necessarily N and may have one to two hetero atoms selected from N, S, and O as the ring-constituting atom, and in another embodiment, examples thereof include a 5- to 6-membered ring, in a further embodiment, pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, and the like, in an even further embodiment, 5-membered ring, and in an even further embodiment, pyrrolyl and imidazolyl.
  • The “cyclic amino” means monocyclic to tricyclic heterocycloalkyl, in which one of the ring-constituting atoms is necessarily N, may have one to two hetero atoms selected from N, S, and O as the ring-constituting atom, and may have a partially unsaturated bond. In another embodiment, it is a ring having a reduction number of 4 to 9, in a further embodiment, examples thereof include azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, homopiperidinyl, 3-azabicyclo[3.1.0]hexanyl, tetrahydropyridyl, octahydrocyclopenta[c]pyrrolyl, quinuclidinyl, and the like, in an even further embodiment, examples thereof include cyclic amino of a 6-membered ring, in an even further embodiment, examples thereof include piperidinyl, piperazinyl, morpholinyl, and tetrahydropyridyl, and in an even further embodiment, examples thereof include azetidinyl, pyrrolidinyl, piperidinyl, and tetrahydropyridyl.
  • In the present specification, the expression “which may be substituted with one to five R1s which are the same as or different from each other” means non-substitution or having one to five R1s as the substituents. Further, in the case where a plurality of R1s are present, the R1s may be the same as or different from each other.
  • Embodiments of the present invention will be described below.
  • (1) The 2H-chromene compound or a salt thereof, wherein Y is O, Q is —C(R2B)═C(R2C)—, and m is 0.
  • (2) The 2H-chromene compound or a salt thereof, wherein R4A and R4B are combined with N to which they bind to form cyclic amino selected from azetidinyl, pyrrolidinyl, piperidinyl, and tetrahydropyridyl, which is substituted with group(s) selected from Group G and may be substituted with lower alkyl or halogen.
  • (3) The 2H-chromene compound or a salt thereof, wherein the group represented by Group G is —C(═O)OH or —C(═O)NHS(═O)2CH3.
  • (4) The 2H-chromene compound or a salt thereof, wherein A is phenyl, pyridyl, or thienyl, which may be substituted with one to three R1s which may be the same as or different from each other.
  • (5) The 2H-chromene compound or a salt thereof, wherein L is -(lower alkylene)-O—, lower alkenylene, or lower alkynylene.
  • (6) The 2H-chromene compound or a salt thereof, wherein R2A is —H or lower alkyl, R2B is —H, R2C is —H or halogen, R3 is —H or halogen, R1 is halogen, lower alkyl, halogeno-lower alkyl, phenyl, pyrrolyl, cycloalkyl, —O-(lower alkyl), or —O-(halogeno-lower alkyl), and further, L is —CH2—O—, —CH═CH—, or 3-butynylene.
  • (7) The 2H-chromene compound or a salt thereof, wherein R4A and R4B are combined with N to which they bind to form piperidinyl or tetrahydropyridyl, which is substituted with —C(═O)OH, L is —CH2—O—, R2A is —H, R2B is —H, R2C is —H or halogen, R3 is —H, and A is phenyl or pyridyl, which is substituted with two R1s which are the same as or different from each other, in which R1 is halogen, halogeno-lower alkyl, —O-(lower alkyl), or —O-(halogeno-lower alkyl).
  • (8) The 2H-chromene compound or a salt thereof, wherein R4A and R4B are combined with N to which they bind to piperidinyl which is substituted with —C(═O)OH and A is phenyl which is substituted with two R1s which are the same as or different from each other.
  • (9) The 2H-chromene compound or a salt thereof, wherein R4A and R4B are combined with N to which they bind to form tetrahydropyridyl which is substituted with —C(═O)OH, A is pyridyl which is substituted with two R1s which are the same as or different from each other.
  • Examples of the specific compound included in the present invention include the following compounds or the salts thereof:
    • 1-{[7-({3-chloro-4-[(1S)-2,2,2-trifluoro-1-methylethoxy]benzyl}oxy)-2H-chromen-3-yl]methyl}-1,2,5,6-tetrahydropyridine-3-carboxylic acid,
    • 1-({7-[(3-chloro-4-isopropylbenzyl)oxy]-2H-chromen-3-yl}methyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid,
    • 1-[(7-[4-isopropoxy-3-(trifluoromethyl)benzyl]oxy}-2H-chromen-3-yl)methyl]-1,2,5,6-tetrahydropyridine-3-carboxylic acid,
    • 1-{[7-({3-chloro-4-[2-fluoro-1-(fluoromethyl)ethoxy]benzyl}oxy)-2H-chromen-3-yl]methyl}-1,2,3,6-tetrahydropyridine-4-carboxylic acid,
    • 1-{[7-(5-chloro-6-[(1S)-2,2,2-trifluoro-1-methylethoxy]pyridin-3-yl}methoxy)-2H-chromen-3-yl]methyl}-1,2,5,6-tetrahydropyridine-3-carboxylic acid,
    • (3R)-1-{[7-({4-[(1,3-difluoropropan-2-yl)oxy]-3-(trifluoromethyl)benzyl]oxy)-5-fluoro-2H-chromen-3-yl]methyl}piperidine-3-carboxylic acid,
    • 1-[(7-{[4-cyclopentyl-3-(trifluoromethyl)benzyl]oxy}-2H-chromen-3-yl)methyl]-1,2,5,6-tetrahydropyridine-3-carboxylic acid,
    • (3R)-1-{[7-({3-chloro-4-[(1,3-difluoropropan-2-yl)oxy]benzyl}oxy)-5-fluoro-2H-chromen-3-yl]methyl}piperidine-3-carboxylic acid,
    • (3S)-1-{[7-({4-[(1,3-difluoropropan-2-yl)oxy]-3-(trifluoromethyl)benzyl}oxy)-5-fluoro-2H-chromen-3-yl]methyl}piperidine-3-carboxylic acid,
    • (3R)-1-[(7-{[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)benzyl]oxy}-2H-chromen-3-yl)methyl]piperidine-3-carboxylic acid,
    • (3R)-1-[(7-[3-(trifluoromethyl)-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzyl]oxy}-2H-chromen-3-yl)methyl]piperidine-3-carboxylic acid,
    • (3S)-1-[(7-[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)benzyl]oxy}-5-fluoro-2H-chromen-3-yl)methyl]piperidine-3-carboxylic acid,
    • (3R)-1-{[7-({4-[(1,3-difluoropropan-2-yl)oxy]-3-(trifluoromethyl)benzyl}oxy)-5-fluoro-2H-chromen-3-yl]methyl}-N-(methylsulfonyl)piperidine-3-carboxamide, or
    • 1-[(7-{[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)benzyl]oxy}-2H-chromen-3-yl)methyl]piperidine-4-carboxylic acid.
  • The compound of the formula (I) may exist in the form of tautomers or geometrical isomers depending on the kind of the substituents. In the present specification, the compound of the formula (I) shall be described in only one form of isomer, yet the present invention includes other isomers, isolated forms of the isomers, or a mixture thereof.
  • In addition, the compound of the formula (I) may have asymmetric carbon atoms or axial chirality in some cases, and correspondingly, it may exist in the form of optical isomers. The present invention includes both an isolated form of the optical isomers of the compound of the formula (I) or a mixture thereof.
  • Moreover, the present invention also includes a pharmaceutically acceptable prodrug of the compound represented by the formula (I). The pharmaceutically acceptable prodrug is a compound having a group which can be converted into an amino group, a hydroxyl group, a carboxyl group, or the like through solvolysis or under physiological conditions. Examples of the group forming the prodrug include the groups described in Prog. Med., 5, 2157-2161 (1985) and Pharmaceutical Research and Development, Drug Design, Hirokawa Publishing Company (1990), Vol. 7, 163-198.
  • Furthermore, the salt of the compound of the formula (I) is a pharmaceutically acceptable salt of the compound of the formula (I) and may form an acid addition salt or a salt with a base depending on the kind of substituents. Specific examples thereof include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyltartaric acid, ditolyltartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid, and the like, and salts with inorganic bases such as sodium, potassium, magnesium, calcium, aluminum, and the like or organic bases such as methylamine, ethylamine, ethanolamine, lysine, ornithine, and the like, salts with various amino acids or amino acid derivatives such as acetylleucine and the like, ammonium salts, etc.
  • Moreover, the present invention also includes various hydrates or solvates, and polymorphic crystal substances of the compound of the formula (I) and a salt thereof. In addition, the present invention also includes compounds labeled with various radioactive or non-radioactive isotopes.
  • In the present specification, the following abbreviations may be used in some cases.
  • ADDP=1,1′-(azodicarbonyl)dipiperidine, AIBN=2,2′-azobisisobutyronitrile, AcOH=acetic acid, CDI=1,1′-carbonylbis-1H-imidazole, DAST=(diethylamino)sulfur trifluoride, DBU=1,8-diazabicyclo[5.4.0]undec-7-ene, DCC=dicyclohexylcarbodiimide, DCE=dichloroethane, DCM=dichloromethane, DIBAL=diisobutylaluminum hydride, DIBOC=di-tert-butyl dicarbonate, DIC=N,N′-diisopropylcarbodiimide, DIPEA=diisopropylethylamine, DMA=N,N′-dimethylacetamide, DMAP=4-(N,N′-dimethylamino)pyridine, DME=dimethoxyethane, DMF=N,N′-dimethylformamide, DMSO=dimethylsulfoxide, DPPA=diphenylphosphorylazide, DPPP=1,3-bis(diphenylphosphino)propane, EDCI.HCl=N-[3-(dimethylamino)propyl]-N′-ethylcarboxamide hydrochloride, Et=ethyl, Et2O=diethylether, TEA=triethylamine, EtOAc=ethyl acetate, EtOH=ethanol, HOBt=1-hydroxy-1H-benzotriazole, IPE=diisopropylether, t-BuOK=potassium tertiary butoxide, LAH=lithium aluminum hydride, MS4 Angstrom=molecular sieves 4 Angstrom, MeCN=acetonitrile, MeOH=methanol, MgSO4=anhydrous magnesium sulfate, NB S=N-bromosuccinimide, NCS=N-chlorosuccinimide, NMP=N-methylpyrrolidone, NT=not tested, Na2SO4=anhydrous sodium sulfate, NaBH(OAc)3=sodium triacetoxyborohydride, NaBH4=sodium borohydride, NaOEt=sodium ethoxide, NaOH=sodium hydroxide, NaOMe=sodium methoxide, TBP=tri-normal butylphosphine, PDC=pyridinium dichromate, POCl3=phosphorous oxychloride, PPh3=triphenylphosphine, Pd(OAc)2=palladium (II) acetate, Pd(PPh3)4=tetrakis(triphenylphosphine)palladium (0), TEA=triethylamine, TFA=trifluoroacetic acid, THF=tetrahydrofuran, TMEDA=N,N,N′N′-tetramethylethylenediamine, Tf=CF3S(═O)2—, brine=saturated brine, i-PrOH=2-propanol, n-BuLi=normal butyllithium, n-BuOH=normal butylalcohol, t-BuOH=tertiary butylalcohol, and tert=tertiary.
  • (Preparation Methods)
  • The compound of the formula (I) and a salt thereof can be prepared using the characteristics based on the basic structure or the type of substituents thereof and by applying various known synthesis methods. During the preparation, replacing the relevant functional group with a suitable protective group (a group that can be easily converted into the functional group) at the stage from starting material to an intermediate may be effective depending on the type of the functional group in production technology in some cases. The protective group for such a functional group may include, for example, the protective groups described in “Greene's Protective Groups in Organic Synthesis (4th Ed., 2006)” written by P. G. M. Wuts and T. W. Greene, and one of these may be selected and used as necessary depending on the reaction conditions. In this kind of method, a desired compound can be obtained by introducing the protective group, by carrying out the reaction and by eliminating the protective group, as necessary.
  • In addition, the prodrug of the compound of the formula (I) can be prepared by introducing a specific group or by carrying out the reaction using the obtained compound of the formula (I) at the stage from a starting material to an intermediate, just as in the case of the above-mentioned protective group. The reaction can be carried out using methods known to those skilled in the art, such as ordinary esterification, amidation, dehydration, and the like.
  • Hereinbelow, the representative preparation methods for the compound of the formula (I) will be described. Each of the production processes may also be carried out with reference to the References appended in the present description. Further, the preparation methods of the present invention are not limited to the examples as shown below.
  • <Production Process 1>
  • Figure US20120178735A1-20120712-C00006
  • The compound (I) of the present invention can be obtained by subjecting a compound (A) and a compound (B) to reductive amination.
  • The process in Step 1 is reductive amination. The compound (A) and the compound (B) are used in equivalent amounts or with either thereof in an excess amount, and the mixture is stirred under any condition from at −45° C. to under refluxing, particularly, from 0° C. to room temperature, usually for 0.1 hour to 5 days, in a vehicle which is inert to the reaction, in the presence of a reducing agent. Examples of the vehicle include alcohols such as MeOH, EtOH, and the like; ethers such as Et2O, THF, dioxane, DME, and the like; halogenated hydrocarbons such as DCM, DCE, chloroform, and the like; and a mixed vehicle thereof. Examples of the reducing agent include NaBH3CN, NaBH(OAc)3, NaBH4, and the like. It may be preferable in some cases to carry out the reaction in the presence of a dehydrating agent such as molecular sieves and the like, or an acid such as acetic acid, hydrochloric acid, a titanium (IV) isopropoxide complex, and the like. An imine that is a reaction intermediate may be isolated as a stable intermediate, and by reducing the imine intermediate, the compound (I) can be obtained. Further, the reaction can be carried out in a vehicle such as MeOH, EtOH, EtOAc, and the like in the presence or absence of an acid such as acetic acid, hydrochloric acid, and the like, using a reduction catalyst (for example, palladium on carbon, Raney nickel, and the like), instead of the reducing agent. In this case, the reaction is carried out under a hydrogen atmosphere from normal pressure to 50 atmospheres, under any temperature condition from cooling to heating.
    • [References] (1) “Comprehensive Organic Functional Group Transformations II” written by A. R. Katritzky and R. J. K. Taylor, Vol. 2, Elsevier Pergamon, 2005, (2) “Jikken Kagaku Koza (Courses in Experimental Chemistry) (5th Edition)” edited by The Chemical Society of Japan, Vol. 14 (2005) (Maruzen)
  • <Production Process 2>
  • Figure US20120178735A1-20120712-C00007
  • (wherein Hal represents halogen).
  • The compound (I) of the present invention can be obtained by alkylating the compound (C) with the compound (B).
  • The process in Step 2 is alkylation. The compound (B) and the compound (C) are used in equivalent amounts or with either thereof in an excess amount, and the mixture is stirred under any temperature condition from cooling to heating and refluxing, preferably from 0° C. to 80° C., usually for 0.1 hour to 5 days, in a vehicle which is inert to the reaction or without a vehicle. Examples of the vehicle include aromatic hydrocarbons; ethers; halogenated hydrocarbons; DMF, DMSO, EtOAc, and MeCN; and a mixed vehicle thereof. It may be advantageous in some cases for the smooth progress of the reaction to carry out the reaction in the presence of an organic base such as TEA, DIPEA, or N-methylmorpholine, and the like, or an inorganic base such as K2CO3, Na2CO3 or KOH, and the like. It may be advantageous in some cases for the smooth progress of the reaction to add an inorganic salt such as NaI and the like to a reaction system.
    • [Reference] “Jikken Kagaku Koza (Courses in Experimental Chemistry) (5th Edition)” edited by The Chemical Society of Japan, Vol. 14 (2005) (Maruzen)
  • <Intermediate Production Process 1>
  • Figure US20120178735A1-20120712-C00008
  • (wherein Tf represents CF3S(═O)2— and L1 represents lower alkylene or lower alkenylene).
  • The compound (A-1) can be prepared by a Sonogashira reaction from a compound (D).
  • The Step 3-1 is triflation. The compound (E) can be prepared by subjecting a compound (D) to undergo a reaction with trifluoromethanesulfonic anhydride. As the vehicle that usually does not disturb the reaction among the halogenated hydrocarbons, the reaction is carried out in the presence of organic bases such as pyridine, TEA, DIPEA, and the like under any temperature condition from −10° C. to ice-cooling. Further, the organic base may be used in combination with a vehicle.
  • Step 3-2 is a so-called Sonogashira reaction. The compound (A-1) can be prepared by adding a catalytic amount of a Pd(0) catalyst and a base to a compound (E) to allow terminal acetylene to undergo a reaction. It may be advantageous in some cases for the smooth progress of the reaction to add copper iodide to a reaction system. Examples of the vehicle include ethers; aromatic hydrocarbons such as toluene, xylene, and the like; DMF, DMSO, EtOAc; and a mixed vehicle thereof. For example, a base such as TEA, pyrrolidine, and the like may be used in combination with a vehicle. As for a reaction temperature, the reaction can be carried out under any temperature condition from room temperature to under reflux.
    • [Reference] K. Sonogashira, Tetrahedron Letters, 1975, 50, pp. 4467.
  • <Intermediate Production Process 2>
  • Figure US20120178735A1-20120712-C00009
  • The compound (A-2) can be prepared by reducing a compound (G) and dehydrating it, and formylating the obtained compound (J).
  • The Step 4-1 is a reduction reaction of a ketone. The compound (G) is treated with an equivalent amount or excess amount of a reducing agent under any temperature condition from cooling to heating, preferably from −20° C. to 80° C., usually for 0.1 hour to 3 days, in a vehicle which is inert to the reaction. Examples of the vehicle include ethers; alcohols; aromatic hydrocarbons; DMF, DMSO, EtOAc, and a mixed vehicle thereof. As the reducing agent, hydride reducing agents such as NaBH4, DIBAL, and the like, metal reducing agents such as sodium, zinc, iron, and the like, and further, the reducing agents in the following References are suitably used.
    • [References] (1) “Reductions in Organic Chemistry, 2nd ed. (ACS Monograph: 188)” written by M. Hudlicky, ACS, 1996, (2) “Comprehensive Organic Transformations” written by R. C. Larock, 2nd ed., VCH Publishers, Inc., 1999, (3) “Oxidation and Reduction in Organic Synthesis (Oxford Chemistry Primers 6)” written by T. J. Donohoe, Oxford Science Publications, 2000, (4) “Jikken Kagaku Koza (Courses in Experimental Chemistry) (5th Edition)” edited by The Chemical Society of Japan, Vol. 14 (2005) (Maruzen)
  • The Step 4-2 is a dehydration reaction. Usually, a starting material is stirred in concentrated sulfuric acid under a warming condition, and then distillation is continued until the eluent no longer exits.
  • The Step 4-3 is formylation. The compound (A-2) is obtained by the reaction of the compound (J) with a formamide derivative. Here, the formamide derivative means a formamide compound in which lower alkyls or aryls which are the same as or different from each other bind to nitrogen atoms of the formamide. For a Vilsmeier complex prepared by the reaction of the formamide derivative with POCl3, the aromatic ring is subjected to nucleophilic substitution to produce an ammonium salt. This can be hydrolyzed under a basic condition to obtain a formyl product. In this reaction, a compound (J) and a DMF equivalent are used in equivalent amounts or with either thereof in an excess amount, and the mixture is stirred in a vehicle which is inert to the reaction or without a vehicle, in the presence of a halogenating agent. This reaction is carried out under any temperature condition from room temperature to heating and refluxing, usually for 0.1 hour to 5 days. Examples of the vehicle include halogenated hydrocarbons; ethers; or MeCN. The halogenating agent is used so as to derive a DMF derivative into a Vielsmeier complex, and usually, it is not particularly limited as long as it is a reagent used for halogenations of alcohols, but phosphorous pentachloride, POCl3, or the like may be appropriately used.
    • [Reference] (1) “Strategic Applications of Named Reactions in Organic Synthesis” written by L. Kurti and B. Czako, Elsevier Inc, 2005, pp. 468-469
  • <Intermediate Production Process 3>
  • Figure US20120178735A1-20120712-C00010
  • (wherein Lv represents a leaving group).
  • The compound (A-3) is obtained by the reaction of a compound (K) with a compound (L).
  • The Step 5-1 is alkylation. Examples of the leaving group Lv include halogen, methanesulfonyloxy, p-toluenesulfonyloxy groups, and the like.
  • The compound (K) and the compound (L) are used in equivalent amounts or with either thereof in an excess amount, and the mixture is stirred in a vehicle which is inert to the reaction or without a vehicle, under any temperature condition from cooling to heating and refluxing, preferably from 0° C. to 80° C., usually for 0.1 hour to 5 days. Examples of the vehicle include aromatic hydrocarbons; ethers; halogenated hydrocarbons; DMF, DMSO, EtOAc, MeCN; and a mixed vehicle thereof. It may be advantageous in some cases for the smooth progress of the reaction to carry out the reaction in the presence of organic bases such as TEA, DIPEA, N-methylmorpholine, and the like, or inorganic bases such as K2CO3, Na2CO3, KOH, and the like. It may be advantageous in some cases for the smooth progress of the reaction to add inorganic salts such as NaI and the like to a reaction system.
    • [Reference] “Jikken Kagaku Koza (Courses in Experimental Chemistry) (5th Edition)” edited by The Chemical Society of Japan, Vol. 14 (2005) (Maruzen)
  • <Intermediate Production Process 4>
  • Figure US20120178735A1-20120712-C00011
  • The compound (C) can be obtained from the compound (A) via the compound (M).
  • The Step 6-1 is reduction. The compound (M) can be obtained by stirring the compound (A) with an equivalent amount or excess amount of a reducing agent in a vehicle which is inert to the reaction, under any temperature condition from cooling to heating, preferably from −20° C. to 80° C., usually for 0.1 hour to 3 days. Examples of the vehicle used are not particularly limited, but include ethers such as diethylether, THF, dioxane, and dimethoxyethane, alcohols such as MeOH, EtOH, 2-propanol, and the like, aromatic hydrocarbons such as benzene, toluene, xylene, and the like, DMF, DMSO, EtOAc, and a mixed vehicle thereof. As the reducing agent, hydride reducing agents such as NaBH4, DIBAL, and the like, metal reducing agents such as sodium, zinc, iron, and the like, and the reducing agents in the following References are suitably used.
    • REFERENCES
    • “Reductions in Organic Chemistry, 2nd ed. (ACS Monograph: 188)” written by M. Hudlicky, ACS, 1996
    • “Comprehensive Organic Transformations” written by R. C. Larock, 2nd ed., VCH Publishers, Inc., 1999
    • “Oxidation and Reduction in Organic Synthesis (Oxford Chemistry Primers 6)” written by T. J. Donohoe, Oxford Science Publications, 2000
    • “Jikken Kagaku Koza (Courses in Experimental Chemistry) (5th Edition)” edited by The Chemical Society of Japan, Vol. 14 (2005) (Maruzen)
  • The Step 6-2 is halogenation. The compound (C) can be obtained by subjecting the compound (M) to halogenation. As the halogenating agent, a halogenating agent for converting a hydroxyl group to halogen is used. The halogenating agent is not particularly limited, but, for example, PBr3, HBr, BBr3, PCl3, PCl5, or the like is used. As the vehicle, ethers are preferable, and for example, THF, diethylether, dimethoxyethane, methyl-t-butylether, dioxane, 2-methyltetrahydrofuran, or the like is used.
  • <Intermediate Production Process 5>
  • Figure US20120178735A1-20120712-C00012
  • (wherein X represents —O— or a bond, R represents a protecting group of a carboxylic group, R′ and R″ represent lower alkyl, n and p each represent an integer of 0 to 4, which are the same as or different from each other, and further, a sum of n and p represents 4 or less.
    Figure US20120178735A1-20120712-P00001
    represents a single bond or a double bond).
  • The compound (T) can be prepared by sequentially performing a Wittig reaction, reduction, oxidation, and construction of a chromene skeleton from the compound (N). The compound (T) in which
    Figure US20120178735A1-20120712-P00001
    is a single bond is obtained by carrying out a reduction reaction at a step which does not disturb the reaction.
  • The Step 7-1 is a phosphorus ylide-forming reaction. The compound (O) is obtained by reacting the compound (N) with, for example, triethyl phosphite or the like, usually in a vehicle which does not disturb the reaction. Examples of the vehicle include aromatic hydrocarbons; ethers; halogenated hydrocarbons; ketones such as acetone, ethylmethylketone, and the like; DMF, DMSO, EtOAc, MeCN; and a mixed vehicle thereof. As for a reaction temperature, the reaction can be carried out under any temperature condition from −20° C. to heating.
  • The Step 7-2 is a so-called Wittig reaction. The compound (O) can be reacted with an aldehyde compound (P) to prepare a compound (Q). By the aldehyde addition of phosphoryl group-substituting carbanions, olefins can be obtained through a Wittig-like mechanism. The reaction temperature is any of the conditions from 0° C. to warming.
    • [References] (1) J. Boutagy CRV, 79, 87, 1974, (2) W. S. Wadsworth Jr OR, 25, 73, 1977.
  • The Step 7-3 is a reduction reaction. As the reducing agent, LiAlH4, LiAlH(OMe)3, or DIBAL is used, and the reaction can be carried out in a vehicle which is inert to the reaction, such as THF, ethers, and the like, usually under any temperature condition from cooling to heating.
  • The Step 7-4 is an oxidation reaction. As the oxidizing agent, manganese dioxide or PDC is used. Examples of the vehicle usually include halogenated hydrocarbons and the like. As for the reaction temperature, the reaction is carried out under any temperature condition from 0° C. to heating, usually at room temperature. As other methods, there is a method using a DMSO-POCl3-based reagent. A method using a reagent such as DCC, acid anhydrides, chlorine, or Me2S—NCS-based reagents (Corey-Kim oxidation) or using a Dess-Martin Periodinane, instead of POCl3, can also be used. The reaction usually proceeds under any temperature condition from room temperature to warming. Examples of the vehicle are not particularly limited, but include aromatic hydrocarbons; ethers; halogenated hydrocarbons; MeCN, and a mixed vehicle thereof.
  • The Step 7-5 is a chromene ring-constituting reaction. The compound (T) can be prepared by adding an acrolein derivative to the compound (S), followed by stirring under any temperature condition from room temperature to heating in the presence of an inorganic base such as K2CO3 and the like. Examples of the vehicle include aromatic hydrocarbons; ethers; halogenated hydrocarbons; MeCN, and a mixed vehicle thereof. Usually, ether-based vehicles such as THF, DME, dioxane, and the like are used.
  • The compound in which
    Figure US20120178735A1-20120712-P00001
    of a compound (T) is a single bond is obtained by reducing some compounds among the compound (P) through the compound (S). This is a so-called reduction reaction of olefins. Usually, the compound is stirred in a vehicle which is inert to the reaction in the presence of a metal catalyst, usually for 1 hour to 5 days, under a hydrogen atmosphere. This reaction is usually carried out under any temperature condition from cooling to heating, preferably at room temperature. Examples of the vehicle are not particularly limited, but include alcohols such as MeOH, EtOH, i-PrOH, and the like; ethers; water, EtOAc, DMF, DMSO; and a mixed vehicle thereof. As the metal catalyst, palladium catalysts such as palladium on carbon, palladium black, palladium hydroxide, and the like, platinum catalysts such as a platinum plate, platinum oxide, and the like, nickel catalysts such as reduced nickel, Raney nickel, and the like, rhodium catalysts, iron catalysts such as reduced iron and the like, etc. are suitably used. Instead of hydrogen gas, formic acid or ammonium formate in an equivalent amount or in an excess amount can also be used as a hydrogen source for the compound.
    • [References] (1) “Reductions in Organic Chemistry, 2nd ed. (ACS Monograph: 188)” written by M. Hudlicky, ACS, 1996, (2) “Jikken Kagaku Koza (Courses in Experimental Chemistry) (5th Edition)” edited by The Chemical Society of Japan, Vol. 19 (2005) (Maruzen)
  • Furthermore, some compounds represented by the formula (I) can also be prepared by any combination of the steps that can usually be employed by a person skilled in the art, such as known alkylation, acylation, substitution reaction, oxidation, reduction, hydrolysis, deprotection, halogenation, and the like, from the compound of the present invention prepared as above.
  • For example, for alkylation, an alkylation reaction that is usually used by a person skilled in the art can be employed, and the alkylation can be carried out in an organic vehicle which is inert to the reaction, such as ethers; aromatic hydrocarbons; halogenated hydrocarbons; DMF, MeCN; aprotic polar vehicles, and the like, under cooling, from under cooling to room temperature, or from at room temperature to under heating, in the presence of bases such as NaH; carbonic acid alkali; hydrogen carbonate alkali; alkoxide; tertiary amine; organic bases, and the like.
  • Further, for example, acylation can employ an acylation reaction that is usually used by a person skilled in the art can be employed, but the acylation is carried out in an organic vehicle which is inert to the reaction, such as ethers; aromatic hydrocarbons; halogenated hydrocarbons; esters such as EtOAc, and the like; MeCN; aprotic vehicles, and the like, using a condensing agent such as EDCI.HCl, CDI, diphenylphosphorylanide, and the like, depending on the reaction condition, but usually under cooling, under any temperature condition from cooling to room temperature, or under any temperature condition room temperature to heating, particularly in the presence of HOBt.
  • The compounds of the formula (I) can be isolated and purified as their free compounds, salts, hydrates, solvates, or polymorphic crystal substances thereof. The salts of the compound of the formula (I) can be prepared by carrying out a conventional salt-forming reaction.
  • Isolation and purification are carried out by employing ordinary chemical operations such as extraction, fractional crystallization, various types of fractional chromatography, and the like.
  • Various isomers can be prepared by selecting an appropriate starting compound or separated by using the difference in the physicochemical properties between the isomers. For example, the optical isomers can be obtained by means of a general method for designing optical resolution of racemic products (for example, fractional crystallization for inducing diastereomer salts with optically active bases or acids, chromatography using a chiral column or the like, and others), and further, the isomers can also be prepared from an appropriate optically active starting compound.
  • The pharmacological activity of the compound of the formula (I) was confirmed by the tests shown below.
    • Test Example 1 Evaluation of In Vitro S1P1 Receptor Agonist Activity in Biological Body
  • (Method 1) Method for Evaluation on Receptor Agonist Action by GTP[γ-35S] Binding Assay Using Membrane of Human S1P1 Expressing Cell
  • The in vitro S1P1 agonist action of the compound of the present invention was evaluated by the increase in the functional binding activity of GTP[γ-35S] to G-protein using the membrane of a human S1P1 expressing cell. A cDNA encoding a human S1P1 was cloned from a human colorectal cDNA library and introduced to an expression vector pcDNA3.1 to construct a S1P1-pcDNA3.1. Then, by Lipofectamine 2000 (GIBCO), the S1P1-pcDNA3.1 was transfected into a CHO cell, and cultured in a Ham's F-12 culture medium containing 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 1 mg/mL G418 disulfate, to obtain a stable, G418-resistant strain. The cultured human S1P1 expressing cells were isolated in a 1 mM EDTA.2Na-containing PBS, and disrupted under ice-cooling by a homogenizer made of glass in a 1 mM Tris HCl (pH 7.4) buffer solution containing 0.1 mM EDTA and a protein inhibitor. It was centrifuged at 1,400×10 min, and a supernatant was further centrifuged at 4° C. for 60 min at 100,000×g, and suspended in a 10 mM Tris HCl (pH 7.4) buffer solution containing 1 mM EDTA to purify the membrane. The obtained membrane (0.13 mg/mL) and 50 pM GTP[γ-35S] (NEN; inactive 1250 Ci/mmol) were reacted in a 20 mM HEPES (pH 7.0) buffer solution (total amount: 150 μL) containing 100 mM NaCl, 10 mM MgCl2, 0.1% fatty acid-free BSA, and 5 μM GDP for 1 hour together with the compound of the present invention (10−12 to 10−5 M), and then a membrane was recovered on a GF-C filter plate with a Cell Harvester (Packard, FilterMate). The filter plate was dried at 50° C. for 60 min, and Microscinti-o (Packard) was added thereto for measurement by a liquids scintillation counter for a microplate (Packard, TOP count). For evaluation of the human S1P1 agonist action of the compound of the present invention and the comparative compound, the percentages with the rate of a maximum reaction to make the GTP[γ-35S] bonds saturated in the presence of the compound being set at 100%, and the rate of the reaction of the GTP[γ-35S] bonds in the absence of the compound being set at 0% were used, a non-linear regression curve was plotted, and a concentration to cause an agonist action operating 50% of the maximum reaction was defined as an EC50 value (nM).
  • (Method 2) Method for Evaluation of Receptor Agonist Action by Ca2+ Influx Assay Using Human S1P1 Expressing Cell
  • The in vitro S1P1 agonist action of the compound of the present invention was evaluated by the increase in the Ca2+ concentration in a human S1P1 expressing cell. A cDNA encoding a human S1P1 was cloned from a human colorectal cDNA library and introduced to an expression vector pcDNA3.1 to construct a S1P1-pcDNA3.1. Then, by Lipofectamine 2000 (GIBCO), the S1P1-pcDNA3.1 was transfected into a CHO cell, and cultured in a Ham's F-12 culture medium containing 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 1 mg/mL G418 disulfate, to obtain a stable, G418-resistant strain. The cultured human S1P1 expressing cells were isolated in a 1 mM EDTA.2Na-containing PBS and suspended in a Ham's F-12 culture medium containing 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. This cell suspension was dispensed to a 96-well plate at 50000 cells/well, and cultured at a CO2 incubator (5% CO2, 37° C.) overnight. The culture medium was replaced with a calcium-sensitive fluorescent reagent (FLIPR (registered trademark) calcium 3 assay kit, molecular device)-containing loading buffer (Hank's balance salt solution, 20 mM HEPES, 2.5 mM probenecid) and left stand at a CO2 incubator (5% CO2, 37° C.) for 1 hour. The plate was set at a Functional Drug Screening System FDSS6000 (Hamamatsu Photonics K. K.), and persistently measured 124 times every 1.02 second at an excitation wavelength of 480 nm. The test compound (final concentration 1042 to 10−5 M) was added at the same time as the 12th measurement, and the change in the Ca2+concentration in cells was evaluated by the change in the fluorescent strength. For evaluation of the human S1P1 agonist action of the compound of the present invention and the comparative compound, the percentages with the rate of a maximum reaction to make the increase in the Ca2+ concentration in cells saturated after the addition of the compound being set at 100% and the rate of the increase in the Ca2+ concentration in cells by the addition of a vehicle alone being set at 0% were used, a non-linear regression curve was plotted, and a concentration to cause an agonist action operating 50% of the maximum reaction was defined as an EC50 value (nM).
    • Test Example 2 Evaluation of Reduction of Number of Peripheral Blood Lymphocytes in Rat
  • The action on the peripheral blood lymphocytes were evaluated using rats. 6-to 10-week-old male Lewis rats (Japan Charles River Laboratories Japan, Inc.) were randomly divided into groups (n=3), and the compound of the present invention was suspended in 0.5% methyl cellulose-containing distilled water, and orally administered with a sonde. At 4 hours or 24 hours after administration, 0.2 ml of blood was collected from the ocular fundus under ether anesthesia. To the blood sample were immediately added EDTA.4K and heparin to prevent clotting, and the number of the lymphocytes in blood was measured with an automatic hematocyte analyzer (Sysmex Corp.; XT-2000i). For the reduction of the number of the lymphocytes in peripheral blood by the compound of the present invention, the percentage with the number of the lymphocytes in groups administered with 0.5% methyl cellulose-containing distilled water being set at 100%, as performed at the same time, were used, and the dose to cause 50% reduction of the number of the lymphocytes in the peripheral blood by administration of the compound of the present invention was defined as an ED50 value (mg/kg).
  • The results of Test Example 1 and Test Example 2 on some compounds of the formula (I) are shown in Tables 1 and 2. In the tables, Column A shows in vitro S1P1 agonist action, EC50 values (nM) by the method 1 of Test Example 1 provided that the value with * shows the EC50 values measured by the method 2. Further, Column B shows the action of reducing the number of the lymphocytes in the peripheral blood at 4 hours or 24 hours after administration of the drug of Test Example 2 with ED504 h (mg/kg) or ED5024 h (mg/kg), respectively.
  • As shown in Table 1 and 2, it was confirmed that the compound of the formula (I) of the present invention has an excellent S1P1 agonist action and has a potent action of reducing the number of the lymphocytes in the peripheral blood even at 4 hours or 24 hours after administration in the pharmacological test using rats.
  • TABLE 1
    A: EC50 B: ED504 h
    No (nM) (mg/kg)
    Ex1 1.7 0.016
    Ex25 1.7 0.013
    Ex31 1.2 0.065
    Ex34 2 0.010
    Ex43 6.2 0.26
    Ex44 3.7 0.37
    Ex45 1.5 0.10
    Ex56 2.3 0.067
    Ex62 2.5 0.21
    Ex66 10 0.21
    Ex69 6.3 0.087
    Ex74 5.6 0.59
    Ex81 4.6 0.25
    Ex85 11 0.19
    Ex89 6.1 0.16
    Ex109 5.4 0.26
    Ex116 8.5 0.10
    Ex132 22 0.16
    Ex137 9.4 0.11
    Ex141 5.9 0.099
    Ex143 NT 0.32
    Ex144 NT 0.16
  • TABLE 2
    A: EC50 B: ED5024 h
    No (nM) (mg/kg)
    Ex149 8.7  0.12
    Ex151 1.1* 0.35
    Ex152 6.3* 0.28
    Ex156 16*   0.086
    Ex160 2.2* 0.26
    Ex171 9.0* 0.14
    Ex178 55    0.12
    Ex181  0.68* 0.29
    Ex183 5.5* 0.21
    Ex212 1.1* 0.21
    Ex216 7.8* 0.25
    Ex223 1.1* 0.32
    Ex230 7.0* 0.19
    Ex236 32*   0.10
    • Test Example 3 Evaluation of Increase in Lung Weight in Rats
  • The increased lung weight in rats, one of the undesirable effects observed for conventional S1P1 agonists, was evaluated. 6- to 10-week-old male Lewis or SD rats (Japan Charles River Laboratories Japan, Inc.) were randomly divided into groups (n=3 to 4), and the compound of the present invention was suspended in 0.5% methyl cellulose-containing distilled water, and orally administered with a sonde. For single-time administration, at 24 hours after administration, the weight of the rat was measured, the blood was removed under anesthesia with pentobarbital, and the lung was taken out and its weight was measured. For repeated administration, the administration was made once a day for 7 days, and at 24 hours after the final administration, the weight and the lung weight were measured. For the increased lung weight, the increase rate of the average of the relative weights of the group administered with a suspension of the compound of the present invention in 0.5% methyl cellulose-containing distilled water to the average of the relative weights of the group administered with 0.5% methyl cellulose-containing distilled water was denoted as a percentage and the administration amount showing 10% or more of the increased lung weight was determined as positive.
  • It was confirmed that among the compounds of the present invention, the compounds of Examples 31, 43, 44, 45, 56, 62, 66, 69, 74, 81, 85, 89, 109, 116, 137, 143, 149, 151, 152, 160, 171, 178, 181, 183, 212, 216, 223, 230, and 236 had an increased lung weight of less than 10% even at a dose of 1 mg/kg and a weak action on the lung.
    • Test Example 4 Evaluation of Rejection Inhibiting Action in Heterotopic Rat Abdominal Heart Transplant
  • A heterotopic rat abdominal heart transplant model can be carried out in accordance with the method of Ono and Lindsey (Transplantation, 1969, 517, pp. 225-229). As a donor, 6- to 8-week male ACI rats (CLEA Japan, Inc.) were employed, and the hearts were exposed under anesthesia with pentobarbital. The left and right vena cava other than aorta and pulmonary artery, pulmonary veins, and inferior vena cava were ligated at once and the aorta and the pulmonary vein were detached and removed as a graft. 6- to 8-week male Lewis rats (Japan Charles River Laboratories Japan, Inc.) were used as recipients. Under anesthesia with pentobarbital, the pulmonary artery end of the graft and the abdominal aorta of the recipient were anastomosed and the pulmonary artery end of the graft and the vena cava of the recipient were anastomosed to prepare a model (grouped into 6 to 10 examples per group). The rejection determination of the transplanted heart promotes the recipient's abdominal palpation every 29 days after transplantation, and the presence or absence of the beating of the graft is determined on the rejection. The compound of the present invention is suspended in 0.5% methylcellulose-containing distilled water and orally administered once or twice a day for 14 days from the date of the transplant. As a control, 0.5% methylcellulose-containing distilled water is orally administered the same number of times during the same period. Simultaneously, 0.02 mg/mL/kg of tacrolimus are administered intramuscularly to all of the groups. By this test, the rejection inhibiting action of the compound of the present invention when tacrolimus is used in combination can be determined.
    • Test Example 5 Evaluation of Infrequent Pulse Expression Using Awake Rats
  • Male Lewis rats were anesthetized with isoflurane inhalation and a polyethylene tube was intubated into the femoral artery and vein. It was connected to a blood pressure measuring amplifier·heart rate unit via a pressure transducer from an arterial line, and the arterial blood pressure and the heart rate were measured. Intravenous line from Vehicle (10% HCO40/tween80/PEG, 90% saline) and the present compounds were intravenously infused persistently at a rate of 1 mL/kg/min for 10 minutes. The measurement data were read (for a total evaluation time of 20 minutes) from a chart of the values before administration, at 1, 2, 5, and 10 min after the start of constant infusion, and at 1, 2, 5, and 10 min after the completion of infusion, and thus, for the heart rate and the blood pressure before administration, the decrease rates (%) before and after infusion were calculated.
  • It was confirmed that among the compounds of the present invention, for example, the compound of Example 230 does not have an influence on the heart rate and the blood pressure at 1 mg/kg administration by the present evaluation, and the infrequent pulse is not expressed.
  • As the results of the tests above, it was confirmed that the compound of the formula (I) of the present invention has an excellent S1P1 agonist action and has a lymphocytic infiltration inhibiting action. Further, as shown in Test Examples 3 and 4 above, Example compounds of some embodiments of the present invention can be an S1P1 agonist action, which has weak undesirable actions in which the undesirable actions are observed in conventional S1P1 agonists, such as increased lung weight, infrequent pulse, and the like and small side-effects.
  • Accordingly, the compound of the formula (I) of the present invention is useful for preventing or treating diseases induced by undesirable lymphocyte infiltration, for example, rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation, autoimmune diseases or inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, lung disorders, asthma, atopic dermatitis, inflammatory bowel disease, arteriosclerosis, ischemic reperfusion disorder, and the like, and diseases induced by abnormal proliferation or accumulation of cells, for example, cancer, leukemia, and the like, particularly for preventing or treating rejection or graft-versus-host diseases during organs, bone marrow, or tissue transplantation, and multiple sclerosis.
  • In addition, the compound of the present invention can be administered as an S1P1 agonist alone, or in combination with at least one agent, in the same or different doses, through the same or different administration routes. Examples of the agent that can be combined include, but are not limited thereto, cyclosporin A, tacrolimus, sirolimus, everolimus, mycophenolate, azathioprine, brequinar, Leflunomide, fingolimod, an anti-IL-2 receptor antibody (for example, daclizumab and the like), an anti-CD3 antibody (for example, OKT3), anti-T cell immunoglobulin (for example, AtGam and the like), belatacept, abatacept, cyclophosphamide, n-interferon, aspirin, acetaminophen, ibuprofen, naproxen, piroxicam, anti-inflammatory steroid (for example, prednisolone, and dexamethasone), and the like.
  • A pharmaceutical composition containing one or two or more kinds of the compound of the formula (I) or a salt thereof as an active ingredient can be prepared using excipients that are usually used in the art, that is, excipients for pharmaceutical preparations, carriers for pharmaceutical preparations, and the like, according to the methods usually used.
  • Administration can be accomplished either by oral administration via tablets, pills, capsules, granules, powders, solutions, and the like, or parenteral administration injections, such as intraarticular, intravenous, or intramuscular injections, and the like, suppositories, ophthalmic solutions, eye ointments, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalations, and the like.
  • The solid composition for oral administration is used in the form of tablets, powders, granules, or the like. In such a solid composition, one or more active ingredient(s) are mixed with at least one inactive excipient, for example, lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinyl pyrrolidone, magnesium aluminometasilicate, and/or the like. According to a usual method, the composition may contain inactive additives, including lubricants such as magnesium stearate like, disintegrating agents such as carboxymethyl starch sodium, stabilizing agents, and solubilization assisting agents. If necessary, tablets or pills may be coated with sugar or a film of a gastric or enteric coating substance.
  • The liquid composition for oral administration contains pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, or the like, and also contains generally used inert diluents, for example, purified water or ethanol. In addition to the inert diluent, the liquid composition may also contain auxiliary agents, such as a solubilization assisting agent, a moistening agent, and a suspending agent, as well as sweeteners, flavors, aromatics, and antiseptics.
  • The injections for parenteral administration include sterile, aqueous or non-aqueous solutions, suspensions, or emulsions. As the aqueous solvent, for example, distilled water for injection or physiological saline is included. Examples of the non-aqueous solvent include propylene glycol, polyethylene glycol, vegetable oils such as olive oil and the like, alcohols such as ethanol and the like, polysorbate 80 (pharmacopeia), etc. Such a composition may further contain a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizer, or a solubilizing aid. These are sterilized, for example, by filtration through a bacteria-retaining filter, blending with bactericides, or irradiation. In addition, these can also be used by producing a sterile solid composition, and dissolving or suspending it in sterile water or a sterile vehicle for injection prior to its use.
  • Examples of the formulation for external use include ointments, plasters, creams, jellies, patches, sprays, lotions, eye-drops, eye ointments, and the like. The drug contains generally used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, or the like. Examples of the ointment bases or lotion bases include polyethylene glycol, propylene glycol, white vaseline, bleached beeswax, polyoxyethylene hydrogenated castor oil, glyceryl monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, sorbitan sesquioleate, and the like.
  • Regarding a transmucosal agent such as an inhalation, a transnasal agent, and the like, the transmucosal agents in a solid, liquid or semi-solid state are used, and can be prepared in accordance with a conventionally known method. For example, a known excipient, as well as a pH adjusting agent, an antiseptic, a surfactant, a lubricant, a stabilizer, a thickener, or the like may be appropriately added thereto. For their administration, an appropriate device for inhalation or insufflation may be used. For example, a compound may be administered alone or as a powder of formulated mixture, or as a solution or suspension by combining it with a pharmaceutically acceptable carrier, using a conventionally known device or sprayer, such as a measured administration inhalation device and the like. The dry powder inhaler or the like may be for single or multiple administration use, and a dry powder or a powder-containing capsule may be used. Alternatively, this may be in a form of a pressurized aerosol spray which uses an appropriate ejection agent, for example, chlorofluoroalkane, hydrofluoroalkane, or a suitable gas such as carbon dioxide and the like.
  • Usually, in the case of oral administration, the daily dose is suitably from 0.001 to 100 mg/kg per body weight, preferably from 0.1 to 30 mg/kg, and more preferably from 0.1 to 10 mg/kg, and this is administered in one portion or dividing it into 2 to 4 portions. In the case of intravenous administration, the daily dose is suitably from about 0.0001 to 10 mg/kg per body weight, and this is administered once a day or two or more times a day. In addition, a transmucosal agent is administered at a dose from about 0.001 to 100 mg/kg per body weight, and this is administered once a day or two or more times a day. The dose is appropriately decided in response to an individual case by taking the symptoms, the age, the gender, and the like into consideration.
  • The compound of the formula (I) can be used in combination with various agents for treating or preventing the diseases, in which the compound of the formula (I) as described above is considered effective. The combined preparation may be administered simultaneously or separately and persistently or at a desired time interval. The preparations to be administered simultaneously may be a blend or may be prepared individually.
    • EXAMPLES
  • Furthermore, the following abbreviations may be used in some cases in the Examples, Preparation Examples, and Tables described later.
  • Pr=Preparation Example No., Ex=Example No., RefEx=Reference Example No., Str=Structural Formula, MS=Mass Spectrometric Data, ESI (EI)=Electrospray Ionization Anaylsis Data, FAB=Mass Spectrometric Data according to Fast Atom Bombardment Ionization, Hz=Hertz, CDCl3=deuterated chloroform, DMSO-d6=dimethylsulfoxide d6.
  • Further, the crossed double bonds in the structural formula mean a mixture of a cis-form and a trans-form. In the 1H-NMR data, tetramethylsilane is used as an internal standard unless otherwise specifically described, and δ (ppm) (integrated value, disintegrated pattern) of signals in 1H-NMR in which DMSO-d6 is used as a measurement vehicle. In the present specification, NMR represents 1H-NMR: Proton
  • Nuclear Magnetic Resonance. Further, the suffixes + and − of MS and ESI (EI) each represents positive mass data and negative mass data.
    • Preparation Example 1
  • 7-[(5-Bromo-4-phenyl-2-thienyl)methoxy]-2H-chromene-3-carbaldehyde (120 mg) was dissolved in DMF (2.4 mL). To this reaction liquid were added Zn(CN)2 (65 mL) and Pd(PPh3)4 (65 mg) at room temperature. The reaction mixture was stirred at 100° C. for 5 hours and then poured into 1:1 a mixed vehicle of aqueous NaHCO3 and EtOAc, followed by stirring for 1 hour. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure, followed by purification by silica gel column chromatography (hexane:EtOAc=100:0 to 70:30) to obtain 5-{[(3-formyl-2H-chromen-7-yl)oxy]methyl}-3-phenylthiophene-2-carbonitrile (83 mg) as a pale yellow solid.
    • Preparation Example 2
  • To a solution of methyl 5-bromo-4-phenylthiophene-2-carboxylate in dioxane were added 2-isopropenyl-4,4,5,5-tetramethyl 1,3,2-dioxaborolane and a 2 M aqueous Na2CO3 solution. To the reaction mixture were added palladium acetate and PPh3, followed by stirring at 100° C. for 5 hours. After leaving to be cooled, a saturated aqueous NH4Cl solution was added thereto, followed by extraction with EtOAc. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure, followed by purification by silica gel column chromatography (hexane:EtOAc=95:5 to 80:20) to obtain methyl 5-isopropenyl-4-phenylthiophene-2-carboxylate as a colorless liquid.
  • In the same manner as in Preparation Example 2, the compounds of Preparation Example 2-1 through Preparation Example 2-4 shown in Tables described later were prepared.
    • Preparation Example 3
  • To a solution of DMF (2.5 mL) in DCM (3 mL) was added dropwise POCl3 (2 mL) at 0° C., followed by stirring at room temperature for 30 minutes. Subsequently, to the reaction liquid were added dropwise 8-(benzyloxy-3,4-dihydro-1-benzoxepin-5(2H)-one in DCM (4 mL), followed by stirring at room temperature for 1 hour and at 50° C. for 3 hours. To the reaction liquid was added water, followed by extraction with EtOAc twice. The organic layer was combined, washed with water and brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device; hexane:EtOAc=97:3 to 90:10) to obtain 8-(benzyloxy)-5-chloro-2,3-dihydro-1-benzoxepin-4-carbaldehyde (445 mg).
    • Preparation Example 4
  • To a solution of DMF (2 mL) in DCM (7.5 mL) was added dropwise POCl3 (1.39 mL) at 0° C., followed by stirring at room temperature for 30 minutes. Subsequently, to the reaction liquid was added dropwise a solution of 7-{[tert-butyl(diphenyl)silyl]oxy}-2,3-dihydro-4H-chromen-4-one (2.00 g) in DCM (11 mL), followed by stirring at room temperature for 1 hour and at 50° C. for 3 hours. To the reaction liquid was added water, followed by extraction with EtOAc twice. The organic layer was combined, washed with water and brine, and dried over MgSO4, and the liquid was concentrated. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 80:20) to obtain 4-chloro-7-hydroxy-2H-chromene-3-carbaldehyde (720 mg).
    • Preparation Example 5
  • 7-(benzyloxy)-2,3-dihydro-4H-chromen-4-one was dissolved in THF, a solution (0.97 M, 5 mL) of methylmagnesium bromide in THF was added dropwise thereto at 0° C., followed by stirring at room temperature for 1 hour, and a solution (0.97 M, 5 mL) of methylmagnesium bromide in THF was added dropwise thereto, followed by stirring at room temperature for 2 hours. To the reaction liquid was added a saturated aqueous NH4Cl solution and subsequently 2 M hydrochloric acid (20 mL), followed by stirring at room temperature for 2 hours and then extracting with EtOAc three times. The organic layer was combined, washed with water and brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=95:5 to 90:10) to obtain 7-(benzyloxy)-4-methyl 2H-chromene (445 mg) as a colorless transparent liquid.
  • In the same manner as in Preparation Example 5, the compound of Preparation Example 5-1 shown in Tables described later was prepared.
    • Preparation Example 6
  • To a solution of 2-hydroxy-4-[(2-methoxy-4-propylphenoxy)methyl]benzaldehyde (120 mg) in dioxane (2.4 mL) were added K2CO3 (55.2 mg) and acrolein (0.267 mL) at 25° C. The reaction mixture was warmed to 100° C., followed by stirring at 100° C. for 15 hours. The reaction mixture was left to be cooled to 25° C., and then filtered through celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 80:20) to obtain 7-[(2-methoxy-4-propylphenoxy)methyl]-2H-chromene-3-carbaldehyde (104.2 mg) as a colorless liquid.
  • In the same manner as in Preparation Example 6, the compounds of Preparation Example 6-1 through Preparation Example 6-9 and Preparation Example 6-11 shown in Tables described later were prepared.
    • Preparation Example 6-10
  • K2CO3 (835 mg) was suspended in dioxane (40 mL), and 2-hydroxy-4-(methoxymethoxy)benzaldehyde (1 g) and 3-methyl 2-butanal (0.787 mL) were added thereto, followed by stirring at 110° C. overnight. EtOAc was added thereto, the insoluble materials were removed by filtration through celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=95:5 to 70:30) to obtain 7-(methoxymethoxy)-2,2-dimethyl-2H-chromene-3-carbaldehyde (320 mg) as a yellow oil.
    • Preparation Example 7
  • At 0° C., to a mixed vehicle of concentrated HCl (8 mL) and AcOH (1.6 mL) was added tert-butyl 3-cyano-3-(fluoromethyl)azetidine-1-carboxylate (800 mg). The liquid was warmed to 25° C., followed by stirring at 25° C. for 1 hour and then at 100° C. for 5 hours. The reaction liquid was concentrated under reduced pressure, followed by azeotroping with toluene (30 mL) three times. The residue was dissolved in a mixed vehicle of acetone (4.8 mL) and water (8.0 mL), and at 0° C., Na2CO3 (593.7 mg) and DIBOC (1223 mg) were added thereto. The reaction liquid was warmed to 25° C., followed by stirring at 25° C. for 15 hours. Fifteen hours later, the reaction solution was concentrated and acetone was evaporated. The residue was extracted three times (50 mL×3) by the addition of ether (50 mL). The aqueous layer was combined and cooled to 0° C., and at 0° C., 2 M HCl (10 mL) was added thereto to prepare a solution at pH=2 to 3. The precipitated white solid was collected by filtration and washed with hexane (50 mL) to obtain 1-(tert-butoxycarbonyl)-3-(fluoromethyl)azetidine 3-carboxylic acid (801.2 mg) as a white solid.
    • Preparation Example 8
  • tert-Butyl 3-cyano-3-(hydroxymethyl)azetidine-1-carboxylate (5.0 g) was dissolved in DCM (100 mL). At 0° C., DAST (3.74 mL) was added thereto, followed by stirring at 0° C. for 3 hours. Three hours later, to the reaction liquid was added an aqueous NaHCO3 solution (100 mL), followed by extraction with DCM (50 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 50:50) to obtain tert-butyl 3-cyano-3-(fluoromethyl)azetidine-1-carboxylate (1.24 g) as a brown solid.
    • Preparation Example 9
  • 2-Fluoro-4,6-dihydroxybenzaldehyde (12 g) was dissolved in MeCN (250 mL), and cesium carbonate (25.1 g) and chloromethylmethylether (6.95 mL) were added thereto, followed by stirring at room temperature for 1 hour. The insoluble materials were removed by filtration through celite and the filtrate was concentrated. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 94:6) to obtain 2-fluoro-6-hydroxy-4-(methoxymethoxy)benzaldehyde (11.89 g) as a white powder.
  • In the same manner as in Preparation Example 9, the compounds of Preparation Example 9-1 through Preparation Example 9-4 shown in Tables described later were prepared.
    • Preparation Example 10
  • 7-Hydroxy-2,3-dihydro-4H-chromen-4-one (900 mg) was dissolved in DMF (10 mL), and tert-butyl(chloro)diphenylsilane (1.711 mL) and 1H-imidazole (448 mg) were added thereto, followed by stirring at room temperature overnight. To the reaction liquid was added water, followed by extraction with EtOAc three times. The organic layer was combined, washed with water and brine in this order, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=90:10 to 80:20) to obtain 7-{[tert-butyl(diphenyl)silyl]oxy}-2,3-dihydro-4H-chromen-4-one (2.08 g) as a colorless transparent syrup.
  • In the same manner as in Preparation Example 10, the compound of Preparation Example 10-1 shown in Tables described later was prepared.
    • Preparation Example 11
  • To a solution of 7-hydroxy-2H-chromene-3-carbaldehyde in DCM was added pyridine at 0° C. To the reaction liquid was added dropwise trifluoromethanesulfonic anhydride at 0° C. After stirring at room temperature for 1 hour, water was added thereto at 0° C. The mixture was extracted with EtOAc. The organic layer was washed with 1 M HCl, water, and brine in this order, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:EtOAc=95:5 to 80:20) to obtain 3-formyl-2H-chromen-7-yl trifluoromethanesulfonate as a yellow oily substance.
  • In the same manner as in Preparation Example 11, the compound of Preparation Example 11-1 shown in Tables described later was prepared.
    • Preparation Example 12
  • To DMF (1 mL) was added dropwise POCl3 (0.25 mL) at 0° C., followed by stirring at room temperature for 30 minutes. To the reaction mixture was added dropwise a solution of 7-(benzyloxy)-4-methyl 2H-chromene (280 mg) in DCM (1 mL), followed by stirring at room temperature for 3 hours. The reaction liquid was poured into ice-water, followed by extraction with EtOAc three times. The organic layer was combined, washed with water and brine in this order, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=85:15 to 70:30) to obtain 7-(benzyloxy)-4-methyl-2H-chromene-3-carbaldehyde (234 mg) as a pale yellow powder.
  • In the same manner as in Preparation Example 12, the compound of Preparation Example 12-4 was prepared from the compound of Preparation Example 12-1 shown in Tables described later.
    • Preparation Example 13
  • A solution of NaH (105.63 mg) in DMF (5.5 mL) was cooled to 0° C., and methyl 2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(diethoxyphosphoryl)methyl]benzoate (550 mg) was added thereto. The reaction mixture was warmed to 25° C., then stirred for 1 hour, and cooled to 0° C. again, and 2-methoxy-4-propylbenzaldehyde (235.34 mg) was added thereto. The reaction mixture was warmed to 25° C. and then stirred for 15 hours. To the reaction liquid was added a saturated aqueous NH4Cl solution (50 mL), followed by extraction with EtOAc (50 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 70:30) to obtain methyl 2-hydroxy-4-[(E)-2-(2-methoxy-4-propylphenyl)vinyl]benzoate (304.2 mg) as a white solid.
  • In the same manner as in Preparation Example 13, the compound of Preparation Example 13-1 shown in Tables described later was prepared.
    • Preparation Example 14
  • To DMF (40 mL) was added 60% NaH (634 mg) under ice-cooling, and a solution of 4-fluoro-3-(trifluoromethyl)benzonitrile (2 g) in DMF (20 mL) was slowly added thereto. After stirring at room temperature for 5 hours, the reaction was quenched with a saturated NH4Cl solution, followed by extraction with EtOAc. The organic layer was washed with brine, dried over MgSO4, and then filtered. The filtrate was concentrated to obtain 4-isopropoxy-3-(trifluoromethyl)benzonitrile (2.4 g) as a pale yellow solid.
  • In the same manner as in Preparation Example 14, the compounds of Preparation Example 14-1 through Preparation Example 14-16 shown in Tables described later were prepared.
    • Preparation Example 15
  • To a solution of methyl 4-fluoro-2-(trifluoromethyl)benzoate in DMF were added K2CO3 and piperidine, followed by stirring at 100° C. for 3 hours. The reaction mixture was cooled to 0° C., and water was added thereto, followed by extraction with EtOAc. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:EtOAc=100:0 to 90:10) to obtain methyl 4-piperidin-1-yl-2-(trifluoromethyl)benzoate as a colorless oily substance.
  • In the same manner as in Preparation Example 15, the compounds of Preparation Example 15-1 through Preparation Example 15-4 shown in Tables described later were prepared.
    • Preparation Example 16
  • To a solution of methyl 1H-indole-5-carboxylate (1.5 g) in DMF (30 mL) was added NaH (410 mg) at 0° C. The reaction mixture was warmed to 25° C., followed by stirring for 0.5 hours. Then, the reaction mixture was cooled to 0° C. again, and then methyliodide (1.38 mL) was added thereto. The reaction mixture was warmed to 25° C., followed by stirring for 3 hours. To the reaction liquid was added water (50 mL), followed by extraction with EtOAc (50 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, CHCl3:MeOH=100:0 to 98:2) to obtain methyl 1-ethyl-1H-indole-5-carboxylate (1465 mg) as a white solid.
    • Preparation Example 17
  • To a solution of 4-fluoro-2-(trifluoromethyl)benzoic acid in MeOH were added concentrated sulfuric acid at 0° C. The reaction mixture was heated and refluxed for 2 days. The reaction mixture was concentrated under reduced pressure and the residue was diluted with EtOAc. The organic layer was washed with a saturated aqueous NaHCO3 solution, dried over MgSO4, and then concentrated under reduced pressure to obtain methyl 4-fluoro-2-(trifluoromethyl)benzoate as a colorless oily substance.
    • Preparation Example 18
  • The suspension of 4-bromo-5-ethylthiophene-2-carboxylic acid (800 mg) in MeOH (4 mL) was added dropwise SOCl2 (0.50 mL) at 0° C. The reaction mixture was stirred at 0° C. for 1 hour, warmed to 60° C., and then stirred for 15 hours. The reaction liquid was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=98:2 to 70:30) to obtain methyl 4-bromo-5-ethylthiophene-2-carboxylate (765.0 mg) as a colorless liquid.
  • In the same manner as in Preparation Example 18, the compounds of Preparation Example 18-1 through Preparation Example 18-6 shown in Tables described later were prepared.
    • Preparation Example 19
  • To a solution of N-isopropylpropan-2-amine (165.5 mg) in THF (1 mL) was added dropwise a solution of n-butyllithium in hexane (1.6 M, 0.98 mL) at −78° C., followed by warming to 25° C. and then stirring for 30 minutes. After cooling to −78° C. again, a solution of 1-tert-butyl-3-methylpyrrolidine-1,3-dicarboxylate (300 mg) in THF (1 mL) was added dropwise thereto. The reaction mixture was warmed to −40° C. and then stirred for 1 hour. The reaction mixture was cooled to −78° C. again, and a solution of N-fluoro-N-(phenylsulfonyl)benzenesulfonamide (495.1 mg) in THF (1 mL) was added dropwise thereto. The reaction mixture was stirred at −78° C. for 1 hour, then warmed to 25° C., and stirred for 15 hours. Fifteen hours later, to the reaction liquid was added a saturated aqueous NH4Cl solution (30 mL), followed by extraction with EtOAc (30 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 80:20) to obtain 1-tert-butyl 3-methyl-3-fluoropyrrolidine-1,3-dicarboxylate (154.3 mg) as a yellow liquid.
    • Preparation Example 20
  • To a solution of methyl 4-phenylthiophene-2-carboxylate (1.8 g) in DCM (18 mL) was added portionwise pyridinium tribromide (13.2 g) at 0° C. The reaction liquid was warmed to 25° C. and then stirred for 45 hours. The reaction mixture was cooled to 0° C., and a saturated aqueous Na2S2O3 solution (100 mL) was slowly added dropwise. The reaction mixture was extracted with DCM (50 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 90:10) to obtain methyl 5-bromo-4-phenylthiophene-2-carboxylate (2.06 g) as a colorless liquid.
    • Preparation Example 21
  • To a solution of 4-chloro-5,5,5-trifluoro-3-phenylpent-3-en-2-one (950 mg) and methylsulfanylacetate (446 mg) in MeCN (23.8 mL) was added dropwise DBU (0.63 mL) at 25° C., followed by stirring at the same temperature for 15 hours. To the reaction liquid was added a saturated aqueous NH4Cl solution (50 mL), followed by extraction with diethylether (50 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=98:2 to 90:0) to obtain methyl 3-methyl-4-phenyl-5-(trifluoromethyl)thiophene-2-carboxylate (1.08 g) as a colorless liquid.
    • Preparation Example 22
  • To a solution of benzyl 3-cyanopyrrolidine-1-carboxylate (1.0 g) and TEA hydrochloride (2.99 g) in toluene was added sodium azide (1.41 g) at 25° C., followed by stirring at 115° C. for 5 hours. The reaction liquid was left to be cooled and DCM (10 mL) was added thereto. Then, to a 5% aqueous salicylic acid solution (100 mL) was added dropwise the reaction liquid, followed by stirring at 25° C. for 1 hour. The reaction liquid was extracted with EtOAc (30 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 80:20) to obtain benzyl 3-(1H-tetrazol-5-yl)pyrrolidine-1-carboxylate (10.8 g) as a colorless liquid.
    • Preparation Example 23
  • To a solution of methyl 2-{[tert-butyl(dimethyl)silyl]oxy}-4-methylbenzoate (3.4 g) in carbon tetrachloride (68 mL) were added, and NBS (2.16 g) and AIBN (398 mg) were added thereto at room temperature, followed by stirring at 80° C. for 1 hour. Completion of the reaction was confirmed by means of TLC, and to the reaction liquid was added water to stop the reaction, followed by extraction with EtOAc. The organic layer was washed with brine, dried using MgSO4, and then concentrated under reduced pressure, followed by purification by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 95:5) to obtain methyl 4-(bromomethyl)-2-{[tert-butyl(dimethyl)silyl]oxy}benzoate (3.79 g) as a colorless liquid.
    • Preparation Example 23-1
  • To a solution of (2S)-3-(4-chlorophenyl)-2-methylpropan-1-ol (300 mg) in DCM (20 mL) were added N-bromosuccinimide (347 mg) and triphenylphosphine (511 mg) under ice-cooling. The reaction liquid was stirred at room temperature for 2 hours, and then the reaction liquid was poured into water, followed by extraction with chloroform. The organic layer was washed with brine and dried over MgSO4, and then vehicle was evaporated under reduced pressure. The residue was subjected to silica gel column chromatography (hexane:EtOAc=100:0 to 90:10) to obtain 1-[(2S)-3-bromo-2-methylpropyl]-4-chlorobenzene (373 mg) as a colorless liquid.
    • Preparation Example 24
  • To a solution of N-isopropylpropan-2-amine (11.54 mL) in THF (50 mL) was added dropwise a solution of n-butyllithium in hexane (1.6 M, 51.45 mL) at −78° C. The reaction mixture was warmed to 0° C. and then stirred for 30 minutes. The reaction mixture was cooled to −78° C. again, and then a solution of tert-butyl 3-cyanoazetidine-1-carboxylate (5.0 g) in THF (30 mL) was added dropwise, followed by stirring at −78° C. for 1 hour. To the reaction mixture was added dropwise a solution of 1H-benzotriazol-1-yl-methanol (8.19 g) in THF (20 mL) at −78° C., followed by stirring at −78° C. for 3 hours. To the reaction mixture was added a saturated aqueous NH4Cl solution (100 mL), followed by extraction with EtOAc (50 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 50:50) to obtain tert-butyl 3-cyano-3-(hydroxymethyl)azetidine-1-carboxylate (5.68 g) as a white solid.
    • Preparation Example 25
  • A solution of methyl 4-amino-(2-trifluoromethyl)benzoate hydrochloride (1.24 g) and 2,5-dimethoxytetrahydrofuran (773 mg) in AcOH (20 mL) was stirred at 80° C. for 12 hours. The reaction mixture was concentrated under reduced pressure and azeotroped with toluene, and AcOH was evaporated. The obtained yellowish brown oily substance was dissolved in chloroform, and a saturated aqueous NaHCO3 solution was added thereto. The organic layer was washed with a saturated aqueous NaHCO3 solution, water, and brine in this order, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (CHCl3:MeOH=97:3) to obtain methyl 4-(1H-pyrrolo-1-yl)-2-(trifluoromethyl)benzoate (11.8 g).
  • In the same manner as in Preparation Example 25, the compound of Preparation Example 25-1 shown in Tables described later was prepared.
    • Preparation Example 26
  • To a solution of trimethyl(pro-1-pyn-1-yl)silane (877 mg) in THF (60 mL) were added a solution of n-BuLi in hexane (1.58 M, 4.5 mL) was added at −78° C. The reaction mixture was stirred at −78° C. for 3 hours, and then a solution of 1-(bromomethyl)-2,4-bis(trifluoromethyl)benzene (2 g) in THF (10 mL) was added dropwise thereto, followed by stirring for 1 hour. To the reaction liquid was added an aqueous NH4Cl solution, followed by extraction with ether. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:EtOAc=100:0) to obtain {4-[2,4-bis(trifluoromethyl)phenyl]but-1-yn-1-yl}(trimethyl)silane (1.8 g) as a colorless liquid.
    • Preparation Example 27
  • 1-(chloromethyl)-2-methoxy-4-propylbenzene (1.1 g) was dissolved in DMF (20 mL), and 7-hydroxy-2H-chromene-3-carbaldehyde (975 mg) and K2CO3 (1.15 g) were added thereto, followed by stirring at 80° C. for 1 hour. Further, sodium iodide (416 mg) was added thereto, followed by stirring at 80° C. for 1 hour. After confirming completion of the reaction, to the reaction liquid was added water to stop the reaction, followed by extraction with EtOAc three times. The organic layer was combined, washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=95:5 to 80:20) to obtain 7-[(2-methoxy-4-propylbenzyl)oxy]-2H-chromene-3-carbaldehyde (1.21 g) as a yellow powder.
  • In the same manner as in Preparation Example 27, the compounds of Preparation Example 27-1 through Preparation Example 27-6 shown in Tables described later were prepared.
    • Preparation Example 28
  • 7-Hydroxy-2H-chromene-3-carbaldehyde (200 mg) was dissolved in DMF (5 mL), and K2CO3 (235 mg) and 1-(bromomethyl)-2,4-bis(trifluoromethyl)benzene (0.234 mL) were added thereto, followed by stirring at 80° C. for 30 minutes. The reaction liquid was poured into water, and the resulting powder was collected by filtration and dried under reduced pressure to obtain 7-{[2,4-bis(trifluoromethyl)benzyl]oxy}-2H-chromene-3-carbaldehyde (455 mg) as a pale yellow powder.
  • In the same manner as in Preparation Example 28, the compounds of Preparation Example 28-1 through Preparation Example 28-27 shown in Tables described later were prepared.
    • Preparation Example 29
  • To a solution of 3-formyl-2H-chromen-7-yltrifluoromethanesulfonate (520 mg) in DMF (10.4 mL) were added 1-ethynyl-4-(trifluoromethyl)benzene (330 μL), bis(triphenylphosphine)palladium (II) dichloride (355 mg), and copper iodide (I) (161 mg), and TEA (470 μL) at room temperature. The reaction mixture was stirred at 100° C. for 5 hours. To the reaction mixture was added water under ice-cooling, the insoluble materials were separated by filtration, and the filtrate was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:EtOAc) to obtain 7-{[4-(trifluoromethyl)phenyl]ethynyl}-2H-chromene-3-carbaldehyde (189 mg).
  • In the same manner as in Preparation Example 29, the compounds of Preparation Example 29-1 through Preparation Example 29-15 shown in Tables described later were prepared.
    • Preparation Example 30
  • To a solution of Pd(PPh3)4 (542 mg) and TEA (4 mL) in DMF (16 mL) were added 1-bromo-4-isobutylbenzene (1 g) and ethynyl(trimethyl)silane (553 mg) at room temperature, followed by stirring at 60° C. for 4 hours. To the reaction liquid was added 1 M hydrochloric acid, followed by extraction with ether. The insoluble materials were filtered through celite. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane) to obtain [(4-isobutylphenyl)ethynyl](trimethyl)silane (459 mg) as a yellow liquid.
  • In the same manner as in Preparation Example 30, the compound of Preparation Example 30-1 shown in Tables described later was prepared.
    • Preparation Example 31
  • To a solution of copper chloride (10 mg) and Pd(PPh3)4 (60 mg) in DMF (2 mL) were added [(4-isobutylphenyl)ethynyl](trimethyl)silane (288 mg) and 5-fluoro-3-formyl-2H-chromen-7-yl trifluoromethanesulfonate (340 mg) at room temperature, followed by stirring at 80° C. for 12 hours. The reaction liquid was concentrated and the residue was purified by silica gel column chromatography (CHCl3) to obtain 5-fluoro-7-[(4-isobutylphenyl)ethynyl]-2H-chromene-3-carbaldehyde (83 mg) as a yellow solid.
  • In the same manner as in Preparation Example 31, the compound of Preparation Example 31-1 shown in Tables described later was prepared.
    • Preparation Example 32
  • To a solution of 1-[4-phenyl-5-(trifluoromethyl)-2-thienyl]ethanone (1.0 g) in THF (20 mL) was added dropwise DIBAL (0.99 M solution in toluene, 9.34 mL) at −78° C. The reaction mixture was warmed to 25° C. and stirred for 3 hours and a saturated aqueous Rochelle salt solution (50 mL) was added thereto, followed by extraction with EtOAc (50 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=98:2 to 90:10) to obtain 1-[4-phenyl-5-(trifluoromethyl)-2-thienyl]ethanol (0.99 g) as a colorless liquid.
    • Preparation Example 33
  • To a solution of 3-(trifluoromethyl)-4-[(1S)-2,2,2-trifluoro-1-methylethoxy]benzoic acid (1.085 g) in THF (43 mL) was added dropwise a solution of BH3.THF in THF (1 M, 14 mL) at 0° C. The reaction mixture was warmed to room temperature and then stirred for 15 hours. To the reaction liquid was added 1 M hydrochloric acid at 0° C. to stop the reaction, followed by stirring for 30 minutes and extracting with EtOAc. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure to obtain {3-(trifluoromethyl)-4-[(1S)-2,2,2-trifluoro-1-methylethoxy]phenyl}methanol (570 mg) as a white oily substance.
  • In the same manner as in Preparation Example 33, the compounds of Preparation Example 33-1 through Preparation Example 33-21 shown in Tables described later were prepared.
    • Preparation Example 34
  • To a solution of methyl 4-piperidin-1-yl-2-(trifluoromethyl)benzoate (955 mg) in THF (19 mL) were added dropwise a solution of DIBAL in hexane (1 M, 10.0 mL) under ice-cooling, followed by stirring at the same temperature for 2 hours. To the reaction liquid was added dropwise MeOH, and then a saturated aqueous Rochelle salt solution was added thereto, followed by stirring at room temperature for 1 hour. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane:EtOAc) to obtain [4-piperidin-1-yl-2-(trifluoromethyl)phenyl]methanol (846 mg).
  • In the same manner as in Preparation Example 34, the compounds of Preparation Example 34-1 through Preparation Example 34-30 shown in Tables described later were prepared.
    • Preparation Example 35
  • Methyl 2-hydroxy-4-[(2-methoxy-4-propylphenoxy)methyl]benzoate (300 mg) was dissolved in THF (15 mL). To the reaction liquid was added LAH (103.4 mg) at 0° C., followed by warming from 0° C. to 25° C. and then stirring for 3 hours. To the reaction liquid was added a saturated aqueous Rochelle salt solution (30 mL), followed by extraction with EtOAc (30 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 80:20) to obtain 2-(hydroxymethyl)-5-[(2-methoxy-4-propylphenoxy)methyl]phenol (245.2 mg) as a white solid.
  • In the same manner as in Preparation Example 35, the compounds of Preparation Example 35-1 through Preparation Example 35-3 shown in Tables described later were prepared.
    • Preparation Example 36
  • To a solution of NaBH4 (93.1 mg) in EtOH (15 mL) was added dropwise a solution of 7-{[2,4-bis(trifluoromethyl)benzyl]oxy}-2,3-dihydro-4H-thiochromen-4-one (1.0 g) in EtOH (5 mL) at 0° C. The reaction mixture was warmed to 25° C., followed by stirring for 3 hours. The reaction liquid was concentrated under reduced pressure and to the residue were added DCM (20 mL) and then saturated aqueous NH4Cl (30 mL) at 0° C., followed by stirring for 1 hour and extracting with DCM three times (30 mL×3). The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 60:40) to obtain 7-{[2,4-bis(trifluoromethyl)benzyl]oxy}thiochroman-4-ol (845 mg) as a white solid.
  • In the same manner as in Preparation Example 36, the compounds of Preparation Example 36-1 through Preparation Example 36-2 shown in Tables described later were prepared.
    • Preparation Example 37
  • At a normal pressure under a hydrogen gas atmosphere, to a solution of methyl 4-phenyl-5-vinylthiophene-2-carboxylate (250 mg) in EtOH (5 mL) was added Pd/C (50% wet) (50 mg) at 25° C., followed by stirring for 5 hours. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain methyl 5-ethyl-4-phenylthiophene-2-carboxylate (247.3 mg) as a colorless liquid.
  • In the same manner as in Preparation Example 37, the compounds of Preparation Example 37-1 through Preparation Example 37-3 shown in Tables described later were prepared.
    • Preparation Example 38
  • To a solution of 5-fluoro-7-hydroxy-2H-chromene-3-carbaldehyde (275 mg) and 2-(hydroxymethyl)-5-methyl-4-phenyl-thiazole (436 mg) in toluene (8.2 mL) were added ADDP (393 mg) and TBP (315 mg) under ice-cooling. The reaction liquid was stirred at room temperature for 15 hours, then IPE was added thereto, and the solid was removed by filtration. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (hexane:EtOAc=90:20 to 70:30) to obtain 5-fluoro-7-[(5-5-methyl-4-phenyl-1,3-thiazol-2-yl)methoxy]-2H-2H-chromene-3-carbaldehyde (381 mg) as a pale yellow solid.
  • In the same manner as in Preparation Example 38, the compounds of Preparation Example 38-1 through Preparation Example 38-61 shown in Tables described later were prepared.
    • Preparation Example 39
  • To a solution of 5-({[2′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]oxy}methyl)-2-(hydroxymethyl)phenol (520 mg) in chloroform (10 mL) was added manganese dioxide (1 g) at room temperature. The reaction liquid was stirred at room temperature for 16 hours, and then filtered through celite. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (hexane:EtOAc=95:5 to 80:20) to obtain 4-({[2′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]oxy}methyl)-2-hydroxybenzaldehyde (180 mg) as a white solid.
  • In the same manner as in Preparation Example 39, the compounds of Preparation Example 39-1 through Preparation Example 39-6 shown in Tables described later were prepared.
    • Preparation Example 40
  • To a solution of [2-({[2-(trifluoromethyl)biphenyl-4-yl]oxy}methyl)-4,5-dihydro-1-benzothien-6-yl]methanol (1.0 g) in DCM (20 mL) were added PDC (1.36 g) and MS4 Angstrom (1.36 g) at 25° C. The reaction liquid was stirred for 3 hours, and then filtered through celite. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 80:20) to obtain 2-({[2-(trifluoromethyl)biphenyl-4-yl]oxy}methyl)-4,5-dihydro-1-benzothiophene-6-carbaldehyde (345 mg) as a colorless liquid.
    • Preparation Example 41
  • To a solution of [1-(tert-butoxycarbonyl)piperidin-4-yl]acetic acid (200 mg) in dioxane (1 mL) was added a 4 M hydrogen chloride dioxane solution (1 mL). The reaction liquid was stirred at room temperature for 15 hours, and then concentrated under reduced pressure to obtain piperidin-4-yl acetic acid hydrochloride (140 mg) as a white solid.
  • In the same manner as in Preparation Example 41, the compounds of Preparation Example 41-1 through Preparation Example 41-5 shown in Tables described later were prepared.
    • Preparation Example 42
  • Benzyl 3-(1H-tetrazol-5-yl)pyrrolidine-1-carboxylate (300 mg) was added to a mixed solution of concentrated hydrochloric acid (3 mL) and AcOH (0.6 mL), followed by stirring at 100° C. for 5 hours. The reaction liquid was concentrated and then azeotroped with toluene three times (30 mL×3). The residue was dissolved in a mixed solution of acetone (0.9 mL) and water (1.5 mL), and then cooled to 0° C., and Na2CO3(174.5 mg) and DIBOC (359.4 mg) were added thereto. The reaction mixture was warmed to 25° C. and then stirred for 15 hours. The reaction liquid was concentrated. To the residue was added diethylether (30 mL) for extraction three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure to obtain tert-butyl 3-(1H-tetrazol-5-yl)pyrrolidine-1-carboxylate (102.7 mg) as a colorless liquid.
    • Preparation Example 43
  • To 1-tert-butyl 3-methyl 3-fluoropyrrolidine-1,3-dicarboxylate (100 mg) was added a mixed solution of concentrated hydrochloric acid (1 mL) and AcOH (0.2 mL) at 0° C. The reaction mixture was warmed to room temperature, stirred for 1 hour, and then stirred at 100° C. for 5 hours. After confirming that the starting materials were lost, the resultant was concentrated under reduced pressure and then azeotroped with toluene three times. The residue was dissolved in a mixed liquid of acetone (0.6 mL) and water (1 mL), and Na2CO3 (64 mg) and DIBOC (132 mg) were added thereto at 0° C., followed by warming to room temperature and then stirring for 15 hours. The reaction mixture was concentrated under reduced pressure and acetone was evaporated. To the residue was added diethylether for liquid separation. The aqueous layer was combined, cooled to 0° C., and adjusted to pH=2 to 3 with 2 M hydrochloric acid. EtOAc was added thereto for extraction. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure to obtain 1-(tert-butoxycarbonyl)-3-fluoropyrrolidine-3-carboxylic acid (70 mg) as a white solid.
    • Preparation Example 44
  • 5-Fluoro-7-(methoxymethoxy)-2H-chromene-3-carbaldehyde (1.5 g) was dissolved in acetone (25 mL), and 1 M HCl (20 mL) was added thereto, followed by heating and refluxing for 5 hours. The reaction liquid was concentrated and the residue was dissolved in EtOAc, washed with water and brine, and dried over MgSO4, and the filtrate was concentrated. The residue was washed with chloroform to obtain 5-fluoro-7-hydroxy-2H-chromene-3-carbaldehyde (0.95 g) as a yellow powder.
  • In the same manner as in Preparation Example 44, the compounds of Preparation Example 44-1 through Preparation Example 44-6 shown in Tables described later were prepared.
    • Preparation Example 45
  • 7-(Methoxymethoxy)-2,2-dimethyl-2H-chromene-3-carbaldehyde (300 mg) was dissolved in EtOH (10 mL), and (1S)-(+)-10-camphor sulfonic acid (421 mg) was added thereto, followed by stirring at 80° C. overnight. To the reaction liquid was added silica gel, followed by concentration. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=90:10 to 70:30) to obtain 7-hydroxy-2,2-dimethyl-2H-chromene-3-carbaldehyde (175 mg) as a red powder.
    • Preparation Example 46
  • To a solution of KOH (358 mg) in MeOH (30 mL) was added {4-[2,4-bis(trifluoromethyl)phenyl]but-1-yn-1-yl}(trimethyl)silane (1.8 g), followed by stirring at room temperature for 18 hours. The reaction liquid was neutralized with 1 M hydrochloric acid and extracted with ether. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:EtOAc=100:0) to obtain 1-but-3-yn-1-yl-2,4-bis(trifluoromethyl)benzene (426 mg) as a colorless liquid.
    • Preparation Example 47
  • To 7-(benzyloxy)-4-methyl-2H-chromene-3-carbaldehyde (230 mg) and 1,2,3,4,5-pentamethylbenzene (608 mg) was added TFA (3 mL), followed by stirring at room temperature overnight. The reaction liquid was poured into an aqueous NaHCO3 solution, followed by extraction with EtOAc three times. The organic layer was combined, washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=80:20 to 20:80) to obtain 7-hydroxy-4-methyl-2H-chromene-3-carbaldehyde (130 mg) as a pale yellow powder.
  • In the same manner as in Preparation Example 47, the compounds of Preparation Example 47-1 through Preparation Example 47-2 shown in Tables described later were prepared.
    • Preparation Example 48
  • 2-Fluoro-4,6-dimethoxybenzaldehyde (22 g) was dissolved in DCM (110 mL), and a solution of BBr3 in DCM (1 M, 300 mL) was added dropwise thereto under ice-cooling, followed by stirring at room temperature overnight. After confirming completion of the reaction, the reaction liquid was poured into ice-water (100 mL), followed by stirring for 1 hour and then extracting with EtOAc three times. The organic layer was combined, washed with water and brine in this order, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=80:20 to 60:40) to obtain 2-fluoro-4,6-dihydroxybenzaldehyde (12 g) as a white powder.
    • Preparation Example 49
  • To a solution of 7-{[2,4-bis(trifluoromethyl)benzyl]oxy}thiochroman-4-ol (800 mg) in toluene (16 mL) was added 4-methylbenzenesulfonic acid (33.7 mg), followed by stirring at 120° C. for 3 hours. To the reaction liquid was added a saturated aqueous NaHCO3 solution (50 mL), followed by extraction with EtOAc (50 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=100:0 to 80:20) to obtain 2,4-bis(trifluoromethyl)benzyl 2H-thiochroman-7-yl ether (753.2 mg) as a colorless liquid.
    • Preparation Example 50
  • A mixture of methyl 4-(bromomethyl)-2-{[tert-butyl(dimethyl)silyl]oxy}benzoate (0.30 g) and triethylphosphite (0.17 g) was mixed at 25° C. and then stirred at 130° C. for 24 hours. The reaction liquid was concentrated under reduced pressure and azeotroped with toluene twice (30 mL×2). The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=40:60 to 10:90) to obtain methyl 2-{[tert-butyl(dimethyl)silyl]oxy}-4-[(diethoxyphosphoryl)methyl]benzoate (0.23 g) as a colorless liquid
    • Preparation Example 51
  • To a solution of 7-[(4-bromo-5-ethyl-2-thienyl)methoxy]-2H-chromene-3-carbaldehyde (150 mg) in dioxane (4.5 mL) were added [2-(trifluoromethyl)phenyl]boric acid and a 2 M aqueous Na2CO3 solution at 25° C. Then, to the reaction mixture were added palladium acetate (4.44 mg) and PPh3 (20.75 mg), followed by warming to 100° C. and stirring for 5 hours. To the reaction liquid was added a saturated aqueous NH4Cl solution (30 mL), followed by extraction with EtOAc (30 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=95:5 to 80:20) to obtain 7-({5-ethyl-4-[2-(trifluoromethyl)phenyl]-2-thienyl}methoxy)-2H-chromene-3-carbaldehyde (134.8 mg) as a pale yellow liquid.
  • In the same manner as in Preparation Example 51, the compounds of Preparation Example 51-1 through Preparation Example 51-5 shown in Tables described later were prepared.
    • Preparation Example 52
  • Under a nitrogen atmosphere, to a solution of [3-chloro-4-(trifluoromethyl)phenyl]methanol (800 ng) and phenylboric acid (1.90 g) in toluene (16 mL) were added potassium phosphate (1.61 g), palladium acetate (42.6 mg), and dicyclohexyl(2′,6′-dimethoxybiphenyl-2-yl)phosphine (195.0 mg) at 25° C. The reaction mixture was warmed to 100° C. and then stirred for 15 hours. To the reaction liquid was added water (30 mL), followed by extraction with EtOAc (30 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (automatic purification device, hexane:EtOAc=70:30 to 50:50) to obtain [6-(trifluoromethyl)biphenyl-3-yl]methanol (678.3 mg) as a yellow solid.
  • In the same manner as in Preparation Example 52, the compounds of Preparation Example 52-1 through Preparation Example 52-4 shown in Tables described later were prepared.
    • Preparation Example 53
  • A solution of {3-chloro-4-[(1S)-2,2,2-trifluoro-1-methylethoxy]phenyl}methanol (284 mg) and SOCl2 (179 μL) in DCM (7 mL) was stirred at room temperature for 2 hours. The reaction liquid was poured into water, followed by extraction with chloroform. The organic layer was washed with brine, dried over MgSO4, and then concentrated under reduced pressure to obtain 2-chloro-4-(chloromethyl)-1-[(1S)-2,2,2-trifluoro-1-methylethoxy]benzene (285 mg) as a colorless liquid.
  • In the same manner as in Preparation Example 53, the compounds of Preparation Example 53-1 through Preparation Example 53-4 shown in Tables described later were prepared.
    • Preparation Example 54
  • To a solution of methyl 4-bromo-3-benzoate (300 mg) in THF (1 mL) were added cyclopentylzinc bromide (9.6 mL) and palladium-tri-tert-butylphosphine (1:2) (123 mg). The reaction liquid was stirred at room temperature for 20 hours. A saturated aqueous NH4Cl solution was added thereto at 0° C., followed by filtration through celite and extraction with EtOAc. The organic layer was washed with brine and dried over MgSO4. The vehicle was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (hexane:EtOAc=100:0 to 90:10) to obtain methyl 3-chloro-4-cyclopentyl benzoate (280 mg) as a yellow solid.
    • Preparation Example 55
  • To a solution of (7-{[2,4-bis(trifluoromethyl)benzyl]oxy}-5-fluoro-2H-chromen-3-yl)methanol (200 mg) in MeCN (5 mL) was added triphenylphosphine dibromide (240 mg). The reaction liquid was stirred at room temperature for 2 hours and concentrated under reduced pressure. To the residue were added EtOAc and IPE, the resulting solid was removed by filtration, and the filtrate was concentrated to obtain 7-{[2,4-bis(trifluoromethyl)benzyl]oxy}-3-(bromomethyl)-5-fluoro-2H-chromene (230 mg) as a brown liquid. 60% sodium hydride (24 mg) was added to a DMF solution (5 mL) at 0° C., and subsequently, ethyl 1H-pyrazole-4-carboxylate (76 mg) was added thereto. The mixture was stirred at room temperature for 0.5 hours, and a solution of 7-{[2,4-bis(trifluoromethyl)benzyl]oxy}-3-(bromomethyl)-5-fluoro-2H-chromene (220 mg) in DMF (5 mL) was added thereto at 0° C. The reaction liquid was stirred at room temperature for 13 hours, quenched with a saturated NH4Cl solution, and then extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:EtOAc=100:0 to 70:30) to obtain ethyl 1-[(7-{[2,4-bis(trifluoromethyl)benzyl]oxy}-5-fluoro-2H-chromen-3-yl)methyl]-1H-pyrazole-4-carboxylate (111 mg) as a pale yellow solid.
  • In the same manner as in Preparation Example 55, the compound of Preparation Example 55-1 shown in Tables described later was prepared.
    • Preparation Example 56
  • A solution of 4-isopropoxy-3-(trifluoromethyl)benzonitrile (2.4 g) and 5 M NaOH (50 mL) in EtOH (50 mL) was heated and refluxed for 18 hours. The solution was cooled to room temperature, acidified by hydrochloric acid, and then extracted with chloroform. The organic layer was washed with brine, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:MeOH=100:0 to 95:5). The product was washed with hexane to obtain 4-isopropoxy-3-(trifluoromethyl)benzoic acid (2.2 g) as a white solid.
  • In the same manner as in Preparation Example 56, the compounds of Preparation Example 56-1 through Preparation Example 56-6 shown in Tables described later were prepared.
    • Preparation Example 57 5-Bromo-3-(trifluoromethyl)-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxy}pyridine (500 mg) was dissolved in a mixed vehicle of DMSO (5 mL) and MeOH (5 mL). Then, TEA (0.42 mL) was added thereto at 25° C., and then Pd(OAc)2 (17 mg) and DPPP (60 mg) were added thereto at 25° C., followed by stirring at 70° C. for 15 hours under a CO atmosphere. To the reaction solution was added water (30 mL), followed by extraction with EtOAc (20 mL) three times. The organic layer was washed with brine, dried over MgSO4, and then filtered, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (automatic purification device, developing solution; hexane:EtOAc=100:0 to 80:20) to obtain methyl 5-(trifluoromethyl)-6-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}nicotinate (403 mg) as a yellow solid. Preparation Example 58
  • To a solution of ethyl (1-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate (2.05 g) in dichloroethane (14 mL) was added 1-chloroethyl-chlorofomrate (1.5 mL) at 0° C. The reaction liquid was heated and refluxed for 2.5 hours, and then concentrated under reduced pressure. The residue was dissolved in MeOH (14 mL), and heated and refluxed for 1 hour. After concentration under reduced pressure, the residue was purified by amino column chromatography (chloroform:methanol=100:0 to 80:20) to obtain ethyl 1,2,3,6-tetrahydropyridin-4-ylacetate (130 mg) as a brown liquid.
  • In the same manner as in Preparation Example 58, the compound of Preparation Example 58-1 shown in Tables described later was prepared.
    • Preparation Example 59
  • Methyl 5,6-dichloronicotinate (1.5 g) and 60% sodium hydride (640 mg) were dissolved in THF (45 mL). 1,3-Difluoropropan-2-ol (1.5 g) was added thereto at 0° C., followed by stirring at 0° C. for 3 hours, and the reaction solution was quenched with aqueous NH4Cl. After extraction with EtOAc, the organic layer was dried over MgSO4 and then filtered, and the desiccant was removed. The vehicle was evaporated under reduced pressure, followed by purification by silica gel column chromatography (hexane:AcOEt=100:0 to 50:50) to obtain methyl 5-chloro-6-[(1,3-difluoropropan-2-yl)oxy]nicotinate (1.56 g) as a colorless liquid.
  • To a solution of methyl 5-chloro-6-[(1,3-difluoropropan-2-yl)oxy]nicotinate (1 g) in THF (20 mL) was added dropwise a 0.99 M solution of DIBAL in toluene (11.3 mL) at 0° C., followed by stirring at 0° C. for 2 hours. Then, the reaction solution was poured into an aqueous Rochelle salt solution, followed by stirring at room temperature for 1 hour. After extraction with an EtOAc-water system, the organic layer was washed with brine, dried over MgSO4, and then filtered, and the desiccant was removed.
  • The vehicle was evaporated under reduced pressure, followed by purification by silica gel column chromatography (Hex:AcOEt=98:2 to 70:30) to obtain {5-chloro-6-[(1,3-difluoropropan-2-yl)oxy]pyridin-3-yl}methanol (650 mg) as a colorless liquid.
    • Preparation Example 60
  • To 5,6-dichloronicotinic acid (2.2 g) was added 1,1,1-trimethoxyethane (4.3 mL), followed by irradiation with microwave at 120° C. for 15 minutes. The reaction mixture was dissolved in EtOAc and washed with water. The organic layer was dried over MgSO4 and the vehicle was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:EtOAc=85:15 to 80:20) to obtain methyl 5,6-dichloronicotinate (2.2 g) as a white solid.
    • Preparation Example 61
  • To a solution of ethyl 4-pyridyl acetate (2 g) in MeCN (20 mL) was added methyliodide (2.3 mL). The reaction liquid was stirred at room temperature overnight and then concentrated under reduced pressure. To the residue was added IPE and the resulting solid was collected by filtration. The solid was dissolved in MeOH, and sodium borohydride (916 mg) was added there at 15° C. or lower.
  • The reaction liquid was stirred at room temperature for 6 hours, and then water was added thereto, followed by extraction with chloroform. The organic layer was washed with brine, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by column chromatography (chloroform:MeOH=100:0 to 90:10) to obtain ethyl (1-methyl-1,2,3,6-tetrahydropyridin-4-yl)acetate (2.08 g) as a pale yellow liquid.
    • Preparation Example 62
  • To a solution of {3-(trifluoromethyl)-4-[(1S)-2,2,2-trifluoro-1-methylethoxy]phenyl}methanol (200 mg) in dichloroethane (5 mL) were added thionyl chloride (111 μL) and a catalytic amount of DMF, followed by stirring at 60° C. for 2 hours. The reaction liquid was concentrated under reduced pressure and then to the residue were added a solution of ethyl (3R)-1-[(7-hydroxy-2H-chromen-3-yl)methyl]piperidine-3-carboxylate (175 mg) in DMF (8.75 mL) and potassium carbonate (152 mg) in this order, followed by stirring at 80° C. for 2 hours. The reaction liquid was cooled to room temperature and poured into water, followed by extraction with EtOAc. The organic layer was washed with water and brine in this order and then dried over anhydrous sodium sulfate, and the vehicle was evaporated. The residue was purified by silica gel column chromatography to obtain ethyl (3R)-1-[(7-{[3-(trifluoromethyl)-4-[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzyl]oxy}-2H-chromen-3-yl)methyl]piperidine-3-carboxylate (271 mg) as a yellow oily substance.
  • In the same manner as in Preparation Example 62, the compounds of Preparation Example 62-1 through Preparation Example 62-19 shown in Tables described later were prepared.
    • Preparation Example 63
  • To a solution of 4-chloro-3-(trifluoromethyl)benzonitrile (1.5 g), iron (III) acetylacetonate (130 mg), and 1-methylpyrrolidin-2-one (4 mL) in THF (45 mL) was added a 1 M solution of cyclopentyl magnesium bromide in THF (8.8 mL) at 5° C., followed by stirring at room temperature for 0.5 hours and diluting with diethylether. 1 M hydrochloric acid was slowly added thereto, followed by extraction with EtOAc. The organic layer was washed with brine, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:EtOAc=100:0 to 95:5) to obtain 4-cyclopentyl-3-(trifluoromethyl)benzonitrile (367 mg) as a white solid.
    • Preparation Example 64
  • To a solution of 7-(methoxymethoxy)-2H-chromene-3-carbaldehyde (5.00 g) and ethyl (3R)-piperidine-3-carboxylate (4.20 mL) in dichloroethane (150 mL) was added sodium triacetoxyborohydride (12.0 g), followed by stirring at 80° C. for 4 hours. The reaction liquid was cooled to room temperature and then saturated aqueous NaHCO3 was added thereto, followed by extraction with chloroform. The organic layer was washed with brine and dried over anhydrous sodium sulfate, and the vehicle was evaporated. The residue was purified by silica gel column chromatography (hexane:EtOAc=4:1) to obtain ethyl (3R)-1-{[7-(methoxymethoxy)-2H-chromen-3-yl]methyl}piperidine-3-carboxylate (7.30 g) as a yellow oily substance.
  • In the same manner as in Preparation Example 64, the compounds of Preparation Example 64-1 through Preparation Example 64-7 shown in Tables described later were prepared.
  • For the Preparation Example Compounds, the structures are shown in Tables 3 to 57, and the physicochemical data and preparation methods are shown in Tables 99 to 107.
    • Example 1
  • To a solution of 1-[(7-{[2,4-bis(trifluoromethyl)benzyl]oxy}-5-fluoro-2H-chromen-3-yl)methyl]pyrrolidine-3-carboxylic acid (98 mg) in DMF (2 mL) was added CDI (46 mg), followed by stirring at 70° C. for 12 hours. To the reaction liquid were added methanesulfonamide (27 mg) and DBU (43 mg) in this order, followed by stirring for 12 hours. To the reaction liquid was added AcOH, followed by concentration under reduced pressure, and the residue was purified by reverse phase column chromatography (H2O:MeCN=100:0 to 90:10) to obtain a yellow amorphous substance (70 mg). This yellow amorphous substance was dissolved in dioxane (1 mL), and a 4 M HCl/dioxane solution (1 mL) was added thereto, followed by stirring and then concentrating under reduced pressure. The residue was washed with hexane to obtain 1-[(7-{[2,4-bis(trifluoromethyl)benzyl]oxy}-5-fluoro-2H-chromen-3-yl)methyl]-N-(methylsulfonyl)pyrrolidine-3-carboxamide hydrochloride (60 mg) as a pale yellow solid.
    • Example 2
  • To a solution of pyrrolidine-3-carboxylic acid hydrochloride in MeOH was added TEA, followed by stirring at room temperature for 10 minutes. The reaction mixture was concentrated under reduced pressure, and a solution of 7-{[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy}-2H-chromene-3-carbaldehyde in MeOH and AcOH were added thereto at room temperature. The reaction mixture was heated to 70° C., stirred for 2 hours, and left to be cooled to 25° C., and NaBH3CN was added thereto at room temperature, followed by stirring at 70° C. for 5 hours. The reaction liquid was purified by reverse phase column chromatography (MeCN:H2O=20:80 to 50:50) and the resulting white solid was washed with diisopropylether to obtain 1-[(7-{[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy}-2H-chromen-3-yl)methyl]pyrrolidine-3-carboxylic acid as a white solid.
    • Example 3
  • Pyrrolidine-3-carboxylic acid hydrochloride (165 mg) was dissolved in MeOH, and TEA was added thereto, followed by stirring at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and then a solution of 7-[2,4-bis(trifluoromethyl)phenyl]ethynyl}-5-fluoro-2H-chromene-3-carbaldehyde in MeOH (8 mL) and AcOH (0.5 mL) were added thereto at room temperature, followed by stirring at 70° C. for 0.5 hours. After leaving to be cooled to room temperature, to the reaction mixture was added NaBH3CN (57 mg) at room temperature, followed by stirring at 50° C. for 2 hours. After confirming completion of the reaction by means of LC, the reaction liquid was purified by reverse phase chromatography (MeCN:H2O=20:80 to 50:50), the resulting amorphous substance (233 mg) was dissolved in dioxane (1 mL), and a 4 M HCl/dioxane solution (1 mL) was added thereto. The reaction liquid was concentrated under reduced pressure and the residue was washed with MeCN to obtain 1-[(7-{[2,4-bis(trifluoromethyl)phenyl]ethynyl}-5-fluoro-2H-chromen-3-yl)methyl]pyrrolidine-3-carboxylic acid hydrochloride (185 mg) as a pale yellow solid.
    • Example 154
  • A solution of ethyl 1-[(7-{[2,4-bis(trifluoromethyl)benzyl]oxy}-5-fluoro-2H-chromen-3-yl)methyl]-1H-pyrazole-4-carboxylate (100 mg) and a 1 M aqueous NaOH solution (0.55 mL) in EtOH/THF (3 mL/1 mL) was stirred at 100° C. for 2 hours, neutralized with 1 M HCl, and extracted with chloroform. The organic layer was washed with brine, dried over MgSO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:methanol=100:0 to 90:10) and the obtained solid was washed with IPE to obtain 1-[(7-{[2,4-bis(trifluoromethyl)benzyl]oxy}-5-fluoro-2H-chromen-3-yl)methyl]-1H-pyrazole-4-carboxylic acid (71 mg) as a white solid.
    • Example 156
  • To a solution of ethyl (3R)-1-[(7-{[3-(trifluoromethyl)-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzyl]oxy}-2H-chromen-3-yl)methyl]piperidine-3-carboxylate (271 mg) in EtOH (5.4 mL)-THF (2.7 mL) was added a 1 M aqueous NaOH solution (923 μL), followed by stirring at 50° C. for 2 hours. The reaction liquid was cooled to room temperature, then 1 M hydrochloric acid (923 μL) was added thereto, and the vehicle was evaporated. The residue was purified by reverse phase chromatography (H2O:MeCN=100:0 to 30:70) to obtain a yellow oily substance, which was dissolved in dioxane (3 mL), treated with 4 N HCl/dioxane (1 mL), and washed with IPE to obtain (3R)-1-[(7-{[3-(trifluoromethyl)-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzyl]oxy}-2H-chromen-3-yl)methyl]piperidine-3-carboxylic acid hydrochloride (215 mg) as a white powder.
  • In the same manner as the methods of Examples 1 to 3, 154, or 156, the compounds of Examples shown in Tables described later were prepared. For the Example Compounds, the structures are shown in Tables 58 to 98, and the physicochemical data and the preparation methods are shown in Tables 108 to 131.
  • TABLE 3
    No Str
    Pr1
    Figure US20120178735A1-20120712-C00013
    Pr2
    Figure US20120178735A1-20120712-C00014
    Pr2-1
    Figure US20120178735A1-20120712-C00015
    Pr2-2
    Figure US20120178735A1-20120712-C00016
    Pr2-3
    Figure US20120178735A1-20120712-C00017
  • TABLE 4
    Figure US20120178735A1-20120712-C00018
         		Pr2-4
    Figure US20120178735A1-20120712-C00019
         		Pr3
    Figure US20120178735A1-20120712-C00020
         		Pr4
    Figure US20120178735A1-20120712-C00021
         		Pr5
    Figure US20120178735A1-20120712-C00022
         		Pr5-1
    Figure US20120178735A1-20120712-C00023
         		Pr6
  • TABLE 5
    Figure US20120178735A1-20120712-C00024
         		Pr6-1
    Figure US20120178735A1-20120712-C00025
         		Pr6-2
    Figure US20120178735A1-20120712-C00026
         		Pr6-3
    Figure US20120178735A1-20120712-C00027
         		Pr6-4
    Figure US20120178735A1-20120712-C00028
         		Pr6-5
    Figure US20120178735A1-20120712-C00029
         		Pr6-6
  • TABLE 6
    Figure US20120178735A1-20120712-C00030
         		Pr6-7
    Figure US20120178735A1-20120712-C00031
         		Pr6-8
    Figure US20120178735A1-20120712-C00032
         		Pr6-9
    Figure US20120178735A1-20120712-C00033
         		Pr6-10
    Figure US20120178735A1-20120712-C00034
         		Pr6-11
    Figure US20120178735A1-20120712-C00035
         		Pr7
    Figure US20120178735A1-20120712-C00036
         		Pr8
  • TABLE 7
    Figure US20120178735A1-20120712-C00037
         		Pr9
    Figure US20120178735A1-20120712-C00038
         		Pr9-1
    Figure US20120178735A1-20120712-C00039
         		Pr9-2
    Figure US20120178735A1-20120712-C00040
         		Pr9-3
    Figure US20120178735A1-20120712-C00041
         		Pr9-4
    Figure US20120178735A1-20120712-C00042
         		Pr10
    Figure US20120178735A1-20120712-C00043
         		Pr10-1
    Figure US20120178735A1-20120712-C00044
         		Pr11
  • TABLE 8
    Figure US20120178735A1-20120712-C00045
         		Pr11-1
    Figure US20120178735A1-20120712-C00046
         		Pr12
    Figure US20120178735A1-20120712-C00047
         		Pr12-1
    Figure US20120178735A1-20120712-C00048
         		Pr12-2
    Figure US20120178735A1-20120712-C00049
         		Pr12-3
    Figure US20120178735A1-20120712-C00050
         		Pr12-4
    Figure US20120178735A1-20120712-C00051
         		Pr13
  • TABLE 9
    Figure US20120178735A1-20120712-C00052
         		Pr13-1
    Figure US20120178735A1-20120712-C00053
         		Pr14
    Figure US20120178735A1-20120712-C00054
         		Pr14-1
    Figure US20120178735A1-20120712-C00055
         		Pr14-2
    Figure US20120178735A1-20120712-C00056
         		Pr14-3
    Figure US20120178735A1-20120712-C00057
         		Pr14-4
  • TABLE 10
    Figure US20120178735A1-20120712-C00058
         		Pr14-5
    Figure US20120178735A1-20120712-C00059
         		Pr14-6
    Figure US20120178735A1-20120712-C00060
         		Pr14-7
    Figure US20120178735A1-20120712-C00061
         		Pr14-8
    Figure US20120178735A1-20120712-C00062
         		Pr14-9
    Figure US20120178735A1-20120712-C00063
         		Pr14-10
    Figure US20120178735A1-20120712-C00064
         		Pr14-11
  • TABLE 11
    Figure US20120178735A1-20120712-C00065
         		Pr14-12
    Figure US20120178735A1-20120712-C00066
         		Pr14-13
    Figure US20120178735A1-20120712-C00067
         		Pr14-14
    Figure US20120178735A1-20120712-C00068
         		Pr14-15
    Figure US20120178735A1-20120712-C00069
         		Pr14-16
    Figure US20120178735A1-20120712-C00070
         		Pr15
    Figure US20120178735A1-20120712-C00071
         		Pr15-1
  • TABLE 12
    Figure US20120178735A1-20120712-C00072
         		Pr15-2
    Figure US20120178735A1-20120712-C00073
         		Pr15-3
    Figure US20120178735A1-20120712-C00074
         		Pr15-4
    Figure US20120178735A1-20120712-C00075
         		Pr16
    Figure US20120178735A1-20120712-C00076
         		Pr17
    Figure US20120178735A1-20120712-C00077
         		Pr18
    Figure US20120178735A1-20120712-C00078
         		Pr18-1
  • TABLE 13
    Figure US20120178735A1-20120712-C00079
         		Pr18-2
    Figure US20120178735A1-20120712-C00080
         		Pr18-3
    Figure US20120178735A1-20120712-C00081
         		Pr18-4
    Figure US20120178735A1-20120712-C00082
         		Pr18-5
    Figure US20120178735A1-20120712-C00083
         		Pr18-6
    Figure US20120178735A1-20120712-C00084
         		Pr19
    Figure US20120178735A1-20120712-C00085
         		Pr20
  • TABLE 14
    Figure US20120178735A1-20120712-C00086
         		Pr21
    Figure US20120178735A1-20120712-C00087
         		Pr22
    Figure US20120178735A1-20120712-C00088
         		Pr23
    Figure US20120178735A1-20120712-C00089
         		Pr23-1
    Figure US20120178735A1-20120712-C00090
         		Pr24
    Figure US20120178735A1-20120712-C00091
         		Pr25
    Figure US20120178735A1-20120712-C00092
         		Pr25-1
  • TABLE 15
    Figure US20120178735A1-20120712-C00093
         		Pr26
    Figure US20120178735A1-20120712-C00094
         		Pr27
    Figure US20120178735A1-20120712-C00095
         		Pr27-1
    Figure US20120178735A1-20120712-C00096
         		Pr27-2
    Figure US20120178735A1-20120712-C00097
         		Pr27-3
    Figure US20120178735A1-20120712-C00098
         		Pr27-4
  • TABLE 16
    Figure US20120178735A1-20120712-C00099
         		Pr27-5
    Figure US20120178735A1-20120712-C00100
         		Pr27-6
    Figure US20120178735A1-20120712-C00101
         		Pr28
    Figure US20120178735A1-20120712-C00102
         		Pr28-1
    Figure US20120178735A1-20120712-C00103
         		Pr28-2
    Figure US20120178735A1-20120712-C00104
         		Pr28-3
    Figure US20120178735A1-20120712-C00105
         		Pr28-4
  • TABLE 17
    Figure US20120178735A1-20120712-C00106
         		Pr28-5
    Figure US20120178735A1-20120712-C00107
         		Pr28-6
    Figure US20120178735A1-20120712-C00108
         		Pr28-7
    Figure US20120178735A1-20120712-C00109
         		Pr28-8
    Figure US20120178735A1-20120712-C00110
         		Pr28-9
    Figure US20120178735A1-20120712-C00111
         		Pr28-10
  • TABLE 18
    Figure US20120178735A1-20120712-C00112
         		Pr28-11
    Figure US20120178735A1-20120712-C00113
         		Pr28-12
    Figure US20120178735A1-20120712-C00114
         		Pr28-14
    Figure US20120178735A1-20120712-C00115
         		Pr28-15
    Figure US20120178735A1-20120712-C00116
         		Pr28-16
    Figure US20120178735A1-20120712-C00117
         		Pr28-17
  • TABLE 19
    Figure US20120178735A1-20120712-C00118
         		Pr28-18
    Figure US20120178735A1-20120712-C00119
         		Pr28-19
    Figure US20120178735A1-20120712-C00120
         		Pr28-20
    Figure US20120178735A1-20120712-C00121
         		Pr28-21
    Figure US20120178735A1-20120712-C00122
         		Pr28-22
    Figure US20120178735A1-20120712-C00123
         		Pr28-23
  • TABLE 20
    Figure US20120178735A1-20120712-C00124
         		Pr28-24
    Figure US20120178735A1-20120712-C00125
         		Pr28-25
    Figure US20120178735A1-20120712-C00126
         		Pr29-26
    Figure US20120178735A1-20120712-C00127
         		Pr28-27
    Figure US20120178735A1-20120712-C00128
         		Pr29
    Figure US20120178735A1-20120712-C00129
         		Pr29-1
  • TABLE 21
    Figure US20120178735A1-20120712-C00130
         		Pr29-2
    Figure US20120178735A1-20120712-C00131
         		Pr29-3
    Figure US20120178735A1-20120712-C00132
         		Pr29-4
    Figure US20120178735A1-20120712-C00133
         		Pr29-5
    Figure US20120178735A1-20120712-C00134
         		Pr29-6
    Figure US20120178735A1-20120712-C00135
         		Pr29-7
    Figure US20120178735A1-20120712-C00136
         		Pr29-8
  • TABLE 22
    Figure US20120178735A1-20120712-C00137
         		Pr29-9
    Figure US20120178735A1-20120712-C00138
         		Pr29-10
    Figure US20120178735A1-20120712-C00139
         		Pr29-11
    Figure US20120178735A1-20120712-C00140
         		Pr29-12
    Figure US20120178735A1-20120712-C00141
         		Pr29-13
    Figure US20120178735A1-20120712-C00142
         		Pr29-14
    Figure US20120178735A1-20120712-C00143
         		Pr29-15
  • TABLE 23
    Figure US20120178735A1-20120712-C00144
         		Pr30
    Figure US20120178735A1-20120712-C00145
         		Pr30-1
    Figure US20120178735A1-20120712-C00146
         		Pr31
    Figure US20120178735A1-20120712-C00147
         		Pr31-1
    Figure US20120178735A1-20120712-C00148
         		Pr32
    Figure US20120178735A1-20120712-C00149
         		Pr33
  • TABLE 24
    Figure US20120178735A1-20120712-C00150
         		Pr33-1
    Figure US20120178735A1-20120712-C00151
         		Pr33-2
    Figure US20120178735A1-20120712-C00152
         		Pr33-3
    Figure US20120178735A1-20120712-C00153
         		Pr33-4
    Figure US20120178735A1-20120712-C00154
         		Pr33-5
    Figure US20120178735A1-20120712-C00155
         		Pr33-6
    Figure US20120178735A1-20120712-C00156
         		Pr33-7
  • TABLE 25
    Figure US20120178735A1-20120712-C00157
         		Pr33-8
    Figure US20120178735A1-20120712-C00158
         		Pr33-9
    Figure US20120178735A1-20120712-C00159
         		Pr33-10
    Figure US20120178735A1-20120712-C00160
         		Pr33-11
    Figure US20120178735A1-20120712-C00161
         		Pr33-12
    Figure US20120178735A1-20120712-C00162
         		Pr33-13
    Figure US20120178735A1-20120712-C00163
         		Pr33-14
    Figure US20120178735A1-20120712-C00164
         		Pr33-15
  • TABLE 26
    Figure US20120178735A1-20120712-C00165
         		Pr33-16
    Figure US20120178735A1-20120712-C00166
         		Pr33-17
    Figure US20120178735A1-20120712-C00167
         		Pr33-18
    Figure US20120178735A1-20120712-C00168
         		Pr33-19
    Figure US20120178735A1-20120712-C00169
         		Pr33-20
    Figure US20120178735A1-20120712-C00170
         		Pr33-21
    Figure US20120178735A1-20120712-C00171
         		Pr34
  • TABLE 27
    Figure US20120178735A1-20120712-C00172
         		Pr34-1
    Figure US20120178735A1-20120712-C00173
         		Pr34-2
    Figure US20120178735A1-20120712-C00174
         		Pr34-3
    Figure US20120178735A1-20120712-C00175
         		Pr34-4
    Figure US20120178735A1-20120712-C00176
         		Pr34-5
    Figure US20120178735A1-20120712-C00177
         		Pr34-6
    Figure US20120178735A1-20120712-C00178
         		Pr34-7
  • TABLE 28
    Figure US20120178735A1-20120712-C00179
         		Pr34-8
    Figure US20120178735A1-20120712-C00180
         		Pr34-9
    Figure US20120178735A1-20120712-C00181
         		Pr34-10
    Figure US20120178735A1-20120712-C00182
         		Pr34-11
    Figure US20120178735A1-20120712-C00183
         		Pr34-12
    Figure US20120178735A1-20120712-C00184
         		Pr34-13
  • TABLE 29
    Figure US20120178735A1-20120712-C00185
         		Pr34-14
    Figure US20120178735A1-20120712-C00186
         		Pr34-15
    Figure US20120178735A1-20120712-C00187
         		Pr34-16
    Figure US20120178735A1-20120712-C00188
         		Pr34-17
    Figure US20120178735A1-20120712-C00189
         		Pr34-18
    Figure US20120178735A1-20120712-C00190
         		Pr34-19
    Figure US20120178735A1-20120712-C00191
         		Pr34-20
  • TABLE 30
    Figure US20120178735A1-20120712-C00192
         		Pr34-21
    Figure US20120178735A1-20120712-C00193
         		Pr34-22
    Figure US20120178735A1-20120712-C00194
         		Pr34-23
    Figure US20120178735A1-20120712-C00195
         		Pr34-24
    Figure US20120178735A1-20120712-C00196
         		Pr34-25
    Figure US20120178735A1-20120712-C00197
         		Pr34-26
    Figure US20120178735A1-20120712-C00198
         		Pr34-27
  • TABLE 31
    Figure US20120178735A1-20120712-C00199
         		Pr34-28
    Figure US20120178735A1-20120712-C00200
         		Pr34-29
    Figure US20120178735A1-20120712-C00201
         		Pr34-30
    Figure US20120178735A1-20120712-C00202
         		Pr35
    Figure US20120178735A1-20120712-C00203
         		Pr35-1
    Figure US20120178735A1-20120712-C00204
         		Pr35-2
    Figure US20120178735A1-20120712-C00205
         		Pr35-3
  • TABLE 32
    Figure US20120178735A1-20120712-C00206
         		Pr36
    Figure US20120178735A1-20120712-C00207
         		Pr36-1
    Figure US20120178735A1-20120712-C00208
         		Pr36-2
    Figure US20120178735A1-20120712-C00209
         		Pr37
    Figure US20120178735A1-20120712-C00210
         		Pr37-1
    Figure US20120178735A1-20120712-C00211
         		Pr37-2
  • TABLE 33
    Figure US20120178735A1-20120712-C00212
         		Pr37-3
    Figure US20120178735A1-20120712-C00213
         		Pr38
    Figure US20120178735A1-20120712-C00214
         		Pr38-1
    Figure US20120178735A1-20120712-C00215
         		Pr38-2
    Figure US20120178735A1-20120712-C00216
         		Pr38-3
  • TABLE 34
    Figure US20120178735A1-20120712-C00217
         		Pr38-4
    Figure US20120178735A1-20120712-C00218
         		Pr38-5
    Figure US20120178735A1-20120712-C00219
         		Pr38-6
    Figure US20120178735A1-20120712-C00220
         		Pr38-7
    Figure US20120178735A1-20120712-C00221
         		Pr38-8
  • TABLE 35
    Figure US20120178735A1-20120712-C00222
         		Pr38-9
    Figure US20120178735A1-20120712-C00223
         		Pr38-10
    Figure US20120178735A1-20120712-C00224
         		Pr38-11
    Figure US20120178735A1-20120712-C00225
         		Pr38-12
    Figure US20120178735A1-20120712-C00226
         		Pr38-13
  • TABLE 36
    Figure US20120178735A1-20120712-C00227
         		Pr38-14
    Figure US20120178735A1-20120712-C00228
         		Pr38-15
    Figure US20120178735A1-20120712-C00229
         		Pr38-16
    Figure US20120178735A1-20120712-C00230
         		Pr38-17
    Figure US20120178735A1-20120712-C00231
         		Pr38-18
    Figure US20120178735A1-20120712-C00232
         		Pr38-19
  • TABLE 37
    Figure US20120178735A1-20120712-C00233
         		Pr38-20
    Figure US20120178735A1-20120712-C00234
         		Pr38-21
    Figure US20120178735A1-20120712-C00235
         		Pr38-22
    Figure US20120178735A1-20120712-C00236
         		Pr38-23
    Figure US20120178735A1-20120712-C00237
         		Pr38-24
  • TABLE 38
    Figure US20120178735A1-20120712-C00238
         		Pr38-25
    Figure US20120178735A1-20120712-C00239
         		Pr38-26
    Figure US20120178735A1-20120712-C00240
         		Pr38-27
    Figure US20120178735A1-20120712-C00241
         		Pr38-28
    Figure US20120178735A1-20120712-C00242
         		Pr38-29
  • TABLE 39
    Figure US20120178735A1-20120712-C00243
         		Pr38-30
    Figure US20120178735A1-20120712-C00244
         		Pr38-31
    Figure US20120178735A1-20120712-C00245
         		Pr38-32
    Figure US20120178735A1-20120712-C00246
         		Pr38-33
    Figure US20120178735A1-20120712-C00247
         		Pr38-34
  • TABLE 40
    Figure US20120178735A1-20120712-C00248
         		Pr38-35
    Figure US20120178735A1-20120712-C00249
         		Pr38-36
    Figure US20120178735A1-20120712-C00250
         		Pr38-37
    Figure US20120178735A1-20120712-C00251
         		Pr38-38
    Figure US20120178735A1-20120712-C00252
         		Pr38-39
    Figure US20120178735A1-20120712-C00253
         		Pr38-40
    Figure US20120178735A1-20120712-C00254
         		Pr38-41
  • TABLE 41
    Figure US20120178735A1-20120712-C00255
         		Pr38-42
    Figure US20120178735A1-20120712-C00256
         		Pr38-43
    Figure US20120178735A1-20120712-C00257
         		Pr38-44
    Figure US20120178735A1-20120712-C00258
         		Pr38-45
    Figure US20120178735A1-20120712-C00259
         		Pr38-46
    Figure US20120178735A1-20120712-C00260
         		Pr38-47
  • TABLE 42
    Figure US20120178735A1-20120712-C00261
         		Pr38-48
    Figure US20120178735A1-20120712-C00262
         		Pr38-49
    Figure US20120178735A1-20120712-C00263
         		Pr38-50
    Figure US20120178735A1-20120712-C00264
         		Pr38-51
    Figure US20120178735A1-20120712-C00265
         		Pr38-52
    Figure US20120178735A1-20120712-C00266
         		Pr38-53
    Figure US20120178735A1-20120712-C00267
         		Pr38-54
  • TABLE 43
    Figure US20120178735A1-20120712-C00268
         		Pr-38-55
    Figure US20120178735A1-20120712-C00269
         		Pr38-56
    Figure US20120178735A1-20120712-C00270
         		Pr38-57
    Figure US20120178735A1-20120712-C00271
         		Pr38-58
    Figure US20120178735A1-20120712-C00272
         		Pr38-59
    Figure US20120178735A1-20120712-C00273
         		Pr38-60
  • TABLE 44
    Figure US20120178735A1-20120712-C00274
         		Pr38-61
    Figure US20120178735A1-20120712-C00275
         		Pr39
    Figure US20120178735A1-20120712-C00276
         		Pr39-1
    Figure US20120178735A1-20120712-C00277
         		Pr39-2
    Figure US20120178735A1-20120712-C00278
         		Pr39-3
    Figure US20120178735A1-20120712-C00279
         		Pr39-4
  • TABLE 45
    Figure US20120178735A1-20120712-C00280
         		Pr39-5
    Figure US20120178735A1-20120712-C00281
         		Pr39-6
    Figure US20120178735A1-20120712-C00282
         		Pr40
    Figure US20120178735A1-20120712-C00283
         		Pr41
    Figure US20120178735A1-20120712-C00284
         		Pr41-1
    Figure US20120178735A1-20120712-C00285
         		Pr41-2
    Figure US20120178735A1-20120712-C00286
         		Pr41-3
  • TABLE 46
    Figure US20120178735A1-20120712-C00287
         		Pr41-4
    Figure US20120178735A1-20120712-C00288
         		Pr41-5
    Figure US20120178735A1-20120712-C00289
         		Pr42
    Figure US20120178735A1-20120712-C00290
         		Pr43
    Figure US20120178735A1-20120712-C00291
         		Pr44
    Figure US20120178735A1-20120712-C00292
         		Pr44-1
    Figure US20120178735A1-20120712-C00293
         		Pr44-2
    Figure US20120178735A1-20120712-C00294
         		Pr44-3
    Figure US20120178735A1-20120712-C00295
         		Pr44-4
  • TABLE 47
    Figure US20120178735A1-20120712-C00296
         		Pr44-5
    Figure US20120178735A1-20120712-C00297
         		Pr44-6
    Figure US20120178735A1-20120712-C00298
         		Pr45
    Figure US20120178735A1-20120712-C00299
         		Pr46
    Figure US20120178735A1-20120712-C00300
         		Pr47
    Figure US20120178735A1-20120712-C00301
         		Pr47-1
    Figure US20120178735A1-20120712-C00302
         		Pr47-2
    Figure US20120178735A1-20120712-C00303
         		Pr48
    Figure US20120178735A1-20120712-C00304
         		Pr48-1
  • TABLE 48
    Figure US20120178735A1-20120712-C00305
         		Pr49
    Figure US20120178735A1-20120712-C00306
         		Pr50
    Figure US20120178735A1-20120712-C00307
         		Pr51
    Figure US20120178735A1-20120712-C00308
         		Pr51-1
    Figure US20120178735A1-20120712-C00309
         		Pr51-2
    Figure US20120178735A1-20120712-C00310
         		Pr51-3
  • TABLE 49
    Figure US20120178735A1-20120712-C00311
         		Pr51-4
    Figure US20120178735A1-20120712-C00312
         		Pr51-5
    Figure US20120178735A1-20120712-C00313
         		Pr52
    Figure US20120178735A1-20120712-C00314
         		Pr52-1
    Figure US20120178735A1-20120712-C00315
         		Pr52-2
    Figure US20120178735A1-20120712-C00316
         		Pr52-3
  • TABLE 50
    Figure US20120178735A1-20120712-C00317
         		Pr52-4
    Figure US20120178735A1-20120712-C00318
         		Pr53
    Figure US20120178735A1-20120712-C00319
         		Pr53-1
    Figure US20120178735A1-20120712-C00320
         		Pr53-2
    Figure US20120178735A1-20120712-C00321
         		Pr53-3
    Figure US20120178735A1-20120712-C00322
         		Pr53-4
    Figure US20120178735A1-20120712-C00323
         		Pr54
  • TABLE 51
    Figure US20120178735A1-20120712-C00324
         		Pr55
    Figure US20120178735A1-20120712-C00325
         		Pr55-1
    Figure US20120178735A1-20120712-C00326
         		Pr56
    Figure US20120178735A1-20120712-C00327
         		Pr56-1
    Figure US20120178735A1-20120712-C00328
         		Pr56-2
    Figure US20120178735A1-20120712-C00329
         		Pr56-3
    Figure US20120178735A1-20120712-C00330
         		Pr56-4
  • TABLE 52
    Figure US20120178735A1-20120712-C00331
         		Pr56-5
    Figure US20120178735A1-20120712-C00332
         		Pr56-6
    Figure US20120178735A1-20120712-C00333
         		Pr57
    Figure US20120178735A1-20120712-C00334
         		Pr58
    Figure US20120178735A1-20120712-C00335
         		Pr58-1
    Figure US20120178735A1-20120712-C00336
         		Pr59
    Figure US20120178735A1-20120712-C00337
         		Pr60
    Figure US20120178735A1-20120712-C00338
         		Pr61
  • TABLE 53
    Figure US20120178735A1-20120712-C00339
         		Pr62
    Figure US20120178735A1-20120712-C00340
         		Pr62-1
    Figure US20120178735A1-20120712-C00341
         		Pr62-2
    Figure US20120178735A1-20120712-C00342
         		Pr62-3
    Figure US20120178735A1-20120712-C00343
         		Pr62-4
    Figure US20120178735A1-20120712-C00344
         		Pr62-5
  • TABLE 54
    Pr62-6
    Figure US20120178735A1-20120712-C00345
    Pr62-7
    Figure US20120178735A1-20120712-C00346
    Pr62-8
    Figure US20120178735A1-20120712-C00347
    Pr62-9
    Figure US20120178735A1-20120712-C00348
     Pr62-10
    Figure US20120178735A1-20120712-C00349
     Pr62-11
    Figure US20120178735A1-20120712-C00350
  • TABLE 55
    Pr62-12
    Figure US20120178735A1-20120712-C00351
    Pr62-13
    Figure US20120178735A1-20120712-C00352
    Pr62-14
    Figure US20120178735A1-20120712-C00353
    Pr62-15
    Figure US20120178735A1-20120712-C00354
    Pr62-16
    Figure US20120178735A1-20120712-C00355
    Pr62-17
    Figure US20120178735A1-20120712-C00356
  • TABLE 56
    Pr62-18
    Figure US20120178735A1-20120712-C00357
    Pr62-19
    Figure US20120178735A1-20120712-C00358
    Pr63
    Figure US20120178735A1-20120712-C00359
    Pr64
    Figure US20120178735A1-20120712-C00360
    Pr64-1
    Figure US20120178735A1-20120712-C00361
    Pr64-2
    Figure US20120178735A1-20120712-C00362
  • TABLE 57
    Pr64-3
    Figure US20120178735A1-20120712-C00363
    Pr64-4
    Figure US20120178735A1-20120712-C00364
    Pr64-5
    Figure US20120178735A1-20120712-C00365
    Pr64-6
    Figure US20120178735A1-20120712-C00366
    Pr64-7
    Figure US20120178735A1-20120712-C00367
  • TABLE 58
    No Str
    Ex 1
    Figure US20120178735A1-20120712-C00368
    Ex 2
    Figure US20120178735A1-20120712-C00369
    Ex 3
    Figure US20120178735A1-20120712-C00370
    Ex 4
    Figure US20120178735A1-20120712-C00371
    Ex 5
    Figure US20120178735A1-20120712-C00372
    Ex 6
    Figure US20120178735A1-20120712-C00373
  • TABLE 59
    Ex 7 
    Figure US20120178735A1-20120712-C00374
    Ex 8 
    Figure US20120178735A1-20120712-C00375
    Ex 9 
    Figure US20120178735A1-20120712-C00376
    Ex 10
    Figure US20120178735A1-20120712-C00377
    Ex 11
    Figure US20120178735A1-20120712-C00378
    Ex 12
    Figure US20120178735A1-20120712-C00379
    Ex 13
    Figure US20120178735A1-20120712-C00380
    Ex 14
    Figure US20120178735A1-20120712-C00381
  • TABLE 60
    Ex 15
    Figure US20120178735A1-20120712-C00382
    Ex 16
    Figure US20120178735A1-20120712-C00383
    Ex 17
    Figure US20120178735A1-20120712-C00384
    Ex 18
    Figure US20120178735A1-20120712-C00385
    Ex 19
    Figure US20120178735A1-20120712-C00386
    Ex 20
    Figure US20120178735A1-20120712-C00387
    Ex 21
    Figure US20120178735A1-20120712-C00388
  • TABLE 61
    Ex 22
    Figure US20120178735A1-20120712-C00389
    Ex 23
    Figure US20120178735A1-20120712-C00390
    Ex 24
    Figure US20120178735A1-20120712-C00391
    Ex 25
    Figure US20120178735A1-20120712-C00392
    Ex 26
    Figure US20120178735A1-20120712-C00393
    Ex 27
    Figure US20120178735A1-20120712-C00394
  • TABLE 62
    Ex 28
    Figure US20120178735A1-20120712-C00395
    Ex 29
    Figure US20120178735A1-20120712-C00396
    Ex 30
    Figure US20120178735A1-20120712-C00397
    Ex 31
    Figure US20120178735A1-20120712-C00398
    Ex 32
    Figure US20120178735A1-20120712-C00399
    Ex 33
    Figure US20120178735A1-20120712-C00400
  • TABLE 63
    Ex 34
    Figure US20120178735A1-20120712-C00401
    Ex 35
    Figure US20120178735A1-20120712-C00402
    Ex 36
    Figure US20120178735A1-20120712-C00403
    Ex 37
    Figure US20120178735A1-20120712-C00404
    Ex 38
    Figure US20120178735A1-20120712-C00405
  • TABLE 64
    Ex 39
    Figure US20120178735A1-20120712-C00406
    Ex 40
    Figure US20120178735A1-20120712-C00407
    Ex 41
    Figure US20120178735A1-20120712-C00408
    Ex 42
    Figure US20120178735A1-20120712-C00409
    Ex 43
    Figure US20120178735A1-20120712-C00410
  • TABLE 65
    Ex 44
    Figure US20120178735A1-20120712-C00411
    Ex 45
    Figure US20120178735A1-20120712-C00412
    Ex 46
    Figure US20120178735A1-20120712-C00413
    Ex 47
    Figure US20120178735A1-20120712-C00414
    Ex 48
    Figure US20120178735A1-20120712-C00415
  • TABLE 66
    Ex 49
    Figure US20120178735A1-20120712-C00416
    Ex 50
    Figure US20120178735A1-20120712-C00417
    Ex 51
    Figure US20120178735A1-20120712-C00418
    Ex 52
    Figure US20120178735A1-20120712-C00419
    Ex 53
    Figure US20120178735A1-20120712-C00420
    Ex 54
    Figure US20120178735A1-20120712-C00421
  • TABLE 67
    Ex 55
    Figure US20120178735A1-20120712-C00422
    Ex 56
    Figure US20120178735A1-20120712-C00423
    Ex 57
    Figure US20120178735A1-20120712-C00424
    Ex 58
    Figure US20120178735A1-20120712-C00425
    Ex 59
    Figure US20120178735A1-20120712-C00426
  • TABLE 68
    Ex 60
    Figure US20120178735A1-20120712-C00427
    Ex 61
    Figure US20120178735A1-20120712-C00428
    Ex 62
    Figure US20120178735A1-20120712-C00429
    Ex 63
    Figure US20120178735A1-20120712-C00430
    Ex 64
    Figure US20120178735A1-20120712-C00431
  • TABLE 69
    Figure US20120178735A1-20120712-C00432
         		Ex65
    Figure US20120178735A1-20120712-C00433
         		Ex66
    Figure US20120178735A1-20120712-C00434
         		Ex67
    Figure US20120178735A1-20120712-C00435
         		Ex68
  • TABLE 70
    Figure US20120178735A1-20120712-C00436
         		Ex69
    Figure US20120178735A1-20120712-C00437
         		Ex70
    Figure US20120178735A1-20120712-C00438
         		Ex71
    Figure US20120178735A1-20120712-C00439
         		Ex72
    Figure US20120178735A1-20120712-C00440
         		Ex73
  • TABLE 71
    Figure US20120178735A1-20120712-C00441
         		Ex74
    Figure US20120178735A1-20120712-C00442
         		Ex75
    Figure US20120178735A1-20120712-C00443
         		Ex76
    Figure US20120178735A1-20120712-C00444
         		Ex77
    Figure US20120178735A1-20120712-C00445
         		Ex78
  • TABLE 72
    Figure US20120178735A1-20120712-C00446
         		Ex79
    Figure US20120178735A1-20120712-C00447
         		Ex80
    Figure US20120178735A1-20120712-C00448
         		Ex81
    Figure US20120178735A1-20120712-C00449
         		Ex82
    Figure US20120178735A1-20120712-C00450
         		Ex83
    Figure US20120178735A1-20120712-C00451
         		Ex84
  • TABLE 73
    Figure US20120178735A1-20120712-C00452
         		Ex85
    Figure US20120178735A1-20120712-C00453
         		Ex86
    Figure US20120178735A1-20120712-C00454
         		Ex87
    Figure US20120178735A1-20120712-C00455
         		Ex88
    Figure US20120178735A1-20120712-C00456
         		Ex89
  • TABLE 74
    Figure US20120178735A1-20120712-C00457
         		Ex90
    Figure US20120178735A1-20120712-C00458
         		Ex91
    Figure US20120178735A1-20120712-C00459
         		Ex92
    Figure US20120178735A1-20120712-C00460
         		Ex93
  • TABLE 75
    Figure US20120178735A1-20120712-C00461
         		Ex94
    Figure US20120178735A1-20120712-C00462
         		Ex95
    Figure US20120178735A1-20120712-C00463
         		Ex96
    Figure US20120178735A1-20120712-C00464
         		Ex97
    Figure US20120178735A1-20120712-C00465
         		Ex98
  • TABLE 76
    Figure US20120178735A1-20120712-C00466
         		Ex99
    Figure US20120178735A1-20120712-C00467
         		Ex100
    Figure US20120178735A1-20120712-C00468
         		Ex101
    Figure US20120178735A1-20120712-C00469
         		Ex102
  • TABLE 77
    Figure US20120178735A1-20120712-C00470
         		Ex103
    Figure US20120178735A1-20120712-C00471
         		Ex104
    Figure US20120178735A1-20120712-C00472
         		Ex105
    Figure US20120178735A1-20120712-C00473
         		Ex106
    Figure US20120178735A1-20120712-C00474
         		Ex107
  • TABLE 78
    Figure US20120178735A1-20120712-C00475
         		Ex108
    Figure US20120178735A1-20120712-C00476
         		Ex109
    Figure US20120178735A1-20120712-C00477
         		Ex110
    Figure US20120178735A1-20120712-C00478
         		Ex111
    Figure US20120178735A1-20120712-C00479
         		Ex112
  • TABLE 79
    Figure US20120178735A1-20120712-C00480
         		Ex113
    Figure US20120178735A1-20120712-C00481
         		Ex114
    Figure US20120178735A1-20120712-C00482
         		Ex115
    Figure US20120178735A1-20120712-C00483
         		Ex116
    Figure US20120178735A1-20120712-C00484
         		Ex117
    Figure US20120178735A1-20120712-C00485
         		Ex118
  • TABLE 80
    Figure US20120178735A1-20120712-C00486
         		Ex119
    Figure US20120178735A1-20120712-C00487
         		Ex120
    Figure US20120178735A1-20120712-C00488
         		Ex121
    Figure US20120178735A1-20120712-C00489
         		Ex122
    Figure US20120178735A1-20120712-C00490
         		Ex123
    Figure US20120178735A1-20120712-C00491
         		Ex124
    Figure US20120178735A1-20120712-C00492
         		Ex125
  • TABLE 81
    Figure US20120178735A1-20120712-C00493
         		Ex126
    Figure US20120178735A1-20120712-C00494
         		Ex127
    Figure US20120178735A1-20120712-C00495
         		Ex128
    Figure US20120178735A1-20120712-C00496
         		Ex129
    Figure US20120178735A1-20120712-C00497
         		Ex130
    Figure US20120178735A1-20120712-C00498
         		Ex131
    Figure US20120178735A1-20120712-C00499
         		Ex132
  • TABLE 82
    Figure US20120178735A1-20120712-C00500
         		Ex133
    Figure US20120178735A1-20120712-C00501
         		Ex134
    Figure US20120178735A1-20120712-C00502
         		Ex135
    Figure US20120178735A1-20120712-C00503
         		Ex136
    Figure US20120178735A1-20120712-C00504
         		Ex137
    Figure US20120178735A1-20120712-C00505
         		Ex138
  • TABLE 83
    Figure US20120178735A1-20120712-C00506
         		Ex139
    Figure US20120178735A1-20120712-C00507
         		Ex140
    Figure US20120178735A1-20120712-C00508
         		Ex141
    Figure US20120178735A1-20120712-C00509
         		Ex142
    Figure US20120178735A1-20120712-C00510
         		Ex143
    Figure US20120178735A1-20120712-C00511
         		Ex144
  • TABLE 84
    Figure US20120178735A1-20120712-C00512
         		Ex145
    Figure US20120178735A1-20120712-C00513
         		Ex146
    Figure US20120178735A1-20120712-C00514
         		Ex147
    Figure US20120178735A1-20120712-C00515
         		Ex148
    Figure US20120178735A1-20120712-C00516
         		Ex149
    Figure US20120178735A1-20120712-C00517
         		Ex150
  • TABLE 85
    Figure US20120178735A1-20120712-C00518
         		Ex151
    Figure US20120178735A1-20120712-C00519
         		Ex152
    Figure US20120178735A1-20120712-C00520
         		Ex153
    Figure US20120178735A1-20120712-C00521
         		Ex154
    Figure US20120178735A1-20120712-C00522
         		Ex155
    Figure US20120178735A1-20120712-C00523
         		Ex156
  • TABLE 86
    Figure US20120178735A1-20120712-C00524
         		Ex157
    Figure US20120178735A1-20120712-C00525
         		Ex158
    Figure US20120178735A1-20120712-C00526
         		Ex159
    Figure US20120178735A1-20120712-C00527
         		Ex160
    Figure US20120178735A1-20120712-C00528
         		Ex161
    Figure US20120178735A1-20120712-C00529
         		Ex162
  • TABLE 87
    Figure US20120178735A1-20120712-C00530
         		Ex163
    Figure US20120178735A1-20120712-C00531
         		Ex164
    Figure US20120178735A1-20120712-C00532
         		Ex165
    Figure US20120178735A1-20120712-C00533
         		Ex166
    Figure US20120178735A1-20120712-C00534
         		Ex167
    Figure US20120178735A1-20120712-C00535
         		Ex168
    Figure US20120178735A1-20120712-C00536
         		Ex169
  • TABLE 88
    Figure US20120178735A1-20120712-C00537
         		Ex170
    Figure US20120178735A1-20120712-C00538
         		Ex171
    Figure US20120178735A1-20120712-C00539
         		Ex172
    Figure US20120178735A1-20120712-C00540
         		Ex173
    Figure US20120178735A1-20120712-C00541
         		Ex174
    Figure US20120178735A1-20120712-C00542
         		Ex175
  • TABLE 89
    Figure US20120178735A1-20120712-C00543
         		Ex176
    Figure US20120178735A1-20120712-C00544
         		Ex177
    Figure US20120178735A1-20120712-C00545
         		Ex178
    Figure US20120178735A1-20120712-C00546
         		Ex179
    Figure US20120178735A1-20120712-C00547
         		Ex180
    Figure US20120178735A1-20120712-C00548
         		Ex181
  • TABLE 90
    Figure US20120178735A1-20120712-C00549
         		Ex182
    Figure US20120178735A1-20120712-C00550
         		Ex183
    Figure US20120178735A1-20120712-C00551
         		Ex184
    Figure US20120178735A1-20120712-C00552
         		Ex185
    Figure US20120178735A1-20120712-C00553
         		Ex186
    Figure US20120178735A1-20120712-C00554
         		Ex187
  • TABLE 91
    Figure US20120178735A1-20120712-C00555
         		Ex188
    Figure US20120178735A1-20120712-C00556
         		Ex189
    Figure US20120178735A1-20120712-C00557
         		Ex190
    Figure US20120178735A1-20120712-C00558
         		Ex191
    Figure US20120178735A1-20120712-C00559
         		Ex192
    Figure US20120178735A1-20120712-C00560
         		Ex193
  • TABLE 92
    Figure US20120178735A1-20120712-C00561
         		Ex194
    Figure US20120178735A1-20120712-C00562
         		Ex195
    Figure US20120178735A1-20120712-C00563
         		Ex196
    Figure US20120178735A1-20120712-C00564
         		Ex197
    Figure US20120178735A1-20120712-C00565
         		Ex198
    Figure US20120178735A1-20120712-C00566
         		Ex199
  • TABLE 93
    Figure US20120178735A1-20120712-C00567
         		Ex200
    Figure US20120178735A1-20120712-C00568
         		Ex201
    Figure US20120178735A1-20120712-C00569
         		Ex202
    Figure US20120178735A1-20120712-C00570
         		Ex203
    Figure US20120178735A1-20120712-C00571
         		Ex204
    Figure US20120178735A1-20120712-C00572
         		Ex205
  • TABLE 94
    Figure US20120178735A1-20120712-C00573
         		Ex206
    Figure US20120178735A1-20120712-C00574
         		Ex207
    Figure US20120178735A1-20120712-C00575
         		Ex208
    Figure US20120178735A1-20120712-C00576
         		Ex209
    Figure US20120178735A1-20120712-C00577
         		Ex210
    Figure US20120178735A1-20120712-C00578
         		Ex211
  • TABLE 95
    Figure US20120178735A1-20120712-C00579
         		Ex212
    Figure US20120178735A1-20120712-C00580
         		Ex213
    Figure US20120178735A1-20120712-C00581
         		Ex214
    Figure US20120178735A1-20120712-C00582
         		Ex215
    Figure US20120178735A1-20120712-C00583
         		Ex216
    Figure US20120178735A1-20120712-C00584
         		Ex217
  • TABLE 96
    Figure US20120178735A1-20120712-C00585
         		Ex218
    Figure US20120178735A1-20120712-C00586
         		Ex219
    Figure US20120178735A1-20120712-C00587
         		Ex220
    Figure US20120178735A1-20120712-C00588
         		Ex221
    Figure US20120178735A1-20120712-C00589
         		Ex222
    Figure US20120178735A1-20120712-C00590
         		Ex223
    Figure US20120178735A1-20120712-C00591
         		Ex224
  • TABLE 97
    Figure US20120178735A1-20120712-C00592
         		Ex225
    Figure US20120178735A1-20120712-C00593
         		Ex226
    Figure US20120178735A1-20120712-C00594
         		Ex227
    Figure US20120178735A1-20120712-C00595
         		Ex228
    Figure US20120178735A1-20120712-C00596
         		Ex229
    Figure US20120178735A1-20120712-C00597
         		Ex230
  • TABLE 98
    Figure US20120178735A1-20120712-C00598
         		Ex231
    Figure US20120178735A1-20120712-C00599
         		Ex232
    Figure US20120178735A1-20120712-C00600
         		Ex233
    Figure US20120178735A1-20120712-C00601
         		Ex234
    Figure US20120178735A1-20120712-C00602
         		Ex235
    Figure US20120178735A1-20120712-C00603
         		Ex236
  • TABLE 99
    Pr DATA
    Pr1 MS+: 396
    Pr2 MS+: 281
    Pr2-1 MS+: 267
    Pr2-2 MS+: 385
    Pr2-3 MS+: 281
    Pr2-4 MS−: 387
    Pr3 NMR: 2.56(2H, t, J = 6.0 Hz), 4.44(2H, t, J = 6.0 Hz), 5.18(2H, s), 5.81(1H, d, J = 2.6
    Hz), 6.98(1H, dd, J = 2.6, 8.9 Hz), 7.32-7.48(5H, m), 7.73(1H, d, J = 8.9 Hz), 10.22(1H, s)
    Pr4 MS−: 209
    Pr5 MS+: 253
    Pr5-1 MS+: 267
    Pr6 MS+: 361
    Pr6-1 NMR: 2.36(3H, s), 3.36(3H, s), 4.86(2H, d), 5.21(2H, s), 6.41(1H, d), 6.56(1H,
    dd), 7.76(1H, d), 9.57(1H, s)
    Pr6-2 MS+: 261
    Pr6-3 MS+: 273
    Pr6-4 NMR: 0.91(3H, t), 1.55-1.66(2H, m), 2.57(2H, t), 3.86(3H, s), 4.96(2H, s), 6.81(1H,
    d), 6.88(1H, s), 7.05(1H, s), 7.16(1H, d), 7.21(1H, dd), 7.38(1H, d), 7.46(1H, d),
    7.56(1H, d), 7.63(1H, s), 9.57(1H, s)
    Pr6-5 MS−: 335
    Pr6-6 MS+: 397
    Pr6-7 MS+: 395
    Pr6-8 MS+: 257
    Pr6-9 MS+: 451
    Pr6-10 MS+: 271
    Pr6-11 MS+: 221
    Pr7 MS+: 256
    Pr8 MS+: 237
    Pr9 ESI−: 199
    Pr9-1 MS−: 195
    Pr9-2 MS+: 235
    Pr9-3 MS−: 195
    Pr9-4 MS+: 183
    Pr10 MS+: 425
    Pr10-1 MS+: 303
    Pr11 NMR: 5.04(2H, d, J = 1.3 Hz), 7.09-7.16(2H, m), 7.59(1H, d, J = 8.4 Hz), 7.67(1H,
    s), 9.61(1H, s)
    Pr11-1 NMR: 5.08(2H, d), 7.04-7.07(1H, m), 7.29(1H, dd), 7.74-7.77(1H, m), 9.68(1H, s)
    Pr12 MS+: 303
    Pr12-1 MS+: 317
    Pr12-2 NMR: 3.87(3H, s), 3.90(3H, s), 6.51-6.56(2H, m), 10.15(1H, d)
    Pr12-3 ESI−: 151
    Pr12-4 NMR: 3.67(2H, s), 5.41(2H, s), 6.90(1H, dd), 7.05(1H, d), 7.47(1H, d), 7.56(1H,
    s), 8.02(1H, d), 8.08-8.20(2H, m), 9.57(1H, s)
    Pr13 MS+: 327
    Pr13-1 MS+: 387
  • TABLE 100
    Pr14 NMR: 1.31(2H, d), 4.89-4.99(1H, m), 7.49(1H, d), 8.09(1H, dd), 8.13(1H, dd)
    Pr14-1 MS+: 319
    Pr14-2 4.56(2H, dt), 6.45(1H, tt), 7.41(1H, d), 7.86(1H, dd), 8.07(1H, d)
    Pr14-3 ESI+: 349, 351
    Pr14-4 ESI+: 284
    Pr14-5 NMR: 1.46(3H, d), 3.91(3H, s), 5.66-5.76(1H, m), 7.56(1H, d), 7.85(1H, d), 7.96
    (1H, s)
    Pr14-6 ESI+: 283
    Pr14-7 EI+: 316
    Pr14-8 ESI+: 299
    Pr14-9 ESI+: 222
    Pr14-10 EI: 302
    Pr14-11 EI: 215
    Pr14-12 NMR: 1.49(3H, d), 3.87(3H, s), 5.12-5.21(1H, m), 8.00(2H, s)
    Pr14-13 ESI+: 230
    Pr14-14 EI+: 227
    Pr14-15 ESI+: 338
    Pr14-16 EI: 243
    Pr15 MS+: 310
    Pr15-1 MS+: 293
    Pr15-2 MS+: 271
    Pr15-3 ESI+: 262
    Pr15-4 ESI+: 274
    Pr16 MS+: 226
    Pr17 NMR: 3.87(3H, s), 7.66-7.73(1H, m), 7.80-7.87(1H, m), 7.94-8.00(1H, m)
    Pr18 NMR: 1.24(3H, t), 2.81(2H, q), 3.82(3H, s), 7.72(1H, s)
    Pr18-1 EI+: 223
    Pr18-2 NMR: 3.87(3H, s), 7.58(1H, t), 7.98(1H, ddd), 8.10(1H, dd)
    Pr18-3 EI+: 222
    Pr18-4 ESI+: 245
    Pr18-5 ESI+: 245
    Pr18-6 EI+: 238
    Pr19 MS+: 270
    Pr20 MS+: 319, 321
    Pr21 MS+: 323
    Pr22 MS+: 296
    Pr23 MS+: 381, 383
    Pr23-1 NMR: 0.93(3H, d), 2.00-2.13(1H, m), 2.46-2.53(1H, m), 2.69(1H, dd), 3.39(1H,
    dd), 3.51(1H, dd), 7.23(2H, d), 7.35(2H, d)
    Pr24 MS+: 235
    Pr25 MS+: 292
    Pr25-1 NMR: 3.93(3H, s), 6.30(2H, dd), 7.01(2H, dd), 7.69(1H, d), 8.32(2H, s)
    Pr26 NMR: 0.06(9H, s), 2.60(2H, t), 3.02(2H, t), 7.84(1H, d), 7.97(1H, s), 8.04(1H, d)
    Pr27 NMR: 0.91(3H, t, J = 7.3 Hz), 1.55-1.66(2H, m), 2.56(2H, t, J = 7.9 Hz), 3.81(3H, s),
    4.92(2H, d, J = 1.0 Hz), 5.03(2H, s), 6.54(1H, d, J = 2.3 Hz), 6.66(1H, dd, J = 2.4, 8.5
    Hz), 6.78(1H, dd, J = 1.3, 7.6 Hz), 6.88(1H, d, J = 1.3 Hz), 7.26(1H, d, J = 7.6 Hz), 7.34
    (1H, d, J = 8.5 Hz), 7.58(1H, s), 9.51(1H, s)
    Pr27-1 MS+: 319
    Pr27-2 MS+: 409
  • TABLE 101
    Pr27-3 MS+: 375
    Pr27-4 MS+: 435, 437
    Pr27-5 MS+: 389
    Pr27-6 MS+: 395
    Pr28 MS−: 401
    Pr28-1 MS+: 389
    Pr28-2 MS+: 351
    Pr28-3 NMR: 4.93(2H, d), 5.28(2H, s), 6.59(1H, d), 6.71(1H, dd), 7.35(1H, d), 7.58(1H,
    m), 7.66(2H, d), 7.78(2H, d), 9.51(1H, s)
    Pr28-4 NMR: 4.93(2H, d), 5.27(2H, s), 6.57(1H, d), 6.69(1H, dd), 7.36(1H, d), 7.58-7.63
    (2H, m), 7.72-7.75(2H, m), 7.81(1H, d), 9.52(1H, s)
    Pr28-5 MS−: 415
    Pr28-6 NMR: 2.71(2H, t, J = 6.4 Hz), 4.50(2H, t, J = 6.4 Hz), 5.18(2H, s), 6.63(1H, d, J = 2.4
    Hz), 6.71(1H, dd, J = 2.4, 8.8 Hz), 7.32-7.47(5H, m), 7.69(1H, d, J = 8.8 Hz)
    Pr28-7 MS+: 439
    Pr28-8 MS+: 331
    Pr28-9 NMR: 2.57(2H, t, J = 6.0 Hz), 4.50(2H, t, J = 6.0 Hz), 5.42(2H, s), 6.85(1H, d, J = 2.6
    Hz), 7.00(1H, dd, J = 2.6, 8.9 Hz), 7.77(1H, d, J = 8.9 Hz), 8.04(1H, d, J = 8.1Hz), 8.12
    (1H, s), 8.17(1H, d, J = 8.1 Hz), 10.23(1H, s)
    Pr28-10 MS+: 431
    Pr28-11 MS−: 435
    Pr28-12 NMR: 4.97(2H, d), 5.39(2H, s), 6.48-6.51(1H, m), 6.70(1H, dd), 7.70(1H, d), 8.02
    (1H, d), 8.11(1H, s), 8.17(1H, d), 9.59(1H, s)
    Pr28-14 MS+: 455
    Pr28-15 MS−: 415
    Pr28-16 MS−: 419
    Pr28-17 MS+: 429
    Pr28-18 ESI+: 469
    Pr28-19 NMR: 0.91(3H, d), 2.10-2.21(1H, m), 2.45-2.53(1H, m), 2.77(1H, dd), 3.79-3.89
    (2H, m), 4.95(2H, d), 6.36-6.38(1H, m), 6.55(1H, dd), 7.22(2H, d), 7.34(2H, d),
    7.69(1H, s), 9.58(1H, s)
    Pr28-20 ESI−: 429
    Pr28-21 ESI+: 399
    Pr28-22 ESI+: 433
    Pr28-23 ESI−: 463
    Pr28-24 ESI+: 435
    Pr28-25 MS+: 365
    Pr28-26 ESI+: 439
    Pr28-27 ESI+: 381
    Pr29 NMR: 5.00(2H, s), 7.11(1H, s), 7.21-7.28(1H, m), 7.43-7.52(2H, m), 7.77-7.85(4H,
    m), 9.61(1H, s)
    Pr29-1 NMR: 4.99(2H, d), 7.04-7.06(1H, m), 7.20(1H, dd), 7.42-7.48(5H, m), 7.55-7.59
    (1H, m), 7.65-7.67(1H, m), 9.60(1H, s)
    Pr29-2 NMR: 3.80(3H, s), 4.98(2H, d), 6.98-7.02(3H, m), 7.16(1H, dd), 7.43(1H, d), 7.51
    (2H, d), 7.64-7.66(1H, m), 9.59(1H, s)
    Pr29-3 NMR: 2.34(3H, s), 4.99(2H, d), 7.01-7.03(1H, m), 7.17(1H, dd), 7.25(2H, d), 7.44
    (1H, d), 7.46(2H, d), 7.64-7.66(1H, m), 9.59(1H, s)
    Pr29-4 NMR: 5.00(2H, d), 7.09-7.11(1H, m), 7.24(1H, dd), 7.48(1H, d), 7.65-7.68(1H,
    m), 7.76(2H, d), 7.92(2H, d), 9.61(1H, s)
  • TABLE 102
    Pr29-5 NMR: 5.00(2H, d), 7.09-7.11(1H, m), 7.24(1H, dd), 7.47(1H, d), 7.65-7.72(2H,
    m), 7.81(1H, dm), 7.88(1H, dm), 7.93-7.96(1H, m), 9.61(1H, s)
    Pr29-6 NMR: 5.00(2H, d), 6.99-7.03(1H, m), 7.18(1H, dd), 7.49(1H, d), 7.61-7.69(2H,
    m), 7.75(1H, t), 7.84(2H, t), 9.61(1H, s)
    Pr29-7 NMR: 1.27-1.86(10H, m), 2.58-2.71(1H, m), 4.95(2H, s), 6.83-6.84(1H, m), 7.00
    (1H, dd), 7.36(1H, d), 7.61-7.63(1H, m), 9.57(1H, s)
    Pr29-8 NMR: 1.22-1.36(2H, m), 1.46-1.68(4H, m), 1.73-1.83(2H, m), 2.02-2.15(1H, m),
    2.44(2H, d), 4.95(2H, d), 6.83-6.86(1H, m), 7.01(1H, dd), 7.36(1H, d), 7.60-7.63
    (1H, m), 9.57(1H, s)
    Pr29-9 NMR: 1.28(9H, s), 4.95(2H, d), 6.80-6.82(1H, m), 6.98(1H, dd), 7.35(1H, d), 7.61-
    7.63(1H, m), 9.57(1H, s)
    Pr29-10 NMR: 0.90(6H, d), 1.44(2H, q), 1.64-1.77(1H, m), 2.44(2H, t), 4.95(2H, d), 6.82-
    6.85(1H, m), 7.00(1H, dd), 7.36(1H, d), 7.60-7.63(1H, m), 9.57(1H, s)
    Pr29-11 NMR: 4.99(2H, d), 7.04-7.06(1H, m), 7.17-7.23(2H, m), 7.42-7.49(2H, m), 7.65-
    7.67(1H, m), 7.69-7.77(1H, m), 9.60(1H, s)
    Pr29-12 NMR: 5.03(2H, d), 7.02(1H, s), 7.19(1H, dd), 7.76-7.85(5H, m), 9.67(1H, s)
    Pr29-13 NMR: 2.72(2H, t), 2.85(2H, t), 4.95(2H, d), 6.79(1H, s), 6.97(1H, dd), 7.19-7.26
    (1H, m), 7.29-7.32(4H, m), 7.35(1H, d), 7.61(1H, s), 9.57(1H, s)
    Pr29-14 NMR: 1.79-1.89(2H, m), 2.44(2H, t), 2.72(2H, t), 4.99(2H, d), 6.78(1H, s), 6.95
    (1H, dd), 7.16-7.33(5H, m), 7.72-7.75(1H, m), 9.65(1H, s)
    Pr29-15 NMR: 2.84(2H, t), 3.13(2H, t), 4.95(2H, d), 6.81(1H, s), 6.97(1H, dd), 7.36(1H, d),
    7.61-7.64(1H, m), 7.92(1H, d), 8.00(1H, s), 8.09(1H, d), 9.56(1H, s)
    Pr30 NMR: 0.24(9H, s), 0.88(6H, d), 1.77-1.90(1H, m), 2.46(2H, d), 7.07(2H, d), 7.37
    (2H, d)
    Pr30-1 NMR: 0.27(9H, s), 7.69-7.75(2H, m), 7.88(1H, s)
    Pr31 NMR: 0.86(6H, d), 1.78-1.92(1H, m), 2.49(2H, d), 5.02(2H, d), 6.93(1H, s), 7.10
    (1H, dd), 7.24(2H, d), 7.49(2H, d), 7.76-7.77(1H, m), 9.66(1H, s)
    Pr31-1 NMR: 5.05(2H, d), 6.96(1H, s), 7.13(1H, dd), 7.78-7.79(1H, m), 8.08(1H, d), 8.16
    (1H, s), 8.17(1H, d), 9.68(1H, s)
    Pr32 NMR: 1.47(3H, d), 4.98-5.05(1H, m), 5.96(1H, d), 7.10(1H, s), 7.35-7.50(5H, m)
    Pr33 MS−: 287
    Pr33-1 NMR: 4.60(1H, d), 4.85(2H, d), 4.90(1H, d), 5.41(1H, t), 7.32(1H, d), 7.38(1H, dd),
    7.70(1H, d)
    Pr33-2 EI+: 226
    Pr33-3 EI+: 232
    Pr33-4 NMR: 4.60(1H, d), 4.85(2H, d), 4.90(1H, d), 5.41(1H, t), 7.32(1H, d), 7.38(1H, dd),
    7.70(1H, d)
    Pr33-5 EI+: 234
    Pr33-6 ESI+: 259
    Pr33-7 ESI+: 257
    Pr33-8 ESI+: 223
    Pr33-9 EI+: 288
    Pr33-10 EI+: 240
    Pr33-11 EI+: 210
    Pr33-12 ESI+: 245
    Pr33-13 EI: 244
    Pr33-14 EI: 220
  • TABLE 103
    Pr33-15 EI: 244
    Pr33-16 ESI+: 260
    Pr33-17 ESI+: 259
    Pr33-18 NMR: 1.44(3H, d), 4.44(2H, d), 5.17-5.29(2H, m), 7.25(1H, dd), 7.31(1H, d), 7.40
    (1H, d)
    Pr33-19 ESI+: 257
    Pr33-20 ESI+: 223
    Pr33-21 ESI−: 287
    Pr34 MS+: 206
    Pr34-1 MS+: 243
    Pr34-2 MS+: 198
    Pr34-3 NMR: 4.72(2H, d), 5.87(1H, t), 7.13(1H, d), 7.41-7.47(2H, m), 7.52-7.58(2H, m)
    Pr34-4 NMR: 4.62(2H, d), 5.63(1H, t), 7.03(1H, s), 7.34-7.41(1H, m), 7.43-7.49(2H, m),
    7.52-7.57(2H, m)
    Pr34-5 NMR: 1.20(3H, t), 2.81(2H, q), 4.58(2H, d), 5.39(1H, t), 6.89(1H, s), 7.28-7.46
    (5H, m)
    Pr34-6 MS+: 255
    Pr34-7 NMR: 1.18(3H, t), 2.71(2H, q), 4.54(2H, d), 5.50(1H, t), 6.84(1H, s)
    Pr34-8 MS+: 255
    Pr34-9 MS+: 304
    Pr34-10 MS−: 267
    Pr34-11 NMR: 4.67(2H, d), 5.54(1H, t), 6.29(2H, t), 7.48(2H, t), 7.79-7.81(2H, m), 7.88-
    7.91(1H, m)
    Pr34-12 NMR: 1.86(3H, s), 4.69(2H, d), 5.80(1H, t), 7.22-7.27(2H, m), 7.42-7.50(3H, m)
    Pr34-13 MS+: 359
    Pr34-14 MS+: 361
    Pr34-15 MS−: 240
    Pr34-16 MS+: 243
    Pr34-17 MS+: 439
    Pr34-18 EI+: 288
    Pr34-19 EI+: 255
    Pr34-20 NMR: 0.88(6H, d), 1.85-1.97(1H, m), 2.60(2H, d), 4.54(2H, d), 5.31(1H, t), 7.40
    (1H, d), 7.51(1H, d), 7.61(1H, s)
    Pr34-21 ESI+: 321, 323
    Pr34-22 ESI+: 256
    Pr34-23 ESI−: 287
    Pr34-24 ESI+: 234
    Pr34-25 EI+: 270
    Pr34-26 EI+: 266
    Pr34-27 EI+: 272
    Pr34-28 EI+: 274
    Pr34-29 NMR: 1.45(3H, d), 4.47(2H, d), 4.95-5.06(1H, m), 5.42(1H, t), 7.44(2H, s)
    Pr34-30 ESI+: 290
    Pr35 MS+: 325
    Pr35-1 MS+: 321
  • TABLE 104
    Pr35-2 MS+: 323
    Pr35-3 ESI−: 391
    Pr36 MS−: 407
    Pr36-1 ESI+: 445
    Pr36-2 EI: 245
    Pr37 MS+: 269
    Pr37-1 MS+: 283
    Pr37-2 MS+: 283
    Pr37-3 MS+: 367
    Pr38 MS+: 382
    Pr38-1 MS+: 324
    Pr38-2 MS+: 356
    Pr38-3 MS+: 331
    Pr38-4 NMR: 4.94(2H, d), 5.44(2H, s), 6.44(1H, d), 6.74(1H, dd), 7.35-7.51(7H, m), 7.59
    (1H, s), 9.52(1H, s)
    Pr38-5 MS+: 418
    Pr38-6 MS+: 453
    Pr38-7 MS−: 449
    Pr38-8 MS+: 349
    Pr38-9 NMR: 3.04(2H, s), 4.93(2H, s), 5.33(2H, s), 6.62(1H, d), 6.72(1H, dd), 7.28-7.43
    (3H, m), 7.44-7.50(2H, m), 7.52-7.60(3H, m), 9.52(1H, s)
    Pr38-10 NMR: 1.21(3H, t), 2.85(2H, q), 4.93(2H, s), 5.29(2H, s), 6.61(1H, d), 6.71(1H, dd),
    7.18(1H, s), 7.31-7.48(6H, m), 7.58(1H, s), 9.51(1H, s)
    Pr38-11 MS−: 433
    Pr38-12 MS+: 391
    Pr38-13 MS+: 433
    Pr38-14 MS−: 445
    Pr38-15 MS+: 455
    Pr38-16 NMR: 1.19(3H, t), 2.74(2H, q), 4.93(2H, s), 5.27(2H, s), 6.58(1H, d), 6.68(1H, dd),
    7.15(1H, s), 7.34(1H, d), 7.57(1H, s), 9.51(1H, s)
    Pr38-17 MS+: 413
    Pr38-18 MS+: 417
    Pr38-19 MS−: 385
    Pr38-20 NMR: 4.97(2H, s), 5.32(2H, s), 6.54(1H, d), 6.72(1H, dd), 7.30-7.43(2H, m), 7.43-
    7.49(4H, m), 7.69-7.72(1H, m), 7.74-7.80(1H, m), 7.90-7.93(1H, m), 9.59(1H, s)
    Pr38-21 MS+: 441
    Pr38-22 MS+: 480
    Pr38-23 MS+: 467
    Pr38-24 MS−: 447
    Pr38-25 NMR: 4.96(2H, s), 5.26(2H, s), 6.32(2H, t), 7.53(2H, t), 7.69-7.71(1H, m), 7.80-
    7.83(1H, m), 7.93-7.97(2H, m), 9.59(1H, s)
    Pr38-26 MS+: 434
    Pr38-27 MS−: 416
    Pr38-28 MS+: 451
  • TABLE 105
    Pr38-29 MS+: 417
    Pr38-30 MS+: 465
    Pr38-31 MS+: 435
    Pr38-32 MS+: 469
    Pr38-33 MS+: 467
    Pr38-34 MS+: 421
    Pr38-35 ESI+: 487
    Pr38-36 ESI+: 369
    Pr38-37 ESI+: 435
    Pr38-38 ESI+: 413
    Pr38-39 ESI+: 399
    Pr38-40 ESI+: 395, 397
    Pr38-41 ESI+: 479, 481
    Pr38-42 ESI+: 436
    Pr38-43 ESI+: 447
    Pr38-44 ESI+: 392
    Pr38-45 ESI+: 429
    Pr38-46 ESI+: 425
    Pr38-47 ESI+: 431
    Pr38-48 ESI+: 403
    Pr38-49 ESI+: 433
    Pr38-50 ESI+: 379
    Pr38-51 ESI+: 447
    Pr38-52 ESI+: 393
    Pr38-53 ESI+: 385
    Pr38-54 ESI+: 391
    Pr38-55 ESI+: 447
    Pr38-56 ESI+: 418
    Pr38-57 ESI+: 451
    Pr38-58 ESI+: 447
    Pr38-59 ESI+: 369
    Pr38-60 ESI+: 448
    Pr38-61 ESI+: 414
    Pr39 MS+: 413
    Pr39-1 MS−: 323
    Pr39-2 MS−: 295
    Pr39-3 MS+: 321
    Pr39-4 MS+: 239
    Pr39-5 MS+: 359
    Pr39-6 MS+: 357
    Pr40 MS+: 437
    Pr41 MS−: 142
    Pr41-1 MS+: 140
    Pr41-2 MS−: 133
    Pr41-3 MS+: 134
    Pr41-4 MS+: 130
    Pr41-5 ESI+: 144
  • TABLE 106
    Pr42 MS+: 262
    Pr43 MS+: 256
    Pr44 MS−: 193
    Pr44-1 NMR: 2.30(3H, s), 4.82(2H, d), 6.13(1H, d), 6.32(1H, dd), 7.71(1H, d), 9.52(1H,
    s), 10.19(1H, brs)
    Pr44-2 MS−: 205
    Pr44-3 ESI−: 189
    Pr44-4 NMR: 4.88(2H, d), 6.28(1H, d), 6.44(1H, dd), 7.22(1H, d), 7.52(1H, s), 9.47(1H,
    s), 10.24(1H, s)
    Pr44-5 MS+: 318
    Pr44-6 MS+: 318
    Pr45 MS−: 203
    Pr46 NMR: 2.56(2H, td), 2.87(1H, t), 3.03(2H, t), 7.85(1H, d), 7.98(1H, s), 8.06(1H, d)
    Pr47 MS+: 191
    Pr47-1 MS−: 223
    Pr47-2 MS+: 227
    Pr48 MS+: 157
    Pr48-1 MS−: 127
    Pr49 NMR: 3.48(2H, dd), 5.33(2H, s), 5.80-5.89(1H, m), 6.47(1H, d), 6.75(1H, dd),
    6.87(1H, d), 7.08(1H, d), 8.00(1H, d), 8.10(1H, s), 8.15(1H, d)
    Pr50 MS+: 417
    Pr51 MS+: 467
    Pr51-1 MS+: 443
    Pr51-2 MS+: 479
    Pr51-3 MS+: 269
    Pr51-4 MS+: 467
    Pr51-5 MS+: 337
    Pr52 MS+: 253
    Pr52-1 MS+: 451
    Pr52-2 NMR: 0.89(6H, d), 1.91-2.03(1H, m), 2.70(2H, d), 3.89(3H, s), 6.63(1H, d), 7.65
    (1H, d), 8.17(1H, s)
    Pr52-3 EI+: 294
    Pr52-4 EI+: 300
    Pr53 NMR: 1.46(3H, d), 4.74(2H, s), 5.27-5.38(1H, m), 7.37(1H, d), 7.42(1H, dd), 7.59
    (1H, d)
    Pr53-1 NMR: 1.29(6H, d), 4.64-4.73(3H, m), 7.16(1H, d), 7.35(1H, dd), 7.51(1H, d)
    Pr53-2 NMR: 1.28(6H, d), 4.74-4.85(3H, m), 7.30(1H, d), 7.65-7.70(2H, m)
    Pr53-3 NMR: 1.44(3H, d), 4.83(2H, s), 5.42-5.53(1H, m), 7.42(1H, d), 7.46(1H, dd), 7.72
    (1H, d)
    Pr53-4 NMR: 4.74(2H, s), 4.87(1H, d), 4.91(1H, d), 7.28(1H, d), 7.42(1H, dd), 7.59(1H, d)
    Pr54 NMR: 1.51-1.85(7H, m), 2.00-2.09(2H, m), 3.86(3H, s), 7.57(1H, s), 7.86(1H,
    dd), 7.91(1H, d)
    Pr55 ESI+: 545
    Pr55-1 ESI+: 552
    Pr56 ESI−: 247
    Pr56-1 MS−: 257
    Pr56-2 ESI−: 235
    Pr56-3 ESI+: 241
    Pr56-4 EI: 234
  • TABLE 107
    Pr56-5 ESI+: 247
    Pr56-6 ESI+: 249
    Pr57 EI+: 317
    Pr58 ESI+: 170
    Pr58-1 ESI+: 156
    Pr59 ESI+: 238
    Pr60 ESI+: 207
    Pr61 ESI+: 184
    Pr62 ESI+: 588
    Pr62-1 ESI+: 431
    Pr62-2 NMR: 1.29(6H, d), 4.75-4.84(1H, m), 4.93(2H, d), 5.12(2H,
    s), 6.57(1H, d), 6.69(1H, dd), 7.29-7.35(2H, m), 7.57(1H,
    s), 7.65-7.69(2H, m), 9.51(1H, s)
    Pr62-3 ESI+: 403
    Pr62-4 ESI+: 421
    Pr62-5
    Pr62-6 ESI+: 574
    Pr62-7 ESI+: 536
    Pr62-8 ESI+: 536
    Pr62-9 ESI+: 588
    Pr62-10 ESI+: 570
    Pr62-11 ESI+: 447
    Pr62-12 ESI+: 395, 397
    Pr62-13 ESI+: 532
    Pr62-14 ESI+: 532
    Pr62-15 ESI+: 544
    Pr62-16 ESI+: 544
    Pr62-17 ESI+: 574
    Pr62-18 ESI+: 545
    Pr62-19 ESI+: 545
    Pr63 ESI+: 262
    Pr64 MS+: 362
    Pr64-1 ESI+: 528
    Pr64-2 ESI+: 532
    Pr64-3 ESI+: 362
    Pr64-4 ESI+: 534
    Pr64-5 ESI+: 546
    Pr64-6 ESI+: 534
    Pr64-7 ESI+: 592
  • TABLE 108
    Ex RefEx Data
    Ex1 Ex1 NMR: 1.93-2.57(2H, m), 3.00-3.75(5H, m), 3.27(3H, s), 3.96(2H, s), 4.90
    (2H, d), 5.34(2H, s), 6.42(1H, s), 6.59(1H, dd), 6.88(1H, s), 8.00(1H, d),
    8.09-8.19(2H, m), 11.11(1H, brs), 12.06(1H, brs),
    MS+: 619
    Ex2 Ex2 NMR: 1.88-1.99(2H, m), 2.38-2.61(2H, m), 2.65-2.73(1H, m), 2.84-2.96
    (1H, m), 3.04-3.14(1H, m), 3.30-3.39(2H, m), 4.69(2H, s), 5.36(2H, s),
    6.34(1H, s), 6.50(1H, d), 6.57(1H, dd), 6.99(1H, d), 7.37(1H, s), 7.41-7.52
    (5H, m)
    MS+: 538
    Ex3 Ex3 NMR: 2.00-2.40(2H, m), 3.04-3.81(5H, m), 3.99(2H, s), 5.03(2H, s), 6.89
    (1H, s), 7.00(1H, s), 7.06(1H, dd), 8.06(1H, d), 8.15(1H, s), 8.16(1H, d),
    11.43(1H, brs), 12.89(1H, brs),
    MS+: 514
    Ex4 Ex2 NMR: 0.90(3H, t, J = 7.4 Hz), 1.55-1.65(2H, m), 2.55(2H, t, J = 7.9 Hz), 3.03
    (2H, s), 3.09-3.41(5H, m), 3.80(3H, s), 4.60(2H, s), 4.94(2H, s), 6.30(1H,
    s), 6.37(1H, d, J = 2.2 Hz), 6.75(1H, dd, J = 2.4, 8.3 Hz), 6.77(1H, dd, J = 1.3,
    8.8 Hz), 6.87(1H, d, J = 1.3 Hz), 6.94(1H, d, J = 8.3 Hz), 7.23(1H, d, J = 7.6 Hz)
    MS−: 422
    Ex5 Ex2 NMR: 3.04(2H, s), 3.12-3.40(5H, m), 4.61(2H, s), 5.11(2H, s), 6.30(1H, s),
    6.44(1H, d, J = 2.3 Hz), 6.54(1H, dd, J = 2.5, 8.2 Hz), 6.96(1H, d, J = 8.2 Hz),
    7.34-7.39(1H, m), 7.44-7.53(4H, m), 7.64-7.70(4H, m)
    MS−: 426
    Ex6 Ex2 NMR: 0.90(3H, t, J = 7.3 Hz), 1.34(6H, s), 1.55-1.65(2H, m), 2.55(2H, t, J =
    7.6 Hz), 3.06(2H, s), 3.11-3.43(5H, m), 3.80(3H, s), 4.93(2H, s), 6.24(1H, s),
    6.37(1H, d, J = 2.2 Hz), 6.46(1H, dd, J = 2.4, 8.3 Hz), 6.77(1H, dd, J = 1.3, 7.6
    Hz), 6.87(1H, d, J = 1.3 Hz), 6.98(1H, d, J = 8.3 Hz), 7.24(1H, d, J = 7.6 Hz)
    MS−: 450
    Ex7 Ex2 NMR: 3.04(2H, s), 3.11-3.41(5H, m), 4.62(2H, s), 5.56(2H, s), 6.03(1H, s),
    6.51(1H, d), 6.60(1H, dd), 6.99(1H, d), 7.46(1H, ddd), 7.54(1H, ddd), 8.00-
    8.03(1H, m), 8.10-8.13(1H, m)
    MS+: 431
    Ex8 Ex2 NMR: 1.92-2.00(2H, m), 2.71(2H, t, J = 7.4 Hz), 3.03(2H, s), 3.10-3.42(5H,
    m), 3.89(2H, t, J = 6.3 Hz), 4.60(2H, s), 6.30(1H, s), 6.33(1H, d, J = 2.3 Hz),
    6.43(1H, dd, J = 2.4, 8.3 Hz), 6.93(1H, d, J = 8.3 Hz), 7.23-7.27(2H, m), 7.31-
    7.35(2H, m)
    MS−: 412
    Ex9 Ex2 NMR: 0.90(3H, t), 1.03(2H, d), 1.44-1.65(4H, m), 1.73-1.83(2H, m), 1.86-
    1.96(3H, m), 2.11-2.21(1H, m), 2.52-2.58(2H, m), 2.70-2.79(2H, m), 2.96
    (2H, brs), 3.79(3H, s), 4.63(2H, s), 4.95(2H, s), 6.37(1H, s), 6.38(1H, d),
    6.48(1H, dd), 6.77(1H, d), 6.86(1H, brs), 6.93(1H, d), 7.23(1H, d)
    MS−: 450
    Ex10 Ex2 NMR: 3.03(2H, s), 3.10-3.41(5H, m), 4.62(2H, s), 5.30(2H, s), 6.31(1H, s),
    6.42(1H, d, J = 2.4 Hz), 6.50(1H, dd, J = 2.6, 8.3 Hz), 6.98(1H, d, J = 8.3 Hz),
    7.98(1H, d, J = 8.3 Hz), 8.09(1H, s), 8.14(1H, d, J = 8.3 Hz)
    MS−: 486
    Ex11 Ex2 NMR: 3.03(2H, s), 3.11-3.40(5H, m), 4.61(2H, s), 5.19(2H, s), 6.30(1H, s),
    6.44(1H, d), 6.52(1H, dd), 6.96(1H, d), 7.64(2H, d), 7.76(2H, d)
    MS+: 442
  • TABLE 109
    Ex12 Ex2 NMR: 3.03(2H, s), 3.11-3.24(3H, m), 3.38(2H, t), 3.81(3H, s), 4.60(2H, s),
    5.00(2H, s), 6.30(1H, s), 6.39(1H, d), 6.49(1H, dd), 6.93-6.98(2H, m), 7.04(1H,
    d), 7.30-7.38(2H, m)
    MS+: 404
    Ex13 Ex2 NMR: 1.34(3H, t), 3.02(2H, s), 3.10-3.24(3H, m), 3.37(2H, t), 4.20(2H, q),
    4.59(2H, s), 5.09(2H, s), 6.29(1H, s), 6.38-6.44(2H, m), 6.52(1H, dd), 6.93(1H,
    d), 7.18(1H, dd), 7.39(1H, d), 7.46(1H, dd), 7.58(1H, s)
    MS−: 417
    Ex14 Ex2 NMR: 0.91(3H, t, J = 7.3 Hz), 1.56-1.66(2H, m), 2.31(2H, t, J = 6.3 Hz), 2.56(2H,
    t, J = 7.8 Hz), 3.18-3.49(7H, m), 3.81(3H, s), 4.43(2H, t, J = 6.3 Hz), 5.00(2H, s),
    6.66(1H, d, J = 2.6 Hz), 7.79(1H, dd, J = 1.2, 7.7 Hz), 6.82(1H, dd, J = 2.6, 8.8 Hz),
    6.88(1H, d, J = 1.3 Hz), 7.27(1H, d, J = 7.7 Hz), 7.41(1H, d, J = 8.8 Hz)
    MS−: 470
    Ex15 Ex2 NMR: 3.03(2H, s), 3.11-3.40(5H, m), 4.62(2H, s), 5.19(2H, s), 6.31(1H, s), 6.41
    (1H, d), 6.50(1H, dd), 6.97(1H, d), 7.56-7.61(1H, m), 7.69-7.74(2H, m), 7.79
    (1H, d)
    MS−: 418
    Ex16 Ex2 NMR: 2.22(3H, s), 3.08(2H, s), 3.11-3.42(5H, m), 4.56(2H, s), 5.28(2H, s),
    6.28(1H, d), 6.42-6.44(2H, m), 7.97(1H, d), 8.10(1H, s), 8.14(1H, d)
    MS−: 500
    Ex17 Ex2 NMR: 0.88(3H, t), 1.53-1.62(2H, m), 2.50-2.57(2H, m), 3.02(2H, s), 3.10-3.40
    (5H, m), 4.60(2H, s), 5.00(2H, s), 6.29(1H, s), 641(1H, d), 6.50(1H, dd), 6.94
    (1H, d), 7.19(2H, d), 7.32(2H, d)
    MS−: 392
    Ex18 Ex2 NMR: 1.98(3H, s), 3.10-3.41(7H, m), 4.55(2H, d, J = 1.3 Hz), 5.32(2H, s), 6.46
    (1H, d, J = 2.6 Hz), 6.57(1H, dd, J = 2.6, 8.5 Hz), 7.17(1H, d, J = 8.6 Hz), 7.98(1H,
    d, J = 8.2 Hz), 8.10(1H, s), 8.14(1H, d, J = 8.2 Hz)
    MS−: 500
    Ex19 Ex2 NMR: 0.90(3H, t, J = 7.3 Hz), 1.55(2H, m), 1.98(3H, s), 2.55(2H, t, J = 7.9 Hz),
    3.10-3.41(7H, m), 3.80(3H, s), 4.53(2H, d, J = 1.3 Hz), 4.96(2H, s), 6.40(1H, d, J =
    2.6 Hz), 6.54(1H, dd, J = 2.5, 8.5 Hz), 6.77(1H, dd, J = 1.3, 7.5 Hz), 6.87(1H, d, J =
    1.3 Hz), 7.13(1H, d, J = 8.5 Hz), 7.24(1H, d, J = 7.5 Hz)
    MS−: 436
    Ex20 Ex2 NMR: 2.32(2H, t, J = 6.0 Hz), 3.15-3.48(7H, m), 4.45(2H, t, J = 6.0 Hz), 5.36(2H,
    s), 6.73(1H, d, J = 2.6 Hz), 6.87(1H, dd, J = 2.6, 8.8 Hz), 7.46(1H, d, J = 8.8 Hz),
    8.02(1H, d, J = 8.1 Hz), 8.11(1H, s), 8.16(1H, d, J = 8.1 Hz)
    MS+: 536
    Ex21 Ex2 NMR: 3.02(2H, s), 3.00-3.25(3H, m), 3.36(2H, t), 4.59(2H, s), 4.99(2H, s),
    6.26-6.29(2H, m), 6.36(1H, dd), 6.91(1H, d), 7.42-7.50(5H, m), 7.62(1H, s),
    7.75-7.83(2H, m)
    MS−: 494
    Ex22 Ex2 NMR: 2.03(3H, s), 2.12(2H, t, J = 6.0 Hz), 3.15-3.45(7H, m), 4.38(2H, t, J = 6.0 Hz),
    5.33(2H, s), 6.65(1H, d, J = 2.6 Hz), 6.79(1H, dd, J = 2.6, 8.6 Hz), 7.25(1H, d, J =
    8.6 Hz), 8.02(1H, d, J = 8.2 Hz), 8.10(1H, s), 8.15(1H, d, J = 8.2 Hz)
    MS−: 514
    Ex23 Ex2 NMR: 0.91(3H, t, J = 7.4 Hz), 1.55-1.66(2H, m), 2.02(3H, s), 2.12(2H, t, J = 5.9 Hz),
    2.56(2H, t, J = 7.8 Hz), 3.13-3.45(7H, m), 3.81(3H, s), 4.37(2H, t, J = 5.9 Hz),
    4.97(2H, s), 4.58(1H, d, J = 2.6 Hz), 6.74(1H, dd, J = 2.6, 8.6 Hz), 6.78(1H, dd, J =
    1.0, 7.6 Hz), 6.88(1H, d, J = 1.0 Hz), 7.2(1H, d, J = 8.6 Hz), 7.26(1H, d, J = 7.6 Hz)
    MS+: 474
  • TABLE 110
    Ex24 Ex2 NMR(CDCl3): 0.95(3H, t, J = 7.3 Hz), 1.58-1.69(2H, m), 2.58(2H, t, J = 7.4 Hz),
    3.36-4.37(10H, m), 4.87(2H, s), 5.03(2H, s), 6.49(1H, d, J = 2.3 Hz), 6.61(1H,
    dd, J = 2.3, 8.7 Hz), 6.71(1H, s), 6.77(1H, d, J = 7.4 Hz), 7.27(1H, d, J = 8.7 Hz),
    7.36(1H, d, J = 8.7 Hz)
    MS−: 456
    Ex25 Ex2 NMR: 3.14-3.45(7H, m), 4.76(2H, s), 5.35(2H, s), 6.56(1H, d, J = 2.5 Hz), 6.68
    (1H, dd, J = 2.5, 8.6 Hz), 7.33(1H, d, J = 8.6 Hz), 8.00(1H, d, J = 8.2 Hz), 8.10(1H,
    s), 8.15(1H, d, J = 8.2 Hz)
    MS−: 520
    Ex26 Ex2 NMR: 0.88(3H, t), 1.50-1.60(2H, m), 2.47(2H, t), 3.06(2H, s), 3.12-3.25(3H,
    m), 3.33-3.42(2H, m), 3.75(3H, s), 4.65(2H, s), 4.93(2H, s), 6.36(1H, s), 6.64
    (1H, dd), 6.77-6.82(2H, m), 6.86(1H, d), 6.89(1H, dd), 7.03(1H, d)
    MS+: 446
    Ex27 Ex2 NMR: 2.91(2H, s), 2.95(2H, t, J = 6.8 Hz), 3.05-3.14(1H, m), 3.27(2H, t, J = 7.2 Hz),
    4.77(2H, s), 5.30(2H, s), 6.38(1H, d, J = 8.5 Hz), 6.46(1H, dd, J = 2.5, 8.5 Hz),
    6.53(1H, d, J = 2.5 Hz), 7.12-7.17(2H, m), 7.38-7.44(1H, m), 7.45-7.50(2H,
    m), 7.97(1H, d, J = 8.3 Hz), 8.09(1H, s), 8.13(1H, d, J = 8.2 Hz)
    MS−: 565
    Ex28 Ex2 MS−: 450
    Ex29 Ex2 NMR: 0.90(3H, t, J = 7.3 Hz), 1.31-1.52(2H, m), 1.53-1.68(4H, m), 1.70-1.80
    (1H, m), 1.93-2.17(2H, m), 2.35-2.46(1H, m), 2.55(2H, t, J = 7.8 Hz), 2.94-3.04
    (1H, m), 3.80(3H, s), 4.65(2H, s), 4.95(2H, s), 6.32(1H, s), 6.38(1H, d, J = 2.1 Hz),
    6.48(1H, dd, J = 2.3, 8.3 Hz), 6.77(1H, d, J = 7.5 Hz), 6.87(1H, s), 6.94(1H, d,
    J = 8.2 Hz), 7.24(1H, d, J = 7.5 Hz)
    MS−: 450
    Ex30 Ex2 NMR: 0.90(3H, t, J = 7.3 Hz), 1.55-1.65(2H, m), 1.67-1.88(3H, m), 2.03-2.15
    (1H, m), 2.43-2.58(3H, m), 3.06-3.13(1H, m), 3.18-3.25(2H, m), 3.45(1H, d, J =
    13.5 Hz), 3.80(3H, s), 4.72(2H, s), 4.95(2H, s), 6.38(1H, s), 6.39(1H, d, J = 2.4
    Hz), 6.48(1H, dd, J = 2.4, 8.3 Hz), 6.77(1H, dd, J = 1.0, 7.6 Hz), 6.87(1H, s), 6.95
    (1H, d, J = 8.3 Hz), 7.24(1H, d, J = 7.6 Hz)
    MS−: 436
    Ex31 Ex2 NMR: 0.90(3H, t, J = 7.3 Hz), 1.55-1.66(2H, m), 1.90-1.99(2H, m), 2.40-3.15
    (9H, m), 3.80(3H, s), 4.66(2H, s), 4.95(2H, s), 6.33(1H, s), 6.39(1H, d, J = 2.4 Hz),
    6.48(1H, dd, J = 2.4, 8.3 Hz), 6.77(1H, dd, J = 1.3, 7.6 Hz), 6.87(1H, d, J = 1.3
    Hz), 6.94(1H, d, J = 8.3 Hz), 7.24(1H, d, J = 7.6 Hz)
    MS−: 436
    Ex32 Ex2 NMR: 3.04(2H, s), 3.10-3..23(3H, m), 3.34-3.43(2H, m), 4.62(2H, s), 5.35(2H,
    s), 6.31(1H, s), 6.49(1H, d), 6.57(1H, dd), 6.99(1H, d), 7.35-7.39(1H, m),
    7.42-7.51(5H, m)
    MS+: 524
    Ex33 Ex2 NMR: 1.52-1.64(6H, m), 3.03(2H, s), 3.10-3.34(9H, m), 4.61(2H, s), 5.01(2H,
    s), 6.30(1H, s), 6.37(1H, d, J = 2.4 Hz), 6.48(1H, dd, J = 2.4, 8.3 Hz), 6.95(1H, d,
    J = 8.3 Hz), 7.15-7.21(2H, m), 7.47(1H, d, J = 8.3 Hz)
    MS−: 501
    Ex34 Ex2 NMR: 3.08(2H, s), 3.12-3.42(5H, m), 4.66(2H, s), 5.31(2H, s), 6.32-6.34(1H,
    m), 6.39(1H, s), 6.50(1H, dd), 7.99(1H, d), 8.09(1H, s), 8.15(1H, d)
    MS−: 504
    Ex35 Ex2 NMR: 3.05(2H, s), 3.10-3.38(5H, m), 3.76(3H, s), 4.56(2H, s), 5.31(2H, s),
    6.08(1H, d), 6.24(1H, d), 6.42(1H, s), 8.00(1H, d), 8.09(1H, s), 8.14(1H, d)
    MS−: 516
  • TABLE 111
    Ex36 Ex2 NMR: 1.65(3H, d), 3.02(2H, s), 3.10-3.23(3H, m), 3.34-3.40(2H, m), 4.61(2H,
    s), 5.87(1H, q), 6.29(1H, s), 6.46(1H, d), 6.54(1H, dd), 6.95(1H, d), 7.30-
    7.38(1H, m), 7.40-7.52(5H, m)
    MS+: 538
    Ex37 Ex2 NMR: 3.04(2H, s), 3.10-3.24(3H, m), 3.32-3.42(2H, m), 4.62(2H, s), 5.35(2H,
    s), 6.31(1H, s), 6.48(1H, d), 6.57(1H, dd), 6.99(1H, d), 7.35-7.39(1H, m),
    7.42-7.48(2H, m), 7.53-7.58(2H, m)
    MS+: 558
    Ex38 Ex2 NMR: 3.05(2H, s), 3.12-3.26(3H, m), 3.32-3.43(2H, m), 4.62(2H, s), 5.27(2H,
    s), 6.31(1H, s), 6.47(1H, d), 6.55(1H, dd), 6.97(1H, d), 7.21-7.33(1H, m),
    7.37-7.45(2H, m), 7.62-7.72(3H, m), 7.86(1H, d)
    MS+: 456
    Ex39 Ex2 NMR: 0.91(3H, t), 1.53-1.66(2H, m), 2.56(2H, t), 3.07(2H, s), 3.13-3.25(3H,
    m), 3.37-3.45(2H, m), 3.84(3H, s), 4.66(2H, s), 6.37(1H, s), 6.79(1H, d), 6.85
    (1H, s), 6.90(1H, s), 7.00-7.10(3H, m), 7.30(1H, d), 7.52(1H, d)
    MS−: 418
    Ex40 Ex2 NMR: 0.89(3H, t), 1.53-1.62(2H, m), 2.51(2H, t), 2.65-2.78(4H, m), 3.05(2H,
    s), 3.10-3.23(3H, m), 3.35-3.43(2H, m), 3.77(3H, s), 4.61(2H, s), 6.32(1H, s),
    6.58(1H, s), 6.63-6.71(2H, m), 6.77(1H, s), 6.91(1H, d), 6.99(1H, d)
    MS+: 444
    Ex41 Ex2 NMR: 3.04(2H, s), 3.10-3.22(3H, m), 3.35-3.42(2H, m), 4.62(2H, s), 5.39(2H,
    s), 6.31(1H, s), 6.48(1H, d), 6.57(1H, dd), 6.99(1H, d), 7.47-7.59(3H, m), 7.63
    (1H, s), 7.70-7.76(2H, m)
    MS+: 481
    Ex42 Ex2 NMR: 1.21(3H, t), 2.84(2H, q), 3.03(2H, s), 3.13-3.24(3H, m), 3.32-3.43(2H,
    m), 4.61(2H, s), 5.19(2H, s), 6.30(1H, s), 6.45(1H, d), 6.54(1H, dd), 6.96(1H,
    d), 7.14(1H, s), 7.30-7.47(5H, m)
    MS−: 460
    Ex43 Ex2 NMR: 3.04(2H, s), 3.09-3.25(3H, m), 3.35-3.43(2H, m), 4.62(2H, s), 5.24(2H,
    s), 6.31(1H, s), 6.46(1H, d), 6.54(1H, dd), 6.97(1H, d), 7.28(1H, s), 7.35-7.43
    (1H, m), 7.43-7.51(2H, m), 7.51-7.57(2H, m)
    MS+: 534, 536
    Ex44 Ex2 NMR: 2.01-3.73(7H, m), 3.87(2H, s), 4.86(2H, s), 5.33(2H, s), 6.51(1H, d, J =
    2.4 Hz), 6.59(1H, dd, J = 2.4, 8.3 Hz), 6.72(1H, s), 7.09(1H, d, J = 8.3 Hz), 7.99
    (1H, d, J = 8.1 Hz), 8.10(1H, s), 8.15(1H, d, J = 8.1 Hz)
    MS−: 500
    Ex45 Ex2 NMR: 1.96-4.01(9H, m), 4.86(2H, s), 5.34(2H, s), 6.41(1H, brs), 6.59(1H, dd,
    J = 2.3, 11.3 Hz), 6.85(1H, brs), 8.00(1H, d, J = 8.1 Hz), 8.11(1H, s), 8.16(1H, s,
    J = 8.1 Hz)
    MS−: 518
  • TABLE 112
    Ex46 Ex2 NMR: 3.08(2H, s), 3.12-3.25(3H, m), 3.34-3.45(2H, m), 4.67(2H, s), 5.37(2H,
    s), 6.36-6.40(2H, m), 6.54(1H, dd), 7.36-7.39(1H, m), 7.41-7.52(5H, m)
    MS−: 518
    Ex47 Ex2 NMR: 2.44(3H, s), 3.03(2H, s), 3.09-3.22(3H, m), 3.34-3.43(2H, m), 4.61(2H,
    s), 5.19(2H, s), 6.30(1H, s), 6.44(1H, d), 6.53(1H, dd), 6.96(1H, d), 7.19(1H,
    s), 7.29-7.38(1H, m), 7.39-7.48(4H, m)
    MS+: 470
    Ex48 Ex2 NMR: 0.88(3H, t), 1.52-1.65(2H, m), 2.78(2H, t), 3.03(2H, s), 3.11-3.47(5H,
    m), 4.61(2H, s), 5.19(2H, s), 6.30(1H, s), 6.45(1H, d), 6.53(1H, dd), 6.96(1H,
    d), 7.13(1H, s), 7.30-7.40(3H, m), 7.41-7.48(2H, m)
    MS+: 498
    Ex49 Ex2 NMR: 0.61-0.68(2H, m), 0.94-1.06(2H, m), 2.10-2.19(1H, m), 2.97-3.09(5H,
    m), 3.21-3.42(2H, m), 4.60(2H, s), 5.15(2H, s), 6.25(1H, s), 6.42(1H, d), 6.52
    (1H, dd), 6.92-6.97(1H, m), 7.19(1H, s), 7.30-7.36(1H, m), 7.42-7.48(2H, m),
    7.52-7.60(2H, m)
    MS−: 472
    Ex50 Ex2 NMR: 3.03(2H, s), 3.08-3.24(3H, m), 3.34-3.42(2H, m), 4.61(2H, s), 5.20(2H,
    s), 6.30(1H, s), 6.45(1H, d), 6.53(1H, dd), 6.96(1H, d), 7.28-7.35(2H, m),
    7.40-7.49(4H, m), 7.60-7.66(1H, m), 7.85(1H, d)
    MS+: 518
    Ex51 Ex2 NMR: 1.44(3H, d), 3.02(2H, brs), 3.09-3.40(5H, m), 4.60(2H, s), 5.07(2H, s),
    5.42-5.52(1H, m), 6.29(1H, s), 6.43(1H, d), 6.51(1H, dd), 6.95(1H, d), 7.50
    (1H, d), 7.70-7.75(2H, m)
    MS−: 530
    Ex52 Ex2 NMR: 2.95-3.64(7H, m), 4.61(2H, s), 4.89(1H, d), 4.94(1H, d), 5.11(2H, s),
    6.28(1H, s), 6.39(1H, d), 6.49(1H, dd), 6.96(1H, d), 7.36-7.45(2H, m), 7.68(1H, d)
    MS+: 540
    Ex53 Ex2 NMR: 1.22(6H, d), 3.00(2H, s), 3.06-3.13(1H, m), 3.25-3.42(5H, m) 4.62(2H,
    s), 5.17(2H, s), 6.28(1H, s), 6.45(1H, d), 6.53(1H, dd), 6.96(1H, d), 7.06(1H,
    s), 7.32-7.38(3H, m), 7.41-7.48(2H, m)
    MS−: 474
    Ex54 Ex2 NMR: 1.21(3H, t), 2.84(2H, q), 2.95-3.16(5H, m), 3.28-3.42(2H, m), 4.61(2H,
    s), 5.19(2H, s), 6.28(1H, s), 6.45(1H, d), 6.53(1H, dd), 6.95(1H, d), 7.23(1H,
    s), 7.60-7.72(4H, m)
    MS+: 552
    Ex55 Ex2 NMR: 1.08(3H, t), 3.00-3.15(5H, m), 3.24-3.51(4H, m), 4.61(2H, s), 5.18(2H,
    s), 6.29(1H, s), 6.44(1H, d), 6.52(1H, dd), 6.91-6.97(2H, m), 7.37(1H, d),
    7.56-7.64(1H, m), 7.66-7.73(1H, m), 7.81-7.87(1H, m)
    MS−: 528
  • TABLE 113
    Ex56 Ex2 NMR: 1.21(3H, t), 1.90-1.99(2H, m), 2.40-2.62(3H, m), 2.63-2.73(1H, m), 2.80-
    2.96(3H, m), 3.13(2H, q), 4.71(2H, s), 5.22(2H, s), 6.38(1H, d), 6.43(1H, s),
    6.51(1H, dd), 7.16(1H, s), 7.30-7.40(3H, m), 7.40-7.48(2H, m)
    MS+: 516
    Ex57 Ex2 NMR: 1.16(3H, t), 2.06(3H, s), 2.67(2H, q), 3.02(2H, s), 3.09-3.20(3H, m),
    3.32-3.43(2H, m), 4.60(2H, s), 5.09(2H, s), 6.29(1H, s), 6.40(1H, d), 6.49(1H,
    dd), 6.85(1H, s), 6.94(1H, d)
    MS+: 422
    Ex58 Ex2 NMR: 1.29-1.53(2H, m), 1.55-1.80(2H, m), 1.94-2.21(2H, m), 2.33-2.44(1H,
    m), 2.52-2.62(1H, m), 2.74(1H, d), 3.07(2H, dd), 4.72(2H, s), 5.31(2H, s), 6.33
    (1H, m), 6.42(1H, s), 6.51(1H, dd), 7.98(1H, d), 8.01(1H, s), 8.15(1H, d)
    MS+: 534
    Ex59 Ex2 NMR: 1.90-2.00(2H, m), 2.41-2.54(2H, m), 2.56(3H, s), 2.56-2.61(1H, m), 2.69
    (1H, t), 2.85-2.96(1H, m), 3.13(2H, dd), 4.71(2H, s), 5.38(2H, s), 6.41(1H,
    m), 6.43(1H, s), 6.55(1H, dd), 7.35-7.41(1H, m), 7.44-7.49(2H, m), 7.65-7.68
    (2H, m)
    MS+: 503
    Ex60 Ex2 NMR: 1.80-1.94(2H, m), 2.41-2.62(2H, m), 2.65-2.73(1H, m), 2.84-2.89(1H,
    m), 3.08-3.41(3H, m), 4.72(2H, s), 5.37(2H, s), 6.38-6.45(2H, m), 6.55(1H,
    dd), 7.38(1H, s), 7.40-7.53(5H, m)
    MS+: 556
    Ex61 Ex2 NMR: 1.88-1.99(2H, m), 2.41-2.64(3H, m), 2.65-2.73(1H, m), 2.85-2.95(1H,
    m), 3.04-3.21(2H, m), 4.72(2H, s), 5.25(2H, s), 6.35(1H, d), 6.43(1H, s), 6.52
    (1H, dd), 7.40-7.57(3H, m), 7.72-7.86(3H, m), 7.98-8.04(2H, m)
    MS+: 550
    Ex62 Ex2 NMR: 1.87-1.97(2H, m), 2.41-3.24(7H, m), 4.72(2H, s), 5.23(2H, s), 6.39(1H,
    d), 6.43(1H, s), 6.54(1H, dd), 7.30-7.34(2H, m), 7.42-7.47(4H, m), 7.74-7.77
    (1H, m), 7.86-7.89(1H, m)
    MS−: 526
    Ex63 Ex2 NMR: 1.79-2.00(2H, m), 2.30-2.41(1H, m), 2.43-2.79(4H, m), 3.09(2H, s), 4.71
    (2H, s), 5.20(2H, s), 6.33(1H, d), 6.40(1H, s), 6.48(1H, dd), 6.60-6.63(1H,
    m), 7.80-7.87(2H, m), 8.12-8.25(2H, m), 8.69(1H, d)
    MS−: 516
    Ex64 Ex2 NMR: 1.78-2.04(2H, m), 2.30-2.79(7H, m), 3.09(2H, s), 3.55(2H, t), 3.78(2H,
    t), 4.70(2H, s), 5.02(2H, s), 6.28(1H, s), 6.38-6.45(2H, m), 6.84-6.89(2H, m),
    7.45-7.52(1H, m)
    MS−: 555
    Ex65 Ex2 NMR: 1.78-2.02(2H, m), 1.95(3H, s), 2.30-2.81(5H, m), 3.08-3.19(2H, m), 4.72
    (2H, s), 5.32(2H, s), 6.40-6.44(2H, m), 6.55(1H, dd), 7.24-7.30(2H, m),
    7.42-7.51(3H, m)
    MS+: 570
  • TABLE 114
    Ex66 Ex2 NMR: 1.20(3H, s), 1.41-1.52(1H, m), 2.24(1H, d), 2.22-2.36(1H, m), 2.43-2.60
    (2H, m), 2.86(1H, d), 3.11(2H, s), 4.72(2H, s), 5.37(2H, s), 6.38-6.42(2H, m),
    6.54(1H, dd), 7.38(1H, s), 7.41-7.52(5H, m)
    MS+: 570
    Ex67 Ex2 NMR: 1.18(3H, t), 1.70-2.01(2H, m), 2.31-3.51(13H, m), 4.67(2H, s), 6.34(1H,
    s), 6.67(1H, s), 6.72-6.81(2H, m), 6.94(1H, s), 7.31-7.38(3H, m), 7.39-7.44
    (2H, m)
    MS+: 496
    Ex68 Ex2 NMR: 1.24(3H, t), 1.91-2.04(2H, m), 2.42-2.75(4H, m), 2.85(2H, q), 2.85-3.60
    (3H, m), 4.72(2H, s), 6.41(1H, s), 6.79(1H, d), 6.97(1H, s), 7.00-7.09(2H, m),
    7.14(1H, s), 7.30-7.50(6H, m)
    MS−: 470
    Ex69 Ex2 NMR: 1.02(3H, d), 2.04-2.09(1H, m), 2.21-2.38(2H, m), 2.56-2.79(3H, m), 3.01-
    3.16(2H, m), 4.72(2H, s), 5.36(2H, s), 6.37-6.44(2H, m), 6.53(1H, dd),
    7.38(1H, s), 7.40-7.53(5H, m)
    MS−: 546
    Ex70 Ex2 NMR: 1.94-2.49(3H, m), 2.95-3.72(4H, m), 3.90(2H, brs), 4.94(2H, s), 5.21(2H,
    s), 6.34(2H, t), 6.41(1H, brs), 6.57(1H, dd), 6.86(1H, brs), 7.54(2H, t), 7.80
    (1H, d), 7.94-7.99(2H, m)
    Ex71 Ex2 NMR: 1.19(3H, s), 1.38-1.52(1H, m), 2.23(1H, d), 2.24-2.34(1H, m), 2.43-2.58
    (2H, m), 2.85(1H, d), 3.10(2H, s), 4.72(2H, s), 5.31(2H, s), 6.33(1H, s), 6.40
    (1H, d), 6.49(1H, dd), 7.99(1H, d), 8.09(1H, s), 8.14(1H, d)
    MS+: 556
    Ex72 Ex2 NMR: 1.20(3H, s), 1.38-1.53(1H, m), 1.95(3H, s), 2.24(1H, d), 2.25-2.35(1H,
    m), 2.40-2.62(2H, m), 2.86(1H, d), 3.11(2H, s), 4.73(2H, s), 5.32(2H, s), 6.39-
    6.41(2H, m), 6.56(1H, d), 7.25-7.32(2H, m), 7.42-7.55(3H, m)
    MS+: 584
    Ex73 Ex2 NMR: 2.01-2.23(2H, m), 2.46-2.79(3H, m), 2.92-3.00(1H, m), 3.12-3.27(2H,
    m), 3.43-3.57(1H, m), 4.75(2H, s), 5.37(2H, s), 6.40(1H, d), 6.45(1H, s), 6.55
    (1H, dd), 7.35-7.42(1H, m), 7.42-7.54(5H, m)
    MS+: 558
    Ex74 Ex2 NMR: 1.72-1.93(1H, m), 2.21-2.48(2H, m), 2.63-2.89(3H, m), 3.16(2H, s), 4.74
    (2H, s), 5.37(2H, s), 6.40(1H, d), 6.43(1H, s), 6.54(1H, dd), 7.34-7.40(1H,
    m), 7.41-7.53(5H, m)
    MS+: 574
    Ex75 Ex2 NMR: 1.18(3H, s), 1.38-1.48(1H, m), 2.22(1H, d), 2.26-2.68(3H, m), 2.85(1H,
    d), 3.05(2H, s), 4.68(2H, s), 4.92(2H, q), 5.11(2H, s), 6.31(1H, s), 6.39(1H,
    d), 6.48(1H, dd), 6.95(1H, d), 7.35-7.45(2H, m), 7.69(1H, d)
    MS+: 568
    Ex76 Ex2 NMR: 1.19(3H, s), 1.44(3H, d), 2.18-2.23(3H, m), 2.39-2.65(2H, m), 2.80-2.88
    (1H, m), 3.02(2H, s), 4.68(2H, s), 5.06(2H, s), 5.43-5.50(1H, m), 6.37(1H,
    brs), 6.43(1H, d), 6.51(1H, dd), 6.94(1H, d), 7.49(1H, d), 7.69-7.75(2H, m)
    MS+ 582
    Ex77 Ex2 NMR: 0.92-1.06(2H, m), 1.52-1.63(1H, m), 2.27-2.35(1H, m), 2.53-2.64(1H,
    m), 2.78-2.85(2H, m), 3.12(2H, s), 4.67(2H, s), 5.37(2H, s), 6.37-6.43(2H, m),
    6.54(1H, dd), 7.35-7.40(1H, m), 7.41-7.53(5H, m)
    MS−: 544
  • TABLE 115
    Ex78 Ex2 NMR: 1.70-1.82(1H, m), 2.38-2.70(3H, m), 3.04-3.14(2H, m), 3.23-3.43(2H,
    m), 4.71(2H, s), 5.37(2H, s), 6.39(1H, d), 6.43(1H, s), 6.55(1H, dd), 7.35-7.39
    (1H, m), 7.41-7.56(5H, m)
    MS−: 600
    Ex79 Ex2 NMR: 2.17-2.27(2H, m), 2.39-2.47(2H, m), 2.92-2.99(2H, m), 3.10(2H, s), 4.72
    (2H, s), 5.31(2H, s), 6.35(1H, s), 6.42-6.56(3H, m), 7.99(1H, d), 8.09(1H,
    s), 8.14(1H, d),
    MS−: 530
    Ex80 Ex2 NMR: 1.09-1.24(2H, m), 1.56-1.68(3H, m), 1.87(2H, t), 2.12(2H, d), 2.77(2H,
    dm), 3.01(2H, s), 4.70(2H, s), 5.32(2H, s), 6.33-6.35(1H, m), 6.40(1H, s), 6.50
    (1H, dd), 7.99(1H, d), 8.10(1H, s), 8.15(1H, d),
    MS−: 546
    Ex81 Ex2 NMR: 1.38(3H, s), 2.96(2H, d), 3.07(2H, s), 3.31(2H, d), 4.46(2H, s), 5.36(2H,
    s), 6.32-6.42(2H, m), 6.54(1H, dd), 7.34-7.40(1H, m), 7.40-7.52(5H, m)
    MS+: 556
    Ex82 Ex2 NMR: 1.84-1.95(2H, m), 2.32(2H, t), 2.59(3H, s), 2.82-3.08(2H, m), 3.73(2H,
    brs), 4.89(2H, s), 5.34(2H, s), 6.40-6.43(1H, m), 6.57(1H, dd), 6.77-6.85(1H,
    m), 8.00(1H, d), 8.11(1H, s), 8.16(1H, d), 11.11(1H, brs), 11.99(1H, brs),
    MS−: 520
    Ex83 Ex2 NMR: 1.76-2.02(2H, m), 2.31-2.85(5H, m), 3.12(2H, s), 3.43(2H, s), 5.32(2H,
    s), 6.37(1H, s), 6.73(1H, s), 6.87(1H, d), 7.07(1H, d), 8.02(1H, d), 8.05-8.15
    (2H, m)
    MS+: 518
    Ex84 Ex2 NMR: 1.21-1.78(5H, m), 1.77-2.00(1H, m), 2.20-2.38(2H, m), 2.37-2.51(1H,
    m), 2.64-2.78(2H, m), 3.02(2H, s), 4.72(2H, s), 5.37(2H, s), 6.34-6.58(3H, m),
    7.38(1H, s), 7.41-7.53(5H, m)
    MS+: 574
    Ex85 Ex2 NMR: 2.10-2.21(2H, m), 2.35-2.43(2H, m), 2.99(2H, s), 3.13(2H, s), 4.72(2H,
    s), 5.31(2H, s), 6.33-6.36(1H, m), 6.44(1H, s), 6.47-6.58(2H, m), 7.99(1H, d),
    8.09(1H, s), 8.14(1H, d),
    MS−: 530
    Ex86 Ex2 NMR: 1.89-1.97(2H, m), 2.01(3H, s), 2.18-2.28(2H, m), 2.43-3.20(9H, m),
    5.26(2H, s), 6.24(2H, dd), 6.83-6.89(2H, m), 6.90-6.95(2H, m), 7.17-7.25(1H,
    m), 7.53(1H, d), 7.84(1H, d), 7.96(1H, d)
    MS+: 533
    Ex87 Ex2 NMR: 1.20(3H, s), 1.40-1.53(1H, m), 2.01(3H, s), 2.19-2.35(4H, m), 2.42-
    2.70(4H, m), 2.84(1H, d), 3.18(2H, s), 5.26(2H, s), 6.24(2H, dd), 6.83-6.89(2H,
    m), 6.91-6.96(2H, m), 7.19(1H, d), 7.53(1H, d), 7.83(1H, d), 7.95(1H, s)
    MS+: 525
    Ex88 Ex2 NMR: 1.20(3H, s), 1.40-1.54(1H, m), 2.01(3H, s), 2.20-2.38(4H, m), 2.40-
    2.69(4H, m), 2.85(1H, d), 3.18(2H, s), 5.38(2H, s), 6.83-6.90(2H, m), 7.20(1H, d),
    7.38(1H, s), 7.43-7.52(5H, m)
    MS+: 542
    Ex89 Ex2 NMR: 1.18(3H, s), 1.38-1.48(1H, m), 2.23(1H, d), 2.25-2.35(1H, m), 2.38-
    2.53(2H, m), 2.84(1H, d), 3.09(2H, s), 4.72(2H, s), 5.24(2H, s), 6.23(2H, dd),
    6.36-6.43(2H, d), 6.52(1H, dd), 6.93(2H, s), 7.53(1H, d), 7.82(1H, d), 7.94(1H, s)
    MS+: 553
  • TABLE 116
    Ex90 Ex2 NMR: 1.19(3H, s), 1.38-1.51(1H, m), 2.23(1H, d), 2.24-2.36(1H, m), 2.42-
    2.57(2H, m), 2.84(1H, d), 3.11(2H, s), 4.72(2H, s), 5.24(2H, s), 6.37-6.43(2H,
    m), 6.53(1H, dd), 7.30-7.37(2H, m), 7.41-7.48(4H, m), 7.76(1H, d), 7.89(1H, s)
    MS+: 542
    Ex91 Ex2 NMR: 1.38(3H, s), 2.01(3H, s), 2.18(2H, t), 2.16(2H, t), 2.97(2H, d), 3.19(2H,
    s), 3.33(2H, d), 5.38(2H, s), 6.84-6.90(2H, m), 7.19(1H, d), 7.38(1H, s), 7.41-
    7.54(5H, m)
    MS+: 550
    Ex92 Ex2 NMR: 1.40(3H, s), 2.02(3H, s), 2.18(2H, t), 2.61(2H, t), 3.00(2H, d), 3.21(2H,
    s), 3.34(2H, d), 5.26(2H, s), 6.24(2H, dd), 6.82-6.89(2H, m), 6.91-6.95(2H,
    m), 7.19(1H, d), 7.53(1H, d), 7.83(1H, dd), 7.96(1H, d)
    MS+: 533
    Ex93 Ex2 NMR: 1.34(3H, s), 2.91(2H, d), 3.05(2H, s), 3.27(2H, d), 4.66(2H, s), 5.22(2H,
    s), 6.34-6.39(2H, m), 6.52(1H, d), 7.28-7.35(2H, m), 7.40-7.48(4H, m),
    7.75(1H, d), 7.88(1H, s)
    MS+: 550
    Ex94 Ex2 NMR: 1.34(3H, s), 2.91(2H, d), 3.05(2H, s), 3.29(2H, d), 4.66(2H, s), 5.23(2H,
    s), 6.23(2H, dd), 6.33-6.39(2H, m), 6.51(1H, d), 6.91-6.95(2H, m), 7.52(1H,
    d), 7.81(1H, d), 7.93(1H, d)
    MS+: 539
    Ex95 Ex2 NMR: 1.35(3H, s), 1.97(3H, s), 2.02(3H, s), 2.19(2H, t), 2.62(2H, t), 2.90-
    2.95(2H, m), 3.18(2H, s), 3.26-3.36(2H, m), 5.33(2H, s), 6.85-6.93(2H, m), 7.20
    (1H, d), 7.25-7.32(2H, m), 7.41-7.54(3H, m)
    MS+: 564
    Ex96 Ex2 NMR: 1.68-2.01(2H, m), 2.31-2.42(1H, m), 2.46-2.62(2H, m), 2.63-2.78(2H,
    m), 3.04-3.18(2H, m), 4.72(2H, s), 5.23(2H, s), 6.40(2H, d), 6.53(1H, dd),
    7.26-7.36(2H, m), 7.40-7.49(4H, m), 7.75(1H, d), 7.88(1H, s)
    MS+: 550
    Ex97 Ex2 NMR: 1.35(3H, s), 2.88-2.94(2H, m), 3.06(2H, s), 3.25-3.36(2H, m), 4.66(2H,
    s), 5.14(2H, s), 6.54(2H, d), 6.51(1H, dd), 7.38-7.50(7H, m), 7.62(1H, s)
    MS+: 516
    Ex98 Ex2 NMR: 2.23-2.30(2H, m), 2.42-2.53(2H, m), 3.03(2H, s), 3.18(2H, s), 4.72(2H,
    s), 5.24(2H, s), 6.41(1H, d), 6.48(1H, s), 6.55(1H, dd), 6.82-6.88(1H, m),
    7.28-7.35(2H, m), 7.40-7.48(4H, m), 7.76(1H, d), 7.89(1H, s)
    MS+: 562
    Ex99 Ex2 NMR: 1.70-2.01(2H, m), 2.32-2.42(1H, m), 2.47-2.62(2H, m), 2.63-2.70(1H,
    m), 2.71-2.87(1H, m), 3.04-3.18(2H, m), 4.72(2H, s), 5.23(2H, s), 6.41(2H,
    d), 6.53(1H, dd), 7.26-7.36(2H, m), 7.40-7.48(4H, m), 7.75(1H, d), 7.88
    (1H, s)
    MS+: 550
    Ex100 Ex2 NMR: 2.03(3H, s), 2.18(2H, t), 2.61(2H, t), 3.11-3.19(2H, m), 3.24(2H, s),
    3.31-3.37(2H, m), 4.64(2H, d), 5.26(2H, s), 6.24(2H, dd), 6.82-6.88(2H, m),
    6.91-6.95(2H, m), 7.17-7.23(1H, m), 7.53(1H, d), 7.80-7.86(1H, m), 7.93-7.97
    (1H, m)
    MS+: 551
    Ex101 Ex2 NMR: 2.02(3H, s), 2.18(2H, t), 2.61(2H, t), 3.12-3.20(2H, m), 3.24(2H, s),
    3.28-3.38(2H, m), 4.65(2H, d), 5.38(2H, s), 6.83-6.91(2H, m), 7.20(1H, d), 7.38
    (1H, s), 7.40-7.53(5H, m)
    MS−: 544
  • TABLE 117
    Ex102 Ex2 NMR: 0.79(3H, t), 1.81(2H, q), 2.02(3H, s), 2.17(2H, t), 2.61(2H, t), 3.00-3.08
    (2H, m), 3.20(2H, s), 3.26-3.35(2H, m), 5.38(2H, s), 6.83-6.88(2H, m), 7.20
    (1H, d), 7.38(1H, d), 7.40-7.54(5H, m)
    MS+: 564
    Ex103 Ex2 NMR: 0.80(3H, t), 1.80(2H, q), 2.97-3.05(2H, m), 3.08(2H, s), 3.34-3.32(2H,
    m), 4.66(2H, s), 5.24(2H, s), 6.24(2H, dd), 6.35-6.41(2H, m), 6.53(1H, dd),
    6.91-6.96(2H, m), 7.53(1H, d), 7.82(1H, d), 7.94(1H, s)
    MS+: 553
    Ex104 Ex2 NMR: 1.20(3H, s), 1.42-1.53(1H, m), 2.01(3H, s), 2.18-2.38(4H, m), 2.41-2.70
    (4H, m), 2.80-2.88(1H, m), 3.19(2H, s), 5.29(2H, s), 6.52(1H, dd), 6.84-6.90
    (2H, m), 7.17-7.24(1H, m), 7.60-7.66(1H, d), 7.75(1H, d), 7.85-7.92(1H,
    m), 7.99(1H, d), 8.05(1H, d)
    MS+: 548
    Ex105 Ex2 NMR: 1.81-2.02(2H, m), 2.01(3H, s), 2.19-2.27(2H, m), 2.41-2.85(7H, m),
    3.18(2H, s), 5.29(2H, s), 6.52(1H, dd), 6.82-6.90(2H, m), 7.17-7.24(1H, m),
    7.63(1H, d), 7.75(1H, d), 7.85-7.90(1H, m), 7.96-8.01(1H, m), 8.05(1H, d)
    MS+: 534
    Ex106 Ex2 NMR: 1.37(3H, s), 2.01(3H, s), 2.18(2H, t), 2.61(2H, t), 2.93-3.01(2H, m), 3.19
    (2H, s), 3.28-3.35(2H, m), 5.28(2H, s), 6.52(1H, dd), 6.80-6.88(2H, m), 7.14-
    7.24(1H, m), 7.60-7.67(1H, m), 7.75(1H, d), 7.85-7.92(1H, m), 7.97-8.02
    (1H, d), 8.04(1H, d)
    MS+: 534
    Ex107 Ex2 NMR: 1.70-2.01(2H, m), 2.30-2.73(5H, m), 3.09(2H, s), 4.72(2H, s), 5.24(2H,
    s), 6.36-6.46(2H, m), 6.53(1H, dd), 7.24-7.37(3H, m), 7.42-7.56(2H, m),
    7.78(1H, d), 7.91(1H, s)
    MS+: 568
    Ex108 Ex2 NMR: 1.70-2.01(2H, m), 2.30-2.73(5H, m), 3.09(2H, s), 4.72(2H, s), 5.24(2H,
    s), 6.36-6.46(2H, m), 6.53(1H, dd), 7.24-7.37(3H, m), 7.42-7.56(2H, m),
    7.78(1H, d), 7.91(1H, s)
    MS+: 568
    Ex109 Ex2 NMR: 1.76-2.00(2H, m), 2.28-2.58(3H, m), 2.60-2.80(2H, m), 3.07-3.17(2H,
    m), 4.72(2H, s), 5.24(2H, s), 6.20-6.26(2H, m), 6.37-6.45(2H, m), 6.53(1H,
    dd), 6.89-6.97(2H, m), 7.53(1H, d), 7.76-7.85(1H, m), 7.90-7.97(1H, m)
    MS+: 539
    Ex110 Ex2 NMR: 1.80-2.01(2H, m), 2.01(3H, s), 2.23(2H, t), 2.35-2.96(7H, m), 3.17(2H,
    s), 5.26(2H, s), 6.21-6.27(2H, m), 6.83-6.90(2H, m), 6.90-6.98(2H, m), 7.15-
    7.25(1H, m), 7.53(1H, d), 7.81-7.88(1H, m), 7.92-7.97(1H, m)
    MS+: 533
    Ex111 Ex2 NMR: 1.76-2.00(2H, m), 2.28-2.58(3H, m), 2.60-2.80(2H, m), 3.07-3.17(2H,
    m), 4.72(2H, s), 5.24(2H, s), 6.20-6.26(2H, m), 6.37-6.45(2H, m), 6.53
    (1H, dd), 6.89-6.97(2H, m), 7.53(1H, d), 7.76-7.85(1H, m), 7.90-7.97(1H, m)
    MS+: 539
  • TABLE 118
    Ex112 Ex2 NMR: 2.10-2.24(2H, m), 2.32-2.43(2H, m), 2.99(2H, s), 3.13(2H, s), 4.72(2H,
    s), 5.37(2H, s), 6.37-6.47(2H, m), 6.55(1H, dd), 7.38(1H, s), 7.40-7.54(6H, m)
    MS−: 544
    Ex113 Ex2 NMR: 2.13-2.25(2H, m), 2.31-2.50(2H, m), 2.97-3.04(2H, m), 3.16(2H, s), 4.72
    (2H, s), 5.25(2H, s), 6.21-6.28(2H, m), 6.38-6.42(1H, m), 6.43-6.46(2H, m),
    6.54(1H, dd), 6.90-6.98(2H, m), 7.53(1H, d), 7.80-7.85(1H, m), 7.92-7.97(1H, m)
    MS+: 551
    Ex114 Ex2 NMR: 1.22(3H, s), 1.46-1.54(1H, m), 2.41-2.48(4H, m), 2.47-2.61(1H, m), 2.67
    (2H, t), 2.83-2.89(1H, m), 3.05-3.10(2H, m), 3.23-3.27(1H, m), 5.35(2H,
    s), 6.37(1H, s), 7.02(1H, s), 7.24-7.47(8H, m)
    MS+: 528
    Ex115 Ex2 NMR: 1.80-2.01(2H, m), 2.01(3H, s), 2.23(2H, t), 2.35-2.96(7H, m), 3.17(2H, s),
    5.26(2H, s), 6.21-6.27(2H, m), 6.83-6.90(2H, m), 6.90-6.98(2H, m), 7.15-
    7.25(1H, m), 7.53(1H, d), 7.81-7.88(1H, m), 7.92-7.97(1H, m)
    MS+: 533
    Ex116 Ex2 NMR: 1.35(3H, s), 2.87-2.95(2H, m), 3.02(2H, s), 3.20-3.32(2H, s), 4.62(2H,
    s), 5.23(2H, s), 6.20-6.26(2H, m), 6.24-6.30(1H, m), 6.46(1H, d), 6.55(1H,
    dd), 6.90-7.00(3H, m), 7.52(1H, d), 7.76-7.85(1H, m), 7.90-7.97(1H, m)
    MS+: 521
    Ex117 Ex2 NMR: 0.89(3H, d), 1.40(3H, s), 2.07-2.18(1H, m), 2.47(1H, dd), 2.76(1H, dd),
    2.99(2H, d), 3.08(2H, s), 3.32(2H, d), 3.71-3.80(2H, m), 4.64(2H, s), 6.21-
    6.23(1H, m), 6.33-6.39(2H, m), 7.21(2H, d), 7.33(2H, d)
    ESI−: 458
    Ex118 Ex2 NMR: 2.16-2.22(2H, m), 2.39-2.46(2H, m), 2.91-2.97(2H, m), 3.08-3.13(2H,
    m), 4.61-4.84(6H, m), 4.92-5.08(3H, m), 6.32-6.40(2H, m), 6.43(1H, s),
    6.47(1H, dd), 7.31(1H, d), 7.37(1H, dd), 7.53(1H, d)
    ESI−: 522
    Ex119 Ex3 NMR: 3.53-3.70(1H, m), 3.80-4.41(5H, m), 4.79(2H, s), 6.72(1H, brs), 7.01
    (1H, s), 7.16(1H, dd, J = 1.4, 7.8 Hz), 7.20(1H, d, J = 7.8 Hz), 7.76(2H, d, J = 8.6
    Hz), 7.80(4H, d, J = 8.6 Hz)
    MS−: 412
    Ex120 Ex3 NMR: 3.57-3.71(1H, m), 3.87-3.99(2H, m), 4.08-4.32(4H, m), 4.83(2H, s), 6.74-
    6.78(1H, m), 6.94-6.97(1H, m), 7.11(1H, dd), 7.12(1H, d), 7.40-7.45(3H,
    m), 7.52-7.57(2H, m), 11.31(1H, brs), 13.14(1H, brs)
    MS−: 344
    Ex121 Ex3 NMR: 3.59-3.69(1H, m), 3.79(3H, s), 3.89-3.97(2H, m), 4.07-4.31(4H, m), 4.82
    (2H, s), 6.73-6.77(1H, m), 6.90-6.92(1H, m), 6.99(2H, d), 7.07(1H, dd), 7.15
    (1H, d), 7.48(2H, d), 11.28(1H, brs), 13.06(1H, brs)
    MS−: 374
  • TABLE 119
    Ex122 Ex3 NMR: 2.34(3H, s), 3.59-3.71(1H, m), 3.87-4.00(2H, m), 4.06-4.34(4H, m), 4.82
    (2H, s), 6.71-6.79(1H, m), 6.92-6.94(1H, m), 7.09(1H, dd), 7.16(1H, d), 7.24
    (2H, d), 7.43(2H, d), 11.13(1H, brs), 13.11(1H, brs)
    MS−: 358
    Ex123 Ex3 NMR: 1.24-1.56(6H, m), 1.57-1.73(2H, m), 1.75-1.86(2H, m), 2.57-2.70(1H,
    m), 3.55-3.70(1H, m), 3.83-3.98(2H, m), 4.02-4.34(4H, m), 4.76(2H, s), 6.68-
    6.76(2H, m), 6.91(1H, dd), 7.08(1H, d), 10.94(1H, brs), 13.08(1H, brs)
    MS−: 350
    Ex124 Ex3 NMR: 3.57-3.72(1H, m), 3.85-4.01(2H, m), 4.04-4.38(4H, m), 4.85(2H, s), 6.74-
    6.79(1H, m), 7.00-7.02(1H, m), 7.15(1H, dd), 7.20(1H, d), 7.68(1H, t), 7.79
    (1H, d), 7.86(1H, d), 7.91(1H, s), 11.31(1H, brs), 13.13(1H, brs)
    MS−: 412
    Ex125 Ex3 NMR: 3.57-3.70(1H, m), 3.89-4.02(2H, m), 4.09-4.35(4H, m), 4.84(2H, s), 6.74-
    6.79(1H, m), 6.91-6.94(1H, m), 7.1(1H, dd), 7.21(1H, d), 7.63(1H, t), 7.73
    (1H, t), 7.80(1H, d), 7.84(1H, d), 11.13(1H, brs), 1311(1H, brs)
    MS−: 412
    Ex126 Ex3 NMR: 1.24-1.56(6H, m), 1.57-1.73(2H, m), 1.75-1.86(2H, m), 2.57-2.70(1H,
    m), 3.55-3.70(1H, m), 3.83-3.98(2H, m), 4.02-4.34(4H, m), 4.76(2H, s),
    6.68-6.76(2H, m), 6.91(1H, dd), 7.08(1H, d), 10.94(1H, brs), 13.08(1H, brs)
    MS−: 350
    Ex127 Ex3 NMR: 1.27(9H, s), 3.56-3.68(1H, m), 3.84-3.96(2H, m), 4.06-4.33(4H, m), 4.77
    (2H, s), 6.68-6.74(2H, m), 6.89(1H, dd), 7.07(1H, d), 11.04(1H, brs), 13.11
    (1H, brs)
    MS−: 324
    Ex128 Ex3 NMR: 1.23-1.34(2H, m), 1.46-1.67(4H, m), 1.72-1.82(2H, m), 2.00-2.13(1H,
    m), 2.41(2H, d), 3.57-3.68(1H, m), 3.86-3.96(2H, m), 4.04-4.32(4H, m), 4.78
    (2H, s), 6.70-6.72(1H, m), 6.74-6.76(1H, m), 6.92(1H, dd), 7.08(1H, d), 11.13
    (1H, brs), 13.09(1H, brs)
    MS−: 350
    Ex129 Ex3 NMR: 0.89(6H, d), 1.43(2H, q), 1.62-1.76(1H, m), 2.41(2H, t), 3.57-3.69(1H,
    m), 3.86-3.96(2H, m), 4.06-4.33(4H, m), 4.78(2H, s), 6.69-6.78(2H, m), 6.91
    (1H, dd), 7.08(1H, d), 11.13(1H, brs), 13.11(1H, brs)
    MS−: 338
    Ex130 Ex3 NMR: 3.57-3.69(1H, m), 3.86-4.00(2H, m), 4.06-4.35(4H, m), 4.82(2H, s), 6.73-
    6.78(1H, m), 6.94-6.97(1H, m), 7.12(1H, d), 7.18(1H, d), 7.19(1H, dt), 7.44
    (1H, dt), 7.67-7.74(1H, m), 11.13(1H, brs), 13.09(1H, brs)
    MS−: 380
    Ex131 Ex3 NMR: 3.56-3.68(1H, m), 3.88-4.33(6H, m), 4.86(2H, s), 6.89(1H, s), 6.93(1H,
    s), 7.10(1H, dd), 7.77(2H, d), 7.82(2H, d), 10.94(1H, brs), 13.09(1H, brs):
    MS−: 430
    Ex132 Ex3 NMR: 2.69(2H, t), 2.84(2H, t), 3.57-3.68(1H, m), 3.91(2H, s), 4.04-4.30(4H,
    m), 4.78(2H, s), 6.69-6.72(2H, m), 6.88(1H, dd), 7.07(1H, dd), 7.19-7.25(1H,
    m), 7.28-7.32(4H, m), 11.11(1H, brs), 13.13(1H, brs),
    MS−: 372
  • TABLE 120
    Ex133 Ex3 NMR: 0.86(6H, d), 1.79-1.90(1H, m), 2.48(2H, d), 3.57-3.69(1H, m), 3.97(2H,
    s), 4.08-4.31(4H, m), 4.86(2H, s), 6.84(1H, s), 6.90(1H, s), 7.01(1H, dd),
    7.23(2H, d), 7.46(2H, d), 11.13(1H, brs), 13.11(1H, brs),
    MS−: 418
    Ex134 Ex3 NMR: 3.53-3.66(1H, m), 3.90(2H, s), 3.99-4.25(4H, m), 4.89(2H, s), 6.84-6.90
    (2H, m), 7.05(1H, dd), 8.06(1H, d), 8.15(1H, s), 8.17(1H, d), 11.31(1H, brs),
    12.89(1H, brs),
    MS−: 498
    Ex135 Ex3 NMR: 2.03-2.38(2H, m), 2.95-4.05(7H, m), 4.86(2H, s), 5.16(2H, s), 6.39(1H,
    s), 6.55(1H, dd), 6.85(1H, s), 7.12-7.17(2H, m), 7.21-7.32(2H, m), 7.38(1H,
    d), 7.43-7.49(2H, m), 7.74(1H, d), 10.85(1H, brs), 12.95(1H, brs)
    MS+: 566
    Ex136 Ex3 NMR: 1.79-1.88(2H, m), 2.02-2.30(2H, m), 2.42(2H, t), 2.71(2H, t), 3.03-3.76
    (5H, m), 3.95(2H, s), 4.93(2H, s), 6.72(1H, s), 6.86(1H, dd), 6.93(1H, s), 7.16-
    7.33(5H, m), 11.06(1H, brs), 12.94(1H, brs),
    MS+: 420
    Ex137 Ex3 NMR: 2.04(3H, s), 2.09-2.35(2H, m), 2.92-3.73(5H, m), 3.83(2H, s), 4.89(2H,
    s), 5.35(2H, s), 6.59(1H, d), 6.70(1H, s), 6.96(1H, d), 8.02(1H, d), 8.11(1H,
    s), 8.16(1H, d), 11.33(1H, brs), 12.89(1H, brs),
    MS−: 514
    Ex138 Ex3 NMR: 2.00-2.34(2H, m), 2.99-3.72(5H, m), 3.87(2H, brs), 4.91(2H, s), 5.20
    (2H, s), 6.77(1H, s), 6.94(1H, s), 7.04(1H, dd), 7.17(1H, d), 7.22-7.51(7H, m),
    11.23(1H, brs), 12.89(1H, brs),
    MS−: 526
    Ex139 Ex3 NMR: 2.80(2H, t), 3.12(2H, t), 2.96-3.66(5H, m), 3.74(2H, brs), 4.72(2H, s),
    6.52(1H, brs), 6.68(1H, s), 6.85(1H, dd), 7.03(1H, d), 7.91(1H, d), 8.00(1H,
    s), 8.09(1H, d)
    Ex140 Ex3 NMR: 0.90(3H, d), 2.08-2.19(1H, m), 2.48(1H, dd), 2.76(1H, dd), 3.51-3.65
    (1H, m), 3.72-3.89(4H, m), 3.96-4.19(4H, m), 4.78(2H, m), 6.27(1H, s), 6.42
    (1H, dd), 6.74-6.82(1H, m), 7.21(2H, d), 7.33(2H, d)
    ESI−: 444
    Ex141 Ex3 NMR: 1.45(3H, d), 2.50-2.61(1H, m), 2.65-2.83(1H, m), 2.94-3.11(1H, m),
    3.43-3.57(1H, m), 3.63-3.77(1H, m), 3.82-4.04(3H, m), 4.87-5.06(2H, m),
    5.13(2H, s), 5.44-5.55(1H, m), 6.43(1H, s), 6.57(1H, d), 6.86-6.95(1H, m), 6.99-
    7.06(1H, m), 7.52(1H, d), 7.71-7.77(2H, m), 11.31(1H, brs), 12.97(1H, brs)
    ESI−: 574
    Ex142 Ex3 NMR: 1.93-2.02(2H, m), 2.51-2.62(1H, m), 2.65-2.81(3H, m), 2.96-3.09(1H,
    m), 3.44-3.55(1H, m), 3.64-3.77(1H, m), NMR: 3.84-4.03(5H, m), 4.84-5.04
    (2H, m), 6.32(1H, s), 6.45(1H, dd), 6.86-6.93(1H, m), 6.99-7.06(1H, m),
    7.25(2H, d), 7.34(2H, d), 11.21(1H, brs), 12.99(1H, brs)
    ESI−: 456
    Ex143 Ex3 NMR: 2.43-2.76(2H, m), 2.97-3.10(1H, m), 3.46-3.55(1H, m), 3.65-3.77(1H,
    m), 3.88-4.04(3H, m), 4.59-5.11(9H, m), 6.41(1H, s), 6.56(1H, d), 6.87-
    6.93(1H, m), 6.99-7.06(1H, m), 7.31(1H, d), 7.37(1H, dd), 7.54(1H, d),
    10.84(1H, brs), 13.00(1H, brs)
    ESI−: 522
  • TABLE 121
    Ex144 Ex3 NMR: 1.45(3H, d), 2.43-2.82(2H, m), 2.95-3.09(1H, m), 3.44-3.58(1H,
    m), 3.62-3.78(1H, m), 3.83-4.07(3H, m), 4.34-5.02(2H, m), 5.06(2H,
    s), 5.26-5.37(1H, m), 6.41(1H, s), 6.55(1H, d), 6.83-7.08(2H, m), 7.36-
    7.43(2H, m), 7.56-7.57(1H, m), 11.03(1H, brs), 13.00(1H, brs)
    ESI−: 540
    Ex145 Ex3 NMR: 1.45(3H, d), 2.51-2.60(1H, m), 2.66-2.82(1H, m), 2.97-3.12(1H,
    m), 3.43-3.54(1H, m), 3.64-3.76(1H, m), 3.83-4.00(3H, m), 4.83-5.00
    (2H, m), 5.11(2H, s), 5.44-5.55(1H, m), 6.52(1H, d), 6.60(1H, dd), 6.71-
    6.81(1H, m), 6.99-7.06(1H, m), 7.09(1H, d), 7.52(1H, d), 7.71-7.76(2H,
    m), 11.20(1H, brs), 12.99(1H, brs)
    ESI−: 556
    Ex146 Ex3 NMR: 1.29(6H, d), 2.52-2.61(1H, m), 2.63-2.77(1H, m), 2.95-3.10(1H,
    m), 3.46-3.55(1H, m), 3.65-3.77(1H, m), 3.86-4.04(3H, m), 4.62-4.72
    (1H, m), 4.85-4.96(2H, m), 5.02(2H, s), 6.41(1H, s), 6.55(1H, d), 6.86-
    6.94(1H, m), 6.98-7.07(1H, m), 7.18(1H, d), 7.34(1H, dd), 7.49(1H, d),
    10.89(1H, brs), 13.00(1H, brs)
    ESI−: 486
    Ex147 Ex3 NMR: 1.29(6H, d), 2.53-2.62(1H, m), 2.64-2.80(1H, m), 2.96-3.10(1H,
    m), 3.44-3.57(1H, m), 3.65-3.79(1H, m), 3.84-4.06(3H, m), 4.75-4.85
    (1H, m), 4.87-5.01(2H, m), 5.09(2H, s), 6.42(1H, s), 6.56(1H, dd), 6.85-
    6.95(1H, m), 6.99-7.07(1H, m), 7.32(1H, d), 7.63-7.68(2H, m), 11.04(1H,
    brs), 13.00(1H, brs)
    ESI−: 520
    Ex148 Ex3 NMR: 1.44(3H, d), 2.52-2.61(1H, m), 2.66-2.81(1H, m), 2.96-3.09(1H,
    m), 3.46-3.55(1H, m), 3.65-3.77(1H, m), 3.85-4.04(3H, m), 4.86-5.05
    (2H, m), 5.15(2H, s), 5.42-5.55(1H, m), 6.41(1H, s), 6.56(1H, dd), 6.88-
    6.94(1H, m), 7.00-7.06(1H, m), 7.43-7.48(2H, m), 7.71(1H, d), 11.19(1H,
    brs), 13.01(1H, brs)
    ESI−: 574
    Ex149 Ex3 NMR: 1.45(3H, d), 2.50-2.61(1H, m), 2.61-2.77(1H, m), 2.94-3.13(1H,
    m), 3.42-3.57(1H, m), 3.64-3.77(1H, m), 3.84-4.02(3H, m), 4.78-4.95
    (2H, m), 5.05(2H, s), 5.25-5.36(1H, m), 6.51(1H, d), 6.59(1H, dd), 6.72-
    6.79(1H, m), 7.00-7.06(1H, m), 7.09(1H, d), 7.36-7.42(2H, m), 7.56(1H,
    d), 10.75(1H, brs), 13.02(1H, brs)
    ESI−: 522
    Ex150 Ex3 NMR: 2.53-2.61(1H, m), 2.63-2.77(1H, m), 2.95-3.10(1H, m), 3.46-3.55
    (1H, m), 3.65-3.77(1H, m), 3.88-4.04(3H, m), 4.85-4.99(4H, m), 5.07
    (2H, s), 6.39-6.45(1H, m), 6.56(1H, dd), 6.84-6.94(1H, m), 6.99-7.07(1H,
    m), 7.23(1H, d), 7.42(1H, dd), 7.57(1H, d), 10.80(1H, brs), 13.03(1H, brs)
    ESI−: 526
    Ex151 Ex3 NMR: 1.29(6H, d), 2.53-2.61(1H, m), 2.63-2.77(1H, m), 2.97-3.11(1H,
    m), 3.45-3.55(1H, m), 3.65-3.77(1H, m), 3.84-4.01(3H, m), 4.62-4.72
    (1H, m), 4.81-4.95(2H, m), 5.01(2H, s), 6.51(1H, d), 6.58(1H, dd), 6.72-
    6.79(1H, m), 7.00-7.06(1H, m), 7.08(1H, d), 7.17(1H, d), 7.34(1H, dd),
    7.49(1H, d), 10.80(1H, brs), 13.01(1H, brs)
    ESI−: 468
  • TABLE 122
    Ex152 Ex1 NMR: 1.34-1.51(1H, m), 1.79-1.96(2H, m), 2.00-2.10(1H, m), 2.73-3.10
    (3H, m), 3.24(3H, s), 3.30-3.54(2H, m), 3.79-3.96(2H, m), 4.59-4.85
    (4H, m), 4.85-4.99(2H, m), 5.09-5.25(1H, m), 5.11(2H, s), 6.42(1H, s),
    6.56(1H, dd), 6.85(1H, s), 7.44(1H, d), 7.67-7.74(2H, m), 10.72(1H, brs),
    12.06(1H, brs)
    ESI+: 637
    Ex153 Ex1 NMR: 1.36-1.51(1H, m), 1.80-1.94(2H, m), 1.98-2.12(1H, m), 2.73-2.86
    (1H, m), 2.79(6H, s), 2.87-3.07(2H, m), 3.28-3.52(2H, m), 3.85(2H, s),
    4.59-4.85(4H, m), 4.86-4.97(2H, m), 5.10-5.25(1H, m), 5.12(2H, s), 6.42
    (1H, s), 6.56(1H, dd), 6.84(1H, s), 7.44(1H, d), 7.67-7.73(2H, m), 10.65
    (1H, brs), 11.72(1H, brs)
    ESI+: 666
    EX154 — NMR: 4.67(2H, s), 4.93(2H, s), 5.32(2H, s), 6.37(1H, s), 6.44(1H, s), 6.54
    (1H, dd), 7.85(1H, s), 7.99(1H, d), 8.09(1H, s), 8.14(1H, d), 8.31(1H, s),
    12.41(1H, brs)
    ESI+: 517
    Ex155 Ex154 NMR: 4.64(2H, s), 4.71(2H, s), 5.31(2H, s), 6.36(2H, s), 6.41(1H, dd), 6.53
    (1H, dd), 6.84(1H, t), 7.42(1H, t), 7.99(1H, d), 8.09(1H, s), 8.14(1H,
    d), 11.77(1H, brs)
    ESI+: 538
    Ex156 — NMR: 1.35-1.52(4H, m), 1.65-2.02(3H, m), 2.72-3.08(3H, m), 3.20-3.60
    (2H, m), 3.72-3.95(2H, m), 4.79-4.96(2H, m), 5.11(2H, s), 5.42-5.55(1H,
    m), 6.52(1H, d, J = 2.4 Hz), 6.59(1H, dd, J = 2.4, 8.4 Hz), 6.71(1H, s),
    7.09(1H, d, J = 8.4 Hz), 7.51(1H, d, J = 9.3 Hz), 7.69-7.78(2H, m), 10.71(1H,
    bs), 12.85(1H, bs)
    ESI+: 560
    Ex157 Ex156 NMR: 1.28(6H, d), 1.38-1.44(2H, m), 1.58-1.65(2H, m), 3.79(2H, brs),
    4.74-4.83(1H, m), 4.82(2H, s), 5.06(2H, s), 6.49(1H, d), 6.57(1H, dd),
    6.62(1H, s), 7.05(1H, d), 7.31(1H, d), 7.63-7.68(2H, m), 9.88(1H, brs)
    FAB−: 476
    Ex158 Ex156 NMR: 1.28(6H, d), 2.12(3H, s), 2.40-2.56(1H, m), 2.62-2.76(1H, m),
    2.97-3.12(1H, m), 3.40-3.51(1H, m), 3.62-3.74(1H, m), 3.84-3.99(3H, m),
    4.75-4.83(1H, m), 4.86(2H, d), 5.07(2H, s), 6.51(1H, d), 6.59(1H, dd),
    6.74(1H, s), 7.09(1H, d), 7.31(1H, d), 7.62-7.68(2H, m), 10.59(1H, brs),
    12.97(1H, brs)
    ESI+: 518
    Ex159 Ex156 NMR: 1.28(6H, d), 1.50-1.71(2H, m), 1.81-1.95(3H, m), 2.20(1.6H, d),
    2.38(0.4H, d), 2.82-2.97(2H, m), 3.40(2H, d), 3.76(1.6H, d), 3.87(0.4H,
    d), 4.74-4.84(1H, m), 4.85(2H, s), 5.07(2H, s), 6.51(1H, d), 6.58(1H, dd),
    6.69(0.8H, s), 6.73(0.2H, s), 7.07(1H, d), 7.31(1H, d), 7.63-7.67(2H, m),
    10.17(0.8H, brs), 10.35(0.2H, brs), 12.21(1H, brs); two rotamers
    (4:1)
    ESI+: 520
    Ex160 Ex156 NMR: 1.35-1.53(2H, m), 1.65-2.12(3H, m), 2.70-3.06(2H, m), 3.25-3.60
    (2H, m), 3.72-3.94(2H, m), 4.88(2H, bs), 4.95(2H, q, J = 8.8 Hz), 5.12(2H,
    s), 6.52(1H, d, J = 2.2 Hz), 6.59(1H, dd, J = 2.4, 8.4 Hz), 6.71(1H, s),
    7.08(1H, d, J = 8.4 Hz), 7.41(1H, d, J = 9.2 Hz), 7.68-7.81(2H, m), 10.62(1H,
    bs), 12.83(1H, bs)
    ESI+: 546
  • TABLE 123
    Ex161 Ex156 NMR: 1.35-1.56(1H, m), 1.60-2.14(3H, m), 2.70-3.12(3H, m), 3.25-3.60
    (2H, m), 3.66-4.00(2H, m), 4.59-5.16(9H, m), 6.50(1H, d, J = 2.3 Hz), 6.58
    (1H, dd, J = 2.4, 8.4 Hz), 6.71(1H, s), 7.08(1H, d, J = 8.4 Hz), 7.31(1H, d,
    J = 8.6 Hz), 7.37(1H, dd, J = 2.0, 8.5 Hz), 7.53(1H, d, J = 2.0 Hz), 10.69(1H,
    bs), 12.84(1H, bs)
    ESI+: 508
    Ex162 Ex156 NMR: 1.28(6H, d), 2.25-2.35(1H, m), 2.44-2.60(1H, m), 3.00-3.14(3H,
    m), 3.44-3.53(1H, m), 3.53-3.64(1H, m), 3.69-3.79(1H, m), 3.81-3.91
    (2H, m), 4.74-4.85(1H, m), 4.84(2H, brs), 5.07(2H, s), 5.58(1H, brs), 6.51
    (1H, d), 6.59(1H, dd), 6.71(1H, s), 7.07(1H, d), 7.31(1H, d), 7.63-7.68
    (2H, m), 10.35(1H, brs), 12.40(1H, brs)
    ESI+: 518
    Ex163 Ex156 NMR: 1.88-2.15(4H, m), 2.44-2.56(0.8H, m), 2.72-2.81(0.2H, m), 2.82-
    3.00(2H, m), 3.38-3.50(2H, m), 3.68-3.86(2H, m), 4.60-4.85(4H, m),
    4.90(2H, s), 4.92-5.09(3H, m), 6.50(1H, d), 6.57(1H, dd), 6.70(0.8H, s),
    6.74(0.2H, s), 7.01-7.09(1H, m), 7.31(1H, d), 7.37(1H, dd), 7.53(1H, d),
    10.78(0.8H, brs), 10.87(0.2H, brs), 12.54(1H, brs); two rotamers(4:1)
    ESI+: 508
    Ex164 Ex156 NMR: 1.44(3H, d), 1.83-1.99(2H, m), 1.99-2.13(2H, m), 2.43-2.53(0.8H,
    m), 2.73-2.82(0.2H, m), 2.83-3.00(2H, m), 3.23-3.38(0.4H, m), 3.39-
    3.50(1.6H, m), 3.68-3.87(2H, m), 4.88(2H, s), 5.11(2H, s), 5.42-5.54
    (1H, m), 6.51(1H, d), 6.59(1H, dd), 6.70(0.8H, s), 6.74(0.2H, s), 7.03-
    7.10(1H, m), 7.51(1H, d), 7.71-7.77(2H, m), 10.49(0.8H, brs), 10.59(0.2H,
    brs), 12.54(1H, brs); two rotamers(4:1)
    ESI+: 560
    Ex165 Ex156 NMR: 1.84-1.99(2H, m), 1.99-2.13(2H, m), 2.45-2.54(0.8H, m), 2.74-
    2.81(0.2H, m), 2.82-3.00(2H, m), 3.25-3.37(0.4H, m), 3.38-3.49(1.6H,
    m), 3.70-3.86(2H, m), 4.58-4.66(1H, m), 4.66-4.77(2H, m), 4.78-4.85
    (1H, m), 4.88(2H, s), 5.10(2H, s), 5.10-5.24(1H, m), 6.51(1H, d), 6.59(1H,
    dd), 6.70(0.8H, s), 6.74(0.2H, s), 7.02-7.10(1H, m), 7.43(1H, d), 7.65-
    7.73(2H, m), 10.53(0.8H, brs), 10.62(0.2H, brs), 12.54(1H, brs); two
    rotamers(4:1)
    ESI+: 542
    Ex166 Ex156 NMR: 3.60(2H, m), 3.69-3.92(2H, m), 4.01-4.08(1H, m), 4.89(2H, s), 5.09
    (2H, s), 6.51(1H, d, J = 2.3 Hz), 6.59(1H, dd, J = 2.4, 8.4 Hz), 6.71(1H,
    s), 7.08(1H, d, J = 8.4 Hz), 7.55(1H, d, J = 8.6 Hz), 7.67(1H, d, J = 1.8 Hz),
    7.72(1H, dd, J = 1.8, 8.6 Hz), 10.71(1H, bs), 12.84(1H, bs)
    ESI+: 504
    Ex167 Ex156 NMR: 0.64-0.70(2H, m), 0.81-0.88(2H, m), 1.85-2.13(4H, m), 2.41-2.57
    (0.8H, m), 2.73-2.80(0.2H, m), 3.21-3.50(4H, m), 3.71-3.87(2H, m),
    4.01-4.08(1H, m), 4.88(2H, s), 5.09(2H, s), 6.51(1H, d), 6.59(1H, dd),
    6.70(0.8H, s), 6.74(0.2H, s), 7.02-7.10(1H, m), 7.55(1H, d), 7.67(1H, d),
    7.72(1H, dd), 10.50-10.75(1H, m), 12.55(1H, brs); two rotamers(4:1)
    ESI+: 504
    Ex168 Ex156 NMR: 1.38-1.55(1H, m), 1.54-1.73(4H, m), 1.77-2.15(7H, m), 2.72-3.08
    (2H, m), 3.18-3.58(4H, m), 3.81(2H, s), 4.90(2H, s), 5.15(2H, s), 6.52
    (1H, d), 6.60(1H, dd), 6.71(1H, s), 7.08(1H, d), 7.60-7.72(3H, m), 10.82
    (1H, brs), 12.84(1H, brs)
    ESI+: 516
  • TABLE 124
    EX169 Ex156 NMR: 1.54-1.75(4H, m), 1.77-2.13(8H, m), 2.83-2.98(2H, m), 3.19-3.49
    (4H, m), 3.72-3.86(2H, m), 4.89(2H, s), 5.15(2H, s), 6.51(1H, d), 6.59
    (1H, dd), 6.70(0.8H, s), 6.74(0.2H, s), 7.02-7.10(1H, m), 7.61-7.72(3H,
    m), 10.61-10.81(1H, m), 12.54(1H, brs); two rotamers(4:1)
    ESI+: 516
    Ex170 Ex156 NMR: 1.45(3H, d), 1.51-1.71(2H, m), 1.80-1.96(3H, m), 2.20(2H, d),
    2.82-2.96(2H, m), 3.35-3.44(2H, m), 3.72-3.78(1.6H, m), 3.84-3.89(0.4H,
    m), 4.87(2H, s), 5.11(2H, s), 5.43-5.54(1H, m), 6.51(1H, d), 6.59(1H,
    dd), 6.69(0.8H, s), 6.73(0.2H, s), 7.07(1H, d), 7.51(1H, d), 7.71-7.75(2H,
    m), 10.36(0.8H, brs), 10.53(0.2H, brs), 12.20(1H, brs); two rotamers(4:1)
    ESI+: 574
    Ex171 Ex156 NMR: 1.80-2.12(4H, m), 2.83-2.99(2H, m), 3.26-3.49(3H, m), 3.73-3.86
    (2H, m), 4.87(2H, s), 4.95(2H, q), 5.12(2H, s), 6.51(1H, d), 6.59(1H, dd),
    6.70(0.8H, s), 6.74(0.2H, s), 7.03-7.10(1H, m), 7.41(1H, d), 7.72-7.78
    (2H, m), 10.38-10.57(1H, m), 12.54(1H, brs); two rotamers(4:1)
    ESI+: 546
    Ex172 Ex156 NMR: 1.49(3H, d), 1.78-1.99(2H, m), 2.00-2.12(1H, m), 2.70-3.15(3H,
    m), 3.30-3.47(2H, m), 3.49-3.57(1H, m), 3.82(2H, s), 4.89(2H, s), 5.07
    (2H, s), 5.43-5.54(1H, m), 6.52(1H, d), 6.59(1H, dd), 6.71(1H, s), 7.09(1H,
    d), 7.51(1H, d), 7.77(1H, dd), 7.86(1H, d), 10.69(1H, brs), 12.84(1H, brs)
    ESI+: 517
    Ex173 Ex156 NMR: 1.49(3H, d), 1.85-2.12(4H, m), 2.82-3.00(2H, m), 3.25-3.50(3H,
    m), 3.72-3.86(2H, m), 4.88(2H, s), 5.07(2H, s), 5.43-5.54(1H, m), 6.51
    (1H, d), 6.59(1H, dd), 6.70(0.8H, s), 6.74(0.2H, s), 7.03-7.09(1H, m),
    7.51(1H, d), 7.77(1H, dd), 7.86(1H, d), 10.45-10.70(1H, m), 12.55(1H,
    brs); two rotamers(4:1)
    ESI+: 517
    Ex174 Ex156 NMR: 1.45(3H, d), 2.81(3H, s), 3.87(2H, s), 4.06(2H, s), 4.83(2H, s), 5.11
    (2H, s), 5.43-5.55(1H, m), 6.51(1H, d), 6.59(1H, dd), 6.71(1H, s), 7.08
    (1H, d), 7.52(1H, d), 7.68-7.77(2H, m)
    ESI+: 520
    Ex175 Ex2 NMR: 1.20-1.31(1H, m), 1.28(6H, d), 1.34-1.47(1H, m), 1.54-1.64(1H,
    m), 1.71-1.81(1H, m), 1.81-2.01(2H, m), 2.10-2.22(1H, m), 2.58-2.65
    (1H, m), 2.75-2.83(1H, m), 2.95(2H, s), 4.66(2H, s), 4.74-4.83(1H, m),
    5.03(2H, s), 6.31(1H, s), 6.43(1H, d), 6.51(1H, dd), 6.95(1H, d), 7.30
    (1H, d), 7.61-7.67(2H, m); (CO2H too broad to be seen)
    ESI+: 528(M + Na)+
    Ex176 Ex2 NMR: 1.17-1.30(1H, m), 1.28(6H, d), 1.33-1.47(1H, m), 1.53-1.63(1H,
    m), 1.71-1.96(3H, m), 2.04-2.19(1H, m), 2.57-2.68(1H, m), 2.76-2.83
    (1H, m), 2.95(2H, s), 4.66(2H, s), 4.74-4.83(1H, m), 5.03(2H, s), 6.31(1H,
    s), 6.43(1H, d), 6.51(1H, dd), 6.95(1H, d), 7.30(1H, d), 7.62-7.67(2H,
    m); (CO2H too broad to be seen)
    ESI+: 528
    Ex177 Ex3 NMR: 0.89(6H, d), 1.84-1.99(1H, m), 2.46-2.78(2H, m), 2.63(2H, d), 2.96-
    3.10(1H, m), 3.43-3.56(1H, m), 3.64-3.77(1H, m), 3.84-4.04(3H,
    m), 4.91(1H, d), 4.99(1H, d), 5.17(1H, s), 6.44(1H, s), 6.58(1H, dd), 6.91
    (1H, s), 7.03(1H, s), 7.49(1H, d), 7.66(1H, d), 7.74(1H, s), 11.09(1H,
    brs), 13.01(1H, brs)
    ESI−: 518
  • TABLE 125
    Ex178 Ex3 NMR: 1.28(6H, d), 2.50-2.60(1H, m), 2.65-2.83(1H, m), 2.97-3.10(1H,
    m), 3.43-3.54(1H, m), 3.64-3.75(1H, m), 3.85-3.98(3H, m), 4.74-4.83
    (1H, m), 4.86(1H, d), 4.93(1H, d), 5.07(2H, s), 6.52(1H, d), 6.59(1H, d),
    6.76(1H, s), 7.03(1H, s), 7.09(1H, d), 7.31(1H, d), 7.63-7.69(2H, m),
    10.96(1H, brs), 12.99(1H, brs)
    ESI−: 502
    Ex179 Ex3 NMR: 2.53-2.62(1H, m), 2.62-2.77(1H, m), 2.98-3.11(1H, m), 3.45-3.55
    (1H, m), 3.66-3.77(1H, m), 3.87-4.00(3H, m), 4.79-4.93(4H, m), 5.05
    (2H, s), 6.51(1H, s), 6.59(1H, d), 6.75(1H, s), 7.03(1H, s), 7.09(1H, d),
    7.29(1H, d), 7.41(1H, dd), 7.56(1H, d), 10.53(1H, brs), 13.04(1H, brs)
    ESI−: 508
    Ex180 Ex3 NMR: 2.55-2.61(1H, m), 2.64-2.77(1H, m), 2.98-3.10(1H, m), 3.45-3.55
    (1H, m), 3.65-3.77(1H, m), 3.85-3.98(3H, m), 4.42(2H, dt), 4.85(1H,
    d), 4.91(1H, d), 5.04(2H, s), 6.42(1H, tt), 6.51(1H, d), 6.59(1H, dd), 6.75
    (1H, s), 7.00-7.05(1H, m), 7.08(1H, d), 7.24(1H, d), 7.38(1H, dd), 7.54(1H,
    d), 10.77(1H, brs), 13.01(1H, brs)
    ESI−: 490
    Ex181 Ex3 NMR: 2.53-2.63(2H, m), 3.03-3.13(1H, m), 3.49-3.58(1H, m), 3.72-3.83
    (1H, m), 3.86-4.00(3H, m), 4.60-4.88(6H, m), 4.93-5.08(1H, m), 5.04
    (2H, s), 6.50(1H, s), 6.59(1H, d), 6.74(1H, s), 6.77(1H, s), 7.07(1H, d),
    7.31(1H, d), 7.37(1H, dd), 7.53(1H, d), 10.50(1H, brs), 12.82(1H, brs)
    ESI+: 528
    Ex182 Ex3 NMR: 1.45(3H, d), 2.42-2.65(2H, m), 2.98-3.14(1H, m), 3.47-3.58(1H,
    m), 3.66-3.78(1H, m), 3.88-4.02(3H, m), 4.80(1H, d), 4.86(1H, d), 5.05
    (2H, s), 5.26-5.36(1H, m), 6.51(1H, s), 6.59(1H, d), 6.75(1H, s), 7.04
    (1H, s), 7.10(1H, d), 7.35(1H, d), 7.44(1H, dd), 7.70(1H, d), 10.17(1H,
    brs), 13.02(1H, brs)
    ESI−: 566
    Ex183 Ex3 NMR: 1.49(3H, d), 2.53-2.72(2H, m), 2.98-3.13(1H, m), 3.46-3.56(1H,
    m), 3.65-3.78(1H, m), 3.88-4.02(3H, m), 4.81(1H, d), 4.88(1H, d), 5.09
    (2H, s), 5.87-5.98(1H, m), 6.54(1H, s), 6.62(1H, d), 6.76(1H, s), 7.04(1H,
    s), 7.11(1H, d), 8.10(1H, d), 8.27(1H, d), 10.26(1H, brs), 13.02(1H, brs)
    ESI+: 547
    Ex184 Ex3 NMR: 1.21-1.34(1H, m), 1.29(6H, d), 1.35-1.48(1H, m), 1.56-1.64(1H,
    m), 1.72-1.81(1H, m), 1.84-2.05(2H, m), 2.17-2.29(1H, m), 2.57-2.65
    (1H, m), 2.73-2.85(1H, m), 2.96(2H, s), 4.60-4.71(1H, m), 4.65(2H, s),
    4.97(2H, s), 6.31(1H, s), 6.41(1H, d), 6.50(1H, dd), 6.95(1H, d), 7.16
    (1H, d), 7.33(1H, dd), 7.48(1H, d); (CO2H too broad to be seen)
    ESI+: 494(M + Na)+
    Ex185 Ex3 NMR: 1.20-1.34(1H, m), 1.29(6H, d), 1.33-1.47(1H, m), 1.53-1.65(1H,
    m), 1.71-1.81(1H, m), 1.83-2.03(2H, m), 2.14-2.27(1H, m), 2.57-2.65
    (1H, m), 2.74-2.83(1H, m), 2.96(2H, s), 4.60-4.72(1H, m), 4.65(2H, s),
    4.97(2H, s), 6.31(1H, s), 6.42(1H, d), 6.50(1H, dd), 6.94(1H, d), 7.16
    (1H, d), 7.33(1H, dd), 7.47(1H, d); (CO2H too broad to be seen)
    ESI+: 494
    Ex186 Ex3 NMR: 1.45(3H, d), 2.46-2.76(2H, m), 2.99-3.11(1H, m), 3.45-3.55(1H,
    m), 3.66-3.77(1H, m), 3.87-3.99(3H, m), 4.84(1H, d), 4.91(1H, d), 5.18
    (2H, s), 5.43-5.54(1H, m), 6.54(1H, d), 6.62(1H, dd), 6.76(1H, s), 7.04(1H,
    s), 7.11(1H, d), 7.24(1H, d), 7.57(1H, s), 7.68(1H, d), 10.61(1H, brs),
    13.02(1H, brs)
    ESI−: 556
  • TABLE 126
    Ex187 Ex3 NMR: 1.19-1.31(1H, m), 1.33-1.48(1H, m), 1.45(3H, d), 1.54-1.64(1H,
    m), 1.72-1.99(3H, m), 2.12-2.23(1H, m), 2.58-2.67(1H, m), 2.77-2.86
    (1H, m), 2.96(2H, m), 4.66(2H, s), 5.00(2H, s), 5.23-5.34(1H, m), 6.30
    (1H, s), 6.42(1H, d), 6.50(1H, dd), 6.94(1H, d), 7.34-7.41(2H, m), 7.54
    (1H, s); (CO2H too broad to be seen)
    ESI+: 526
    Ex188 Ex3 NMR: 1.29(6H, d), 2.45-2.72(2H, m), 3.01-3.15(1H, m), 3.48-3.58(1H,
    m), 3.70-3.83(1H, m), 3.83-3.99(3H, m), 4.61-4.72(1H, m), 4.86(1H,
    d), 4.92(1H, d), 5.01(2H, s), 6.50(1H, d), 6.58(1H, dd), 6.72-6.79(2H,
    m), 7.06(1H, d), 7.17(1H, d), 7.34(1H, dd), 7.48(1H, d), 10.95(1H, brs),
    12.79(1H, brs)
    FAB+: 470
    Ex189 Ex3 NMR: 1.19-1.30(1H, m), 1.33-1.47(1H, m), 1.45(3H, d), 1.53-1.64(1H,
    m), 1.72-1.99(3H, m), 2.10-2.21(1H, m), 2.58-2.69(1H, m), 2.76-2.85
    (1H, m), 2.95(2H, s), 4.66(2H, s), 5.00(2H, s), 5.23-5.34(1H, m), 6.30
    (1H, s), 6.42(1H, d), 6.50(1H, dd), 6.95(1H, d), 7.34-7.41(2H, m), 7.54
    (1H, s); (CO2H too broad to be seen)
    ESI+: 526
    Ex190 Ex3 NMR: 1.19(6H, d), 2.08-2.15(2H, m), 2.32-2.39(2H, m), 2.93-2.99(2H,
    m), 3.07(2H, s), 3.70-3.81(1H, m), 4.57(1H, d), 4.66(2H, s), 4.93(2H, s),
    6.23-6.39(2H, m), 6.42(1H, d), 6.50(1H, dd), 6.89(1H, d), 6.96(1H, d),
    7.44-7.50(2H, m); ( CO2H too broad to be seen)
    ESI+: 503
    Ex191 Ex3 NMR: 2.53-2.72(2H, m), 3.00-3.15(1H, m), 3.46-3.59(1H, m), 3.70-3.84
    (1H, m), 3.83-3.98(3H, m), 4.59-4.96(6H, m), 5.07-5.25(1H, m), 5.10
    (2H, s), 6.51(1H, d), 6.59(1H, dd), 6.71-6.81(2H, m), 7.06(1H, d), 7.44
    (1H, d), 7.66-7.74(2H, m), 11.05(1H, brs), 12.67(1H, brs)
    ESI+: 540
    Ex192 Ex3 NMR: 1.45(3H, d), 1.85-2.14(4H, m), 2.73-3.01(3H, m), 3.37-3.49(2H,
    m), 3.65-3.87(2H, m), 4.89(2H, s), 5.05(2H, s), 5.24-5.36(1H, m), 6.50
    (1H, d), 6.58(1H, dd), 6.66-6.77(1H, m), 7.01-7.10(1H, m), 7.36-7.43
    (2H, m), 7.55(1H, s), 10.76(1H, brs), 12.51(1H, brs)
    ESI+: 526
    Ex193 Ex3 NMR: 1.28(6H, d), 2.77-3.17(1H, m), 3.2-3.63(4H, m), 3.68-4.13(3H,
    m), 4.49-4.69(1H, m), 4.73-4.83(1H, m), 4.83-4.98(2H, m), 5.06(2H,
    s), 6.50(1H, d), 6.58(1H, dd), 6.69(1H, brs), 7.06(1H, d), 7.31(1H, d),
    7.63-7.68(2H, m), 11.90(1H, brs), 13.31(1H, brs)
    ESI+: 508
    Ex194 Ex3 NMR: 1.36-1.53(2H, m), 1.73-1.93(2H, m), 1.99-2.09(1H, m), 2.73-3.05
    (3H, m), 3.49-3.59(1H, m), 3.81(2H, s), 4.58-4.85(4H, m), 4.88(2H, s),
    5.06-5.25(1H, m), 5.10(2H, s), 6.51(1H, d), 6.59(1H, dd), 6.71(1H, s),
    7.08(1H, d), 7.44(1H, d), 7.66-7.74(2H, m), 10.60(1H, brs), 12.83(1H, brs)
    ESI+: 542
    Ex195 Ex3 NMR: 1.97(3H, s), 2.55-2.62(1H, m), 2.65-2.78(1H, m), 2.99-3.13(1H,
    m), 3.46-3.55(1H, m), 3.66-3.77(1H, m), 3.87-4.00(3H, m), 4.87(1H,
    d), 4.94(1H, d), 5.26(2H, s), 6.58(1H, d), 6.66(1H, dd), 6.78(1H, s), 7.03
    (1H, s), 7.10(1H, d), 7.12(1H, d), 7.20-7.26(1H, m), 7.28-7.33(2H, m),
    7.35(1H, d), 7.76(1H, d), 7.90(1H, s), 10.86(1H, brs), 13.00(1H, brs)
    ESI+: 536
  • TABLE 127
    Ex196 Ex3 NMR: 1.93(3H, s), 2.56-2.76(2H, m), 2.98-3.13(1H, m), 3.46-3.57(1H,
    m), 3.66-3.78(1H, m), 3.87-4.01(3H, m), 4.84(1H, d), 4.91(1H, d), 5.25
    (2H, s), 6.57(1H, d), 6.65(1H, d), 6.77(1H, s), 7.04(1H, s), 7.13(1H, d),
    7.25-7.27(1H, m), 7.36(1H, d), 7.39(1H, d), 7.75(1H, d), 7.88(1H, s),
    10.59(1H, brs), 13.00(1H, brs)
    ESI+: 542
    Ex197 Ex3 NMR: 1.45(3H, d), 1.55-1.75(2H, m), 2.10-2.24(2H, m), 2.55-2.76(2H,
    m), 2.99-3.23(2H, m), 3.73-3.94(3H, m), 4.86(2H, s), 5.04(2H, s), 5.24-
    5.35(1H, m), 6.49(1H, d), 6.57(1H, dd), 6.69(1H, s), 7.04(1H, d), 7.35-
    7.42(2H, m), 7.55(1H, s), 10.95(1H, brs), 12.29(1H, brs)
    ESI+: 526
    Ex198 Ex3 NMR: 1.51-1.73(5H, m), 1.78-1.90(2H, m), 1.93-2.08(2H, m), 2.52-2.59
    (1H, m), 2.61-2.74(1H, m), 3.01-3.14(1H, m), 3.20-3.32(1H, m), 3.48-
    3.56(1H, m), 3.71-3.83(1H, m), 3.84-3.96(2H, m), 4.89(1H, d), 4.95(1H,
    d), 5.15(2H, s), 6.52(1H, d), 6.60(1H, dd), 6.73-6.79(2H, m), 7.07
    (1H, d), 7.61-7.71(3H, m), 11.21(1H, brs), 12.79(1H, brs)
    ESI+: 514
    Ex199 Ex3 NMR: 1.34(3H, t), 2.52-2.62(1H, m), 2.64-2.83(1H, m), 2.94-3.12(1H,
    m), 3.43-3.56(1H, m), 3.63-3.78(1H, m), 3.81-4.00(3H, m), 4.18(2H,
    q), 4.81-4.98(2H, m), 5.08(2H, s), 6.51(1H, s), 6.58(1H, d), 6.69-6.79
    (1H, brs), 7.01(1H, s), 7.07(1H, d), 7.27(1H, d), 7.64-7.70(2H, m), 11.21
    (1H, brs), 12.90(1H, brs)
    ESI+: 490
    Ex200 Ex3 NMR: 2.54-2.75(2H, m), 2.98-3.11(1H, m), 3.43-3.56(1H, m), 3.65-3.77
    (1H, m), 3.86-4.00(3H, m), 4.83(1H, d), 4.90(1H, d), 4.93(1H, d), 4.98
    (1H, d), 5.12(2H, s), 6.52(1H, d), 6.60(1H, dd), 6.75(1H, s), 7.03(1H, s),
    7.09(1H, d), 7.41(1H, d), 7.72-7.77(2H, m), 10.61(1H, brs), 13.01(1H, brs)
    ESI+: 544
    Ex201 Ex3 NMR: 1.46(3H, d), 2.55-2.76(2H, m), 2.99-3.11(1H, m), 3.45-3.56(1H,
    m), 3.65-3.77(1H, m), 3.86-4.00(3H, m), 4.85(1H, d), 4.92(1H, d), 4.99-
    5.11(1H, m), 5.09(2H, s), 6.53(1H, d), 6.61(1H, dd), 6.76(1H, s), 7.03
    (1H, s), 7.10(1H, d), 7.61(2H, s), 10.75(1H, brs), 13.01(1H, brs)
    ESI+: 558
    Ex202 Ex3 NMR: 2.26-2.45(4H, m), 2.82-2.94(1H, m), 3.53-3.63(2H, m), 4.27-4.39
    (1H, m), 4.82(2H, s), 5.33(2H, s), 6.40(1H, s), 6.57(1H, dd), 6.76(1H,
    s), 8.00(1H, d), 8.10(1H, s), 8.16(1H, d), 10.07(1H, brs)
    ESI+: 520
    Ex203 Ex3 NMR: 1.37-1.51(1H, m), 1.49(3H, d), 1.77-2.10(4H, m), 2.73-3.05(3H,
    m), 3.46-3.56(1H, m), 3.81(2H, s), 4.89(2H, s), 5.09(2H, s), 5.85-5.98
    (1H, m), 6.53(1H, d), 6.60(1H, dd), 6.71(1H, s), 7.08(1H, d), 8.10(1H, d),
    8.26(1H, d), 10.78(1H, brs), 12.83(1H, brs)
    ESI+: 527
    Ex204 Ex3 NMR: 2.53-2.78(2H, m), 2.99-3.12(1H, m), 3.44-3.56(1H, m), 3.66-3.77
    (1H, m), 3.87-3.99(3H, m), 4.85(1H, d), 4.92(1H, d), 5.10(2H, s), 6.54
    (1H, d), 6.61(1H, dd), 6.76(1H, s), 6.97(2H, d), 7.03(1H, s), 7.11(2H, d),
    7.15(1H, t), 7.36-7.44(3H, m), 7.67(1H, d), 10.67(1H, brs), 12.99(1H, brs)
    ESI+: 504
  • TABLE 128
    Ex205 Ex3 NMR: 1.28(6H, d), 2.50-2.59(1H, m), 2.62-2.73(1H, m), 2.75-2.84(1H,
    m), 2.97-3.14(1H, m), 3.15-3.38(4H, m), 4.19-4.25(1H, m), 4.69(2H,
    s), 4.74-4.84(1H, m), 5.04(2H, s), 6.41-6.47(2H, m), 6.54(1H, dd), 6.98
    (1H, d), 7.31(1H, d), 7.62-7.67(2H, m)
    ESI+: 507
    Ex206 Ex3 NMR: 1.47-1.98(8H, m), 2.53-2.78(2H, m), 2.97-3.11(1H, m), 3.44-3.55
    (1H, m), 3.64-3.76(1H, m), 3.84-3.99(3H, m), 4.81-4.95(3H, m), 5.01
    (2H, s), 6.50(1H, d), 6.58(1H, dd), 6.75(1H, s), 7.03(1H, s), 7.08(1H, d),
    7.15(1H, d), 7.34(1H, dd), 7.48(1H, d), 10.86(1H, brs), 12.95(1H, brs)
    ESI+: 496
    Ex207 Ex3 NMR: 2.54-2.63(2H, m), 3.04-3.14(1H, m), 3.50-3.59(1H, m), 3.73-3.83
    (1H, m), 3.86-4.00(3H, m), 4.86(2H, d), 4.93(1H, d), 4.98(1H, d), 5.12
    (2H, s), 6.52(1H, d), 6.60(1H, dd), 6.74(1H, s), 6.77(1H, s), 7.08(1H, d),
    7.41(1H, d), 7.71-7.78(2H, m), 10.57(1H, brs), 12.81(1H, brs)
    ESI+: 544
    Ex208 Ex3 NMR: 0.64-0.70(2H, m), 0.81-0.88(2H, m), 2.56-2.76(2H, m), 2.99-3.12
    (1H, m), 3.45-3.56(1H, m), 3.65-3.78(1H, m), 3.87-4.00(3H, m), 4.01-
    4.08(1H, m), 4.83(1H, d), 4.90(1H, d), 5.10(2H, s), 6.52(1H, d), 6.60
    (1H, dd), 6.76(1H, s), 7.03(1H, s), 7.09(1H, d), 7.56(1H, d), 7.67(1H, d),
    7.73(1H, dd), 10.61(1H, brs), 13.00(1H, brs)
    ESI+: 502
    Ex209 Ex3 NMR: 2.41-2.61(1H, m), 2.63-2.84(1H, m), 2.90-3.14(1H, m), 3.35-3.58
    (1H, m), 3.61-3.80(1H, m), 3.77-4.07(3H, m), 4.85-5.06(2H, m), 5.35
    (2H, s), 6.45(1H, s), 6.51(1H, s), 6.60(1H, d), 7.01(1H, s), 7.96(1H, d),
    8.06-8.13(2H, m), 11.43(1H, brs), 12.97(1H, brs)
    ESI+: 532
    Ex210 Ex3 NMR: 1.29(6H, d), 1.82-2.12(4H, m), 2.73-3.01(3H, m), 3.39-3.49(2H,
    m), 3.72-3.80(1.6H, m), 3.80-3.86(0.4H, m), 4.61-4.72(1H, m), 4.85(2H,
    s), 5.01(2H, s), 6.46-6.51(1H, m), 6.54-6.60(1H, m), 6.70(0.8H, s), 6.73
    (0.2H, s), 7.01-7.08(1H, m), 7.17(1H, d), 7.33(1H, dd), 7.48(1H, d),
    10.27(0.8H, brs), 10.37(0.2H, brs), 12.52(1H, brs); two rotaners(4:1)
    ESI+: 472
    Ex211 Ex3 NMR: 1.56(3H, s), 3.76-3.93(4H, m), 4.10-4.27(2H, m), 4.59-4.85(6H,
    m), 4.92-5.08(1H, m), 5.02(2H, s), 6.47(1H, d), 6.56(1H, dd), 6.67(1H,
    s), 7.03(1H, d), 7.31(1H, d), 7.36(1H, dd), 7.53(1H, d); (CO2H too
    broad to be seen)
    ESI+: 494
    Ex212 Ex3 NMR: 1.36-1.52(2H, m), 1.76-2.12(3H, m), 2.70-3.08(3H, m), 3.45-3.62
    (1H, m), 3.76-3.96(2H, m), 4.59-4.85(4H, m), 4.92(2H, s), 5.09-5.25
    (1H, m), 5.11(2H, s), 6.41(1H, s), 6.55(1H, dd), 6.84(1H, s), 7.44(1H, s),
    7.67-7.73(2H, m), 10.86(1H, brs), 12.81(1H, brs)
    ESI+: 560
    Ex213 Ex3 NMR: 2.45-2.62(1H, m), 2.65-2.82(1H, m), 2.96-3.10(1H, m), 3.42-3.56
    (1H, m), 3.64-3.78(1H, m), 3.83-4.05(3H, m), 4.94(1H, d), 5.01(1H, d),
    5.32(2H, s), 6.48(1H, s), 6.62(1H, d), 6.91(1H, s), 7.03(1H, s), 8.11(1H,
    s), 8.16(2H, s), 11.27(1H, brs), 12.99(1H, brs)
    ESI+: 532
  • TABLE 129
    Ex214 Ex3 NMR: 1.46-1.66(6H, m), 2.55-2.72(2H, m), 2.76-2.84(4H, m), 2.98-3.10
    (1H, m), 3.45-3.55(1H, m), 3.65-3.78(1H, m), 3.87-4.02(3H, m), 4.82
    (1H, d), 4.88(1H, d), 5.13(2H, s), 6.53(1H, d), 6.61(1H, dd), 6.76(1H, s),
    7.04(1H, s), 7.10(1H, d), 7.52(1H, d), 7.66-7.75(2H, m), 10.42(1H, brs),
    13.01(1H, brs)
    ESI+: 529
    Ex215 Ex3 NMR: 2.54-2.78(2H, m), 2.96-3.08(1H, m), 3.45-3.55(1H, m), 3.65-3.77
    (1H, m), 3.85-4.05(3H, m), 4.85-5.01(4H, m), 5.14(2H, s), 6.43(1H, s),
    6.57(1H, dd), 6.90(1H, s), 7.03(1H, s), 7.42(1H, d), 7.73-7.79(2H, m),
    10.96(1H, brs), 13.00(1H, brs)
    ESI+: 562
    Ex216 Ex3 NMR: 1.51-2.09(9H, m), 2.53-2.62(1H, m), 2.62-2.76(1H, m), 2.97-3.12
    (1H, m), 3.45-3.56(1H, m), 3.64-3.77(1H, m), 3.85-4.00(3H, m), 4.84
    (1H, d), 4.90(1H, d), 5.15(2H, s), 6.52(1H, s), 6.60(1H, d), 6.75(1H, s),
    7.03(1H, s), 7.10(1H, d), 7.61-7.72(3H, m), 10.67(1H, brs), 12.96(1H, brs)
    ESI+: 514
    Ex217 Ex3 NMR: 1.44(3H, d), 2.54-2.68(2H, m), 3.02-3.15(1H, m), 3.49-3.59(1H,
    m), 3.71-3.84(1H, m), 3.84-4.00(3H, m), 4.86(1H, d), 4.91(1H, d), 5.14
    (2H, s), 5.41-5.52(1H, m), 6.49(1H, s), 6.57(1H, d), 6.73-6.80(2H, m),
    7.08(1H, d), 7.42-7.49(2H, m), 7.69(1H, d), 10.79(1H, brs), 12.82(1H, brs)
    ESI+: 558
    Ex218 Ex3 NMR: 0.64-0.70(2H, m), 0.81-0.88(2H, m), 2.54-2.63(2H, m), 3.04-3.14
    (1H, m), 3.50-3.59(1H, m), 3.72-3.83(1H, m), 3.86-3.99(3H, m), 4.01-
    4.07(1H, m), 4.83(1H, d), 4.89(1H, d), 5.09(2H, s), 6.52(1H, s), 6.60(1H,
    d), 6.74(1H, s), 6.77(1H, s), 7.08(1H, d), 7.55(1H, d), 7.67(1H, d), 7.72
    (1H, dd), 10.52(1H, brs), 12.83(1H, brs)
    ESI+: 502
    Ex219 Ex3 NMR: 1.48-1.84(7H, m), 1.96-2.06(2H, m), 2.48-2.68(2H, m), 3.02-3.14
    (1H, m), 3.48-3.58(1H, m), 3.69-3.83(1H, m), 3.84-3.98(3H, m), 4.84
    (1H, d), 4.90(1H, d), 5.07(2H, s), 6.50(1H, d), 6.58(1H, dd), 6.74(1H, s),
    6.77(1H, s), 7.07(1H, d), 7.34(1H, dd), 7.42(1H, d), 7.46(1H, d), 10.74
    (1H, brs), 12.83(1H, brs)
    ESI+: 480
    Ex220 Ex3 NMR: 1.54-1.73(2H, m), 2.07-2.23(2H, m), 2.54-2.70(1H, m), 2.92-3.60
    (4H, m), 3.83(2H, s), 4.87(2H, s), 5.33(2H, s), 6.50(1H, d), 6.58(1H, dd),
    6.70(1H, s), 7.08(1H, d), 7.99(1H, d), 8.10(1H, s), 8.14(1H, d), 10.93
    (1H, brs), 12.29(1H, brs)
    ESI+: 516
    Ex221 Ex3 NMR: 2.54-2.72(2H, m), 3.01-3.13(1H, m), 3.47-3.57(1H, m), 3.70-3.82
    (1H, m), 3.83-3.91(3H, m), 4.83-4.95(4H, m), 5.05(2H, s), 6.50(1H, d),
    6.58(1H, dd), 6.74(1H, s), 6.77(1H, s), 7.06(1H, d), 7.29(1H, d), 7.41
    (1H, dd), 7.56(1H, d), 10.98(1H, brs), 12.77(1H, brs)
    ESI+: 510
    Ex222 Ex3 NMR: 2.53-2.66(2H, m), 3.01-3.12(1H, m), 3.49-3.58(1H, m), 3.71-3.85
    (1H, m), 3.86-4.01(3H, m), 4.58-4.85(4H, m), 4.89(1H, d), 4.96(1H, d),
    5.08-5.25(1H, m), 5.11(2H, s), 6.47(1H, s), 6.56(1H, dd), 6.76(1H, s), 6.89
    (1H, s), 7.44(1H, d), 7.67-7.74(2H, m), 10.86(1H, brs), 12.79(1H, brs)
    ESI+: 558
  • TABLE 130
    Ex223 Ex3 NMR: 1.36-1.53(1H, m), 1.79-1.95(2H, m), 2.00-2.09(1H, m), 2.72-3.04
    (3H, m), 3.32-3.44(1H, m), 3.49-3.58(1H, m), 3.86(2H, s), 4.60-4.84
    (4H, m), 4.93(2H, s), 4.93-5.09(1H, m), 5.05(2H, s), 6.40(1H, d), 6.54(1H,
    dd), 6.84(1H, s), 7.31(1H, d), 7.37(1H, dd), 7.54(1H, d), 10.80(1H, brs),
    12.83(1H, brs)
    ESI+: 526
    Ex224 Ex3 NMR: 1.45(3H, d), 2.39-2.68(2H, m), 3.01-3.14(1H, m), 3.46-3.59(1H,
    m), 3.69-3.99(2H, m), 3.89(2H, s), 4.85(1H, d), 4.91(1H, d), 5.05(2H, s),
    5.24-5.36(1H, m), 6.51(1H, d), 6.59(1H, dd), 6.72-6.80(2H, m), 7.07(1H,
    d), 7.35-7.43(2H, m), 7.54-7.57(1H, m), 10.84(1H, brs), 12.82(1H, brs)
    ESI+: 524
    Ex225 Ex3 NMR: 1.50(3H, d), 2.39-2.76(2H, m), 2.96-3.12(1H, m), 3.44-3.57(1H,
    m), 3.64-3.78(1H, m), 3.84-4.00(3H, m), 4.88(2H, s), 5.14(2H, s), 5.94-
    6.09(1H, m), 6.47-6.66(2H, m), 6.77(1H, s), 6.97-7.14(2H, m), 8.29(1H,
    d), 8.58(1H, d), 10.73(1H, brs), 12.91(1H, brs)
    ESI+: 559
    Ex226 Ex3 NMR: 1.38-1.54(1H, m), 1.50(3H, d), 1.78-2.11(3H, m), 2.72-3.09(3H,
    m), 3.30-3.44(1H, m), 3.46-3.57(1H, m), 3.81(2H, s), 4.91(2H, s), 5.16
    (2H, s), 5.96-6.08(1H, m), 6.52-6.57(1H, m), 6.61(1H, dd), 6.72(1H, s),
    7.09(1H, d), 8.30(1H, d), 8.58(1H, d), 10.93(1H, brs), 12.73(1H, brs)
    ESI+: 561
    Ex227 Ex3 NMR: 1.44(3H, d), 1.51-1.71(2H, m), 2.06-2.20(2H, m), 2.38-2.64(2H,
    m), 2.95-3.46(3H, m), 3.56-3.92(2H, m), 4.80(2H, s), 5.10(2H, s), 5.42-
    5.53(1H, m), 6.49(1H, d), 6.57(1H, dd), 6.57-6.67(1H, m), 7.04(1H, d),
    7.51(1H, d), 7.70-7.76(2H, m), 10.61(1H, brs), 12.27(1H, brs)
    ESI+: 560
    Ex228 Ex3 NMR: 2.27-2.49(4H, m), 2.82-2.97(1H, m), 3.56(2H, s), 3.57-3.70(1H,
    m), 4.59-4.85(4H, m), 4.75(2H, s), 4.91-5.08(1H, m), 5.03(2H, s), 6.49
    (1H, d), 6.57(1H, dd), 6.62(1H, s), 7.04(1H, d), 7.31(1H, d), 7.37(1H,
    dd), 7.53(1H, d), 8.85-9.21(2H, m), 12.38(1H, brs)
    ESI+: 494
    Ex229 Ex3 NMR: 1.36-1.52(1H, m), 1.59-1.96(3H, m), 1.99-2.11(1H, m), 2.72-2.96
    (2H, m), 3.36-3.46(1H, m), 3.50-3.60(1H, m), 3.88(2H, s), 4.67-4.86
    (4H, m), 4.90(2H, s), 5.09(2H, s), 5.61-5.78(1H, m), 6.44(1H, d), 6.58(1H,
    dd), 6.82(1H, s), 8.06(1H, d), 8.23(1H, d), 10.29(1H, brs), 12.84(1H, brs)
    ESI+: 527
    Ex230 Ex3 NMR: 1.37-1.52(1H, m), 1.62-1.93(3H, m), 1.99-2.10(1H, m), 2.71-2.97
    (2H, m), 3.36-3.45(1H, m), 3.49-3.62(1H, m), 3.88(2H, s), 4.58-4.86
    (4H, m), 4.89(2H, s), 5.08-5.25(1H, m), 5.11(2H, s), 6.42(1H, s), 6.56(1H,
    dd), 6.84(1H, s), 7.44(1H, d), 7.65-7.73(2H, m), 10.37(1H, brs), 12.83
    (1H, brs)
    ESI+: 560
    Ex231 Ex3 NMR: 1.74-1.94(2H, m), 1.95-2.14(3H, m), 2.81-3.01(2H, m), 3.40-3.51
    (2H, m), 3.84(1.4H, d), 3.89(0.6H, d), 4.58-4.86(4H, m), 4.88(2H, s),
    5.08-5.25(1H, m), 5.11(2H, s), 6.42(1H, s), 6.53-6.60(1H, m), 6.84(0.7H,
    s), 6.89(0.3H, s), 7.44(1H, d), 7.66-7.74(2H, m), 10.08(0.7H, brs),
    10.18(0.3H, brs), 12.52(1H, brs); two rotamers(7:3)
    ESI+: 560
  • TABLE 131
    Ex232 Ex3 NMR: 1.45(3H, d), 2.30-2.47(4H, m), 2.83-2.97(1H, m), 3.54(2H, s), 3.56-
    3.67(1H, m), 4.79(2H, s), 5.10(2H, s), 5.44-5.54(1H, m), 6.50(1H, d),
    6.58(1H, dd), 6.64(1H, s), 7.04(1H, d), 7.52(1H, d), 7.70-7.76(2H, m),
    9.16-9.55(2H, brs), 12.38(1H, brs)
    ESI+: 546
    Ex233 Ex3 NMR: 1.17(2.1H, s), 1.26(0.9H, s), 1.71-1.90(2H, m), 2.05-2.22(2H,
    m), 2.72-2.90(1.4H, m), 2.99-3.14(0.6H, m), 3.21-3.45(2H, m), 3.70-3.90
    (2H, m), 4.60-4.90(6H, m), 4.92-5.08(3H, m), 6.49(1H, d), 6.57(1H, dd),
    6.71(1H, s), 7.01-7.08(1H, m), 7.31(1H, d), 7.36(1H, dd), 7.53(1H,
    d), 10.26-10.50(1H, m), 12.73(1H, brs); two rotamers(7:3)
    ESI+: 522
    Ex234 Ex3 NMR: 1.86-2.03(2H, m), 2.08-2.20(2H, m), 2.85-3.13(3H, m), 3.14-3.30
    (1H, m), 3.46-3.57(1H, m), 3.73-3.90(2H, m), 4.60-4.83(4H, m), 4.84
    (2H, s), 4.92-5.09(1H, m), 5.04(2H, s), 6.50(1H, d), 6.58(1H, dd), 6.71
    (1H, s), 7.07(1H, d), 7.31(1H, d), 7.37(1H, dd), 7.53(1H, d), 10.10-10.43
    (1H, m), 12.44(1H, brs)
    ESI+: 548
    Ex235 Ex3 NMR: 1.37-1.52(1H, m), 1.81-1.93(2H, m), 1.99-2.10(1H, m), 2.72-3.04
    (3H, m), 3.31-3.44(1H, m), 3.49-3.59(1H, m), 3.87(2H, s), 4.61-4.85
    (4H, m), 4.92(2H, s), 4.94-5.09(1H, m), 5.05(2H, s), 6.41(1H, s), 6.55
    (1H, dd), 6.85(1H, s), 7.31(1H, d), 7.37(1H, dd), 7.54(1H, d), 10.67(1H,
    brs), 12.80(1H, brs)
    ESI+: 526
    Ex236 Ex156 NMR: 1.36-1.52(1H, m), 1.79-2.10(3H, m), 2.72-3.06(3H, m), 3.31-3.44
    (1H, m), 3.48-3.59(1H, m), 3.86(2H, s), 4.88-5.01(4H, m), 5.13(2H, s),
    6.42(1H, d), 6.56(1H, dd), 6.85(1H, s), 7.42(1H, d), 7.72-7.78(2H, m),
    10.89(1H, brs), 12.84(1H, brs)
    ESI+: 564
    • INDUSTRIAL APPLICABILITY
  • The compound of the present invention has an S1P1 agonist action and can be used for prevention or treatment of diseases induced by undesirable lymphocyte infiltration, for example, autoimmune diseases or inflammatory diseases such as graft rejection or graft-versus-host diseases during organ, bone marrow, or tissue transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, lung disorders, asthma, atopic dermatitis, inflammatory bowel disease, arteriosclerosis, ischemic reperfusion disorder, and diseases induced by abnormal proliferation or accumulation of cells, for example, cancer, leukemia, and the like.

Claims (20)

1. A method for preventing or treating a disease induced by undesirable lymphocyte infiltration associated with S1P1, comprising administering to a patient an effective amount of a 2H-chromene compound represented by the following formula (1):
Figure US20120178735A1-20120712-C00604
(wherein A represents lower alkyl, cycloalkyl, aryl, or heteroaryl, wherein aryl and heteroaryl may respectively be substituted with one to five R1s which are the same as or different from each other, other;
R1 represents halogen, —CN, —NO2, lower alkyl, lower alkenyl, lower alkynyl, halogeno-lower alkyl, aryl, heteroaryl, cycloalkyl, —OH, —O-(lower alkyl), —O-(halogeno-lower alkyl), —O-(aryl), —O-(cycloalkyl), —O-(heteroaryl), —NH2, —NH(lower alkyl), —NH(halogeno-lower alkyl), —N(lower alkyl)2, or cyclic amino, wherein aryl, heteroaryl, cycloalkyl, and cyclic amino may respectively be substituted with one to five substituents which are the same as or different from each other and selected from the group consisting of halogen, —CN, lower alkyl and halogeno-lower alkyl;
L represents lower alkylene, lower alkenylene, lower alkynylene, -(lower alkylene)-O—, —O-(lower alkylene)-, or -(lower alkylene)-O-(lower alkylene)-;
Q represents S or —C(R2B)═C(R2C)—;
R2A, R2B, and R2C independently represent —H, halogen, lower alkyl, halogeno-lower alkyl, —O-(lower alkyl), or —O-(halogeno-lower alkyl);
Y represents O, S, or —CH2—, provided that wherein Y is —CH2—, Q is S;
m represents 0 or 1;
R3 represents —H, halogen, lower alkyl, halogeno-lower alkyl, or aryl;
R4A represents —H or lower alkyl;
R4B represents lower alkyl substituted with a group selected from Group G or cycloalkyl substituted with a group selected from Group G;
or R4A and R4B are combined with N to which they bind to form cyclic amino substituted with a group selected from Group G, in which the cyclic amino may further contain one to four substituents which are the same as or different from each other and selected from the group consisting of halogen, lower alkyl, and halogeno-lower alkyl; and
Group G represents, —C(═O)OH, tetrazolyl, —C(═O)NHS(═O)2(lower alkyl), -(lower alkylene)-C(═O)OH, or
Figure US20120178735A1-20120712-C00605
or a salt thereof.
2. The method as described in claim 1, wherein Y is O, Q is —C(R2B)═C(R2C)—, and m is 0.
3. The method as described in claim 2, wherein R4A and R4B are combined with N to which they bind to form azetidinyl, pyrrolidinyl, piperidinyl or tetrahydropyridyl, which is substituted with a group selected from Group G, and which may further be substituted with lower alkyl or halogen.
4. The method as described in claim 3, wherein the group represented by Group G is —C(═O)OH or —C(═O)NHS(═O)2CH3.
5. The method as described in claim 4, wherein A is phenyl, pyridyl, or thienyl, substituted with one to three R1s which are the same as or different from each other.
6. The method as described in claim 5, wherein L is -(lower alkylene)-O—, lower alkenylene, or lower alkynylene.
7. The method as described in claim 6, wherein R2A is —H or lower alkyl; R2B is —H; R2C is —H or halogen; R3 is —H or halogen; R1 is halogen, lower alkyl, halogeno-lower alkyl, phenyl, pyrrolyl, cycloalkyl, —O-(lower alkyl), or —O-(halogeno-lower alkyl); and L is —CH2—O—, —CH═CH—, or 3-butynylene.
8. The method as described in claim 7, wherein R4A and R4B are combined with N to which they bind to form piperidinyl or tetrahydropyridyl, which is substituted with —C(═O)OH; L is —CH2—O—; R2A and R2B are —H; R2C is —H or halogen; R3 is —H; and A is phenyl or pyridyl, which is substituted with two R1s which are independently halogen, halogeno-lower alkyl, —O-(lower alkyl) or —O-(halogeno-lower alkyl).
9. The method as described in claim 8, wherein R4A and R4B are combined with N to which they bind to form piperidinyl which is substituted with —C(═O)OH; and A is phenyl which is substituted with two R1s which are the same as or different from each other.
10. The method as described in claim 8, wherein R4A and R4B are combined with N to which they bind to form tetrahydropyridyl which is substituted with —C(═O)OH; and A is pyridyl which is substituted with two R1s which are the same as or different from each other.
11. The method of claim 1, wherein said 2H-chromene compound is:
1-{[7-({3-chloro-4-[(1S)-2,2,2-trifluoro-1-methylethoxy]benzyl}oxy)-2H-chromen-3-yl]methyl}-1,2,5,6-tetrahydropyridine-3-carboxylic acid,
1-({7-[(3-chloro-4-isopropylbenzyl)oxy]-2H-chromen-3-yl}methyl)-1,2,5,6-tetrahydropyridine-3-carboxylic acid,
1-[(7-{[4-isopropoxy-3-(trifluoromethyl)benzyl]oxy}-2H-chromen-3-yl)methyl]-1,2,5,6-tetrahydropyridine-3-carboxylic acid,
1-{[7-({3-chloro-4-[2-fluoro-1-(fluoromethyl)ethoxy]benzyl}oxy)-2H-chromen-3-yl]methyl}-1,2,3,6-tetrahydropyridine-4-carboxylic acid,
1-{[7-({5-chloro-6-[(1S)-2,2,2-trifluoro-1-methylethoxy]pyridin-3-yl}methoxy)-2H-chromen-3-yl]methyl}-1,2,5,6-tetrahydropyridine-3-carboxylic acid,
(3R)-1-{[7-({4-[(1,3-difluoropropan-2-yl)oxy]-3-(trifluoromethyl)benzyl}oxy)-5-fluoro-2H-chromen-3-yl]methyl}piperidine-3-carboxylic acid,
1-[(7-{[4-cyclopentyl-3-(trifluoromethyl)benzyl]oxy}-2H-chromen-3-yl)methyl]-1,2,5,6-tetrahydropyridine-3-carboxylic acid,
(3R)-1-{[7-({3-chloro-4-[(1,3-difluoropropan-2-yl)oxy]benzyl)oxy)-5-fluoro-2H-chromen-3-yl]methyl}piperidine-3-carboxylic acid,
(3S)-1-{[7-({4-[(1,3-difluoropropan-2-yl)oxy]-3-(trifluoromethyl)benzyl}oxy)-5-fluoro-2H-chromen-3-yl]methyl}piperidine-3-carboxylic acid,
(3R)-1-[(7-{[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)benzyl]oxy}-2H-chromen-3-yl)methyl]piperidine-3-carboxylic acid,
(3R)-1-[(7-{[3-(trifluoromethyl)-4-{[(2S)-1,1,1-trifluoropropan-2-yl]oxy}benzyl]oxy}-2H-chromen-3-yl)methyl]piperidine-3-carboxylic acid,
(3S)-1-[(7-{[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)benzyl]oxy}-5-fluoro-2H-chromen-3-yl)methyl]piperidine-3-carboxylic acid,
(3R)-1-{[7-({4-[(1,3-difluoropropan-2-yl)oxy]-3-(trifluoromethyl)benzyl}oxy)-5-fluoro-2H-chromen-3-yl]methyl}-N-(methylsulfonyl)piperidine-3-carboxamide, or
1-[(7-{[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)benzyl]oxy}-2H-chromen-3-yl)methyl]piperidine-4-carboxylic acid,
or a pharmaceutically acceptable salt thereof.
12-14. (canceled)
15. The method as described in claim 1, wherein the disease is autoimmune or inflammatory disease in human or an animal.
16. The method as described in claim 15, wherein the disease is rejection or graft-versus-host diseases from organ, bone marrow, or tissue transplantation in human or an animal.
17. The method as described in claim 15, wherein the disease is multiple sclerosis.
18-20. (canceled)
21. A method for preventing or treating a disease induced by undesirable lymphocyte infiltration associated with S1P1, comprising administering to a patient an effective amount of compound of the formula
Figure US20120178735A1-20120712-C00606
or a pharmaceutically acceptable salt thereof.
22. The method as described in claim 21, wherein the disease is autoimmune or inflammatory disease in human or an animal.
23. The method as described in claim 22, wherein the disease is rejection or graft-versus-host diseases from organ, bone marrow, or tissue transplantation in human or an animal.
24. The method as described in claim 22, wherein the disease is multiple sclerosis.
US13/396,861 2008-12-05 2012-02-15 2h-chromene compound and derivative thereof Abandoned US20120178735A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/396,861 US20120178735A1 (en) 2008-12-05 2012-02-15 2h-chromene compound and derivative thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008311445 2008-12-05
JPP2008-311445 2008-12-05
PCT/JP2009/070398 WO2010064707A1 (en) 2008-12-05 2009-12-04 2h-chromene compound and derivative thereof
US201113131343A 2011-05-26 2011-05-26
US13/396,861 US20120178735A1 (en) 2008-12-05 2012-02-15 2h-chromene compound and derivative thereof

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2009/070398 Division WO2010064707A1 (en) 2008-12-05 2009-12-04 2h-chromene compound and derivative thereof
US201113131343A Division 2008-12-05 2011-05-26

Publications (1)

Publication Number Publication Date
US20120178735A1 true US20120178735A1 (en) 2012-07-12

Family

ID=42233354

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/131,343 Active US8193378B2 (en) 2008-12-05 2009-12-04 2H-chromene compound and derivative thereof
US13/396,861 Abandoned US20120178735A1 (en) 2008-12-05 2012-02-15 2h-chromene compound and derivative thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/131,343 Active US8193378B2 (en) 2008-12-05 2009-12-04 2H-chromene compound and derivative thereof

Country Status (15)

Country Link
US (2) US8193378B2 (en)
EP (1) EP2354134B1 (en)
JP (1) JP5578083B2 (en)
KR (1) KR101589332B1 (en)
CN (1) CN102239164B (en)
AU (1) AU2009323259A1 (en)
BR (1) BRPI0922135B1 (en)
CA (1) CA2745356C (en)
ES (1) ES2570155T3 (en)
IL (1) IL213261A0 (en)
MX (1) MX2011005954A (en)
PL (1) PL2354134T3 (en)
RU (1) RU2490266C2 (en)
WO (1) WO2010064707A1 (en)
ZA (1) ZA201103928B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629834B2 (en) 2013-04-26 2017-04-25 Kyoto University Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
JP2013521301A (en) * 2010-03-03 2013-06-10 アリーナ ファーマシューティカルズ， インコーポレイテッド Process for the preparation of S1P1 receptor modulators and their crystalline forms
ES2379242B1 (en) * 2010-09-28 2013-03-04 Consejo Superior De Investigaciones Científicas (Csic) CHROME DERIVATIVES
EP2511275A1 (en) * 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
RU2013150173A (en) 2011-04-14 2015-05-20 Аллерган, Инк. METHYLAMINE DERIVATIVES OF Bicyclic Phenyl as Modulators of Sphingosine-1-Phosphate Receptors
US8507686B2 (en) * 2011-04-14 2013-08-13 Allergan, Inc. Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators
EP2697195A1 (en) * 2011-04-14 2014-02-19 Allergan, Inc. Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators
CA2833545A1 (en) * 2011-04-18 2012-10-26 Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
WO2014130565A1 (en) * 2013-02-20 2014-08-28 Allergan, Inc. Substituted diaryl azetidine derivatives as sphingosine receptor modulators
ES2534318B1 (en) * 2013-10-18 2016-01-28 Artax Biopharma Inc. Alkoxide substituted chromene derivatives as inhibitors of the TCR-Nck interaction
ES2534336B1 (en) 2013-10-18 2016-01-28 Artax Biopharma Inc. Chromene derivatives as inhibitors of the TCR-Nck interaction
CN104650022B (en) * 2013-11-20 2018-09-25 浙江奥翔药业股份有限公司 The synthetic method and its midbody compound of Nebivolol
CN105712893A (en) * 2014-12-02 2016-06-29 重庆安格龙翔医药科技有限公司 3-chloro-4-methoxy benzyl amine synthetic method
CN105712891A (en) * 2014-12-02 2016-06-29 重庆安格龙翔医药科技有限公司 Method used for preparing high purity 3-chloro-4-methoxybenzylamine
US10975049B2 (en) * 2016-05-23 2021-04-13 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Nicotinyl alcohol ether derivative, preparation method therefor, and pharmaceutical composition and uses thereof
ES2862949T3 (en) * 2016-07-29 2021-10-08 Mitsubishi Tanabe Pharma Corp Production method of 4-alkoxy-3- (trifluoromethyl) benzyl alcohol
JOP20200186A1 (en) * 2018-02-02 2020-07-29 Univ Kyoto Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
AU2019229258B2 (en) 2018-02-27 2023-09-14 Artax Biopharma Inc. Chromene derivatives as inhibitors of TCR-Nck interaction
HRP20230125T1 (en) * 2018-03-27 2023-06-09 Neuropore Therapies, Inc. Compounds as modulators of tlr2 signaling
EP3825303A4 (en) 2018-07-17 2022-07-06 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
CN109824725B (en) * 2019-03-11 2021-12-10 江西科技师范大学 Preparation method of 4-phosphate-2H-chromene derivative
EP3946599A1 (en) 2019-03-26 2022-02-09 Neuropore Therapies, Inc. Compounds and compositions as modulators of tlr signaling
US20220226299A1 (en) 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
WO2021112461A1 (en) 2019-12-03 2021-06-10 주식회사 엘지화학 Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition comprising same as active agent
US20230146180A1 (en) * 2020-02-11 2023-05-11 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds
CN117136183A (en) * 2021-04-14 2023-11-28 株式会社Lg化学 Novel process for preparing sphingosine-1-phosphate receptor agonists
WO2022220610A1 (en) * 2021-04-14 2022-10-20 주식회사 엘지화학 Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist
KR20220142388A (en) * 2021-04-14 2022-10-21 주식회사 엘지화학 Novel method of preparing sphinosine-1-phosphate receptor agonist

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3807813A1 (en) * 1988-03-10 1989-09-21 Thomae Gmbh Dr K NEW BENZOCYCLOHEPEN DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
ES2098186B1 (en) * 1995-02-09 1998-02-01 Consejo Superior Investigacion PHARMACEUTICAL COMPOSITIONS BASED ON AMINOMETHYLINDOLS FOR THERAPEUTIC APPLICATION AS NEUROPROTECTORS IN PARKINSON AND ALZHEIMER DISEASES.
ES2300119T3 (en) 1997-02-27 2008-06-01 Takeda Pharmaceutical Company Limited AMINA COMPOUNDS, ITS PRODUCTION AND ITS USE AS INHIBITORS OF THE PRODUCTION OF BETA-AMILOID.
JPH11106381A (en) * 1997-09-30 1999-04-20 Ss Pharmaceut Co Ltd Chromene derivative and its salt and medicine containing the same
EP1218336A2 (en) 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
PE20050158A1 (en) 2003-05-19 2005-05-12 Irm Llc IMMUNOSUPPRESSOR COMPOUNDS AND COMPOSITIONS
RU2390519C2 (en) * 2003-08-29 2010-05-27 Оно Фармасьютикал Ко., Лтд. Compound capable of bonding with s1p receptor and pharmaceutical application thereof
CN1874991A (en) * 2003-08-29 2006-12-06 小野药品工业株式会社 Compound capable of binding S1P receptor and pharmaceutical use thereof
WO2006001463A1 (en) * 2004-06-23 2006-01-05 Ono Pharmaceutical Co., Ltd. Compound having s1p receptor binding potency and use thereof
EP1781595A1 (en) * 2004-08-13 2007-05-09 Praecis Pharmaceuticals Inc. Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
JP4318087B2 (en) 2004-12-13 2009-08-19 小野薬品工業株式会社 Aminocarboxylic acid derivatives and their pharmaceutical use
CN101115709B (en) * 2004-12-13 2011-04-13 小野药品工业株式会社 Aminocarboxylic acid derivative and medicinal use thereof
WO2007092638A1 (en) * 2006-02-09 2007-08-16 University Of Virginia Patent Foundation Bicyclic sphingosine 1-phosphate analogs
WO2007129473A1 (en) 2006-05-09 2007-11-15 Daiichi Sankyo Company, Limited Bicyclic aryl derivative
EP2364089B1 (en) * 2008-10-30 2016-12-07 Biogen MA Inc. Heterobicyclic sphingosine 1-phosphate analogs

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Bagdanoff et al. "Inhibition of Sphin....." J. Med. Chem. v.53 pp 8650-8662 (2010) *
Buzard et al. "Recent progress in....." EXp. Opin. Ther. Patents 18(10) 1141-1159 (2008) *
Crosignani et al. "Discovery of a....." Gioorg. Med. Chem. 20, pp1516-1510 (2010) *
Cusack et al. "S1P1 receptor....." Currnt Opin. Drug Disc. Develop. 13(4) pp481-488 (2010) *
Essortment "Autoimmune diseases" p.1 (2012) *
Fisher et al. "Tamoxifen for....." JNCI 90(18) pp1371-1388 (1998) *
Jordan "Tamoxifen....." Nature Review p.205-213 (2003) *
Marek's disease "Wikipedia" p.1 (2012) *
Saetta "Airway pathology...." Eur. Respir. J. 18 suppl 34 pp 18s-23s (2001) *
Tsubota et al. "Milkulicz's......" Inv. Opthal. Visual Sci. 41(7) pp 1666-1673 (2000) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629834B2 (en) 2013-04-26 2017-04-25 Kyoto University Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same

Also Published As

Publication number Publication date
EP2354134A1 (en) 2011-08-10
IL213261A0 (en) 2011-07-31
CA2745356A1 (en) 2010-06-10
MX2011005954A (en) 2011-10-11
JPWO2010064707A1 (en) 2012-05-10
ZA201103928B (en) 2012-08-29
BRPI0922135A2 (en) 2018-06-05
EP2354134A4 (en) 2012-08-29
CN102239164B (en) 2013-10-30
KR20110091865A (en) 2011-08-16
KR101589332B1 (en) 2016-01-27
CA2745356C (en) 2016-12-20
EP2354134B1 (en) 2016-02-24
US20110230463A1 (en) 2011-09-22
BRPI0922135B1 (en) 2021-07-13
US8193378B2 (en) 2012-06-05
RU2490266C2 (en) 2013-08-20
JP5578083B2 (en) 2014-08-27
WO2010064707A1 (en) 2010-06-10
AU2009323259A1 (en) 2011-06-23
CN102239164A (en) 2011-11-09
PL2354134T3 (en) 2016-07-29
ES2570155T3 (en) 2016-05-17

Similar Documents

Publication Publication Date Title
US8193378B2 (en) 2H-chromene compound and derivative thereof
JP4430941B2 (en) Edg receptor agonist
US8153658B2 (en) Piperidine derivative or salt thereof
KR101521405B1 (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
JP6453231B2 (en) Urea derivative or pharmacologically acceptable salt thereof
EP2308869B1 (en) Azole compound
SK8762001A3 (en) Piperidines as CCR5 modulators
JP5837482B2 (en) Pyrazole oxadiazole derivative
JPH11509175A (en) N-heteroarylpyridinesulfonamide derivatives and their use as endothelin antagonists
CA2824460A1 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
WO2022174883A1 (en) 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
CN1606554B (en) Beta-lactamyl vasopressin v1a antagonists
EP3059239B1 (en) Sulfur-containing bicyclic compound
WO2022174882A1 (en) 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
JP2021519776A (en) OX2R compound
US20240190860A1 (en) 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors
US20060074244A1 (en) Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway
JP2006527720A (en) Thiazoles as inhibitors of the ALK-5 receptor
JP2007186422A (en) Arylsulfide derivative
RU2774273C2 (en) New naphthyridinone derivatives and their use in treatment of arrhythmia
US20060004051A1 (en) Compounds
JP2001504128A (en) N- (imidazolylbutyl) benzenesulfonamide derivatives, their production and their therapeutic applications
WO2023170025A1 (en) Amido cyclopropyl derivatives as lpa receptor inhibitors
CN117777102A (en) BTK inhibitor and preparation method and application thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION